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Introduction 
This thesis consists of a number of collaborative studies aimed 
at the improvement of the diagnosis and care of children with 
diabetes mellitus. For the reader, who is not familiar with me-
dical problems, a brief account is given of the clinical "be-
havior" of the disease ( 1) . It is perhaps clarifying to describe 
a disease as an entity which may display a behavior as if it were 
a living being. For non-medical people it sheds some light on the 
magic doctors seem to operate with. 
The many variables by which diseases may manifest their behavior 
imply that doctors, in caring for patients, constantly perform 
experiments. During a single week of active practice with a com-
plex disease as diabetes, the clinician conducts more experiments 
than most of his laboratory collegues do in a year. 
The urge of some adolescents with diabetes mellitus to perform 
even more experiments at home, without their doctors knowing it, 
generates an even more lively behavior of this disease. 
In a psychologic or social sense, the word "behavior" refers to a 
person's attitude in various situations in life. In a more gene-
ral sense, the concept of behavior applies to the interaction of 
an entity to its environment. With this concept, we can contem-
plate the behavior of a disease during its interaction with the 
human host (patient) , who provides the environment in which the 
disease conducts its "life". 
The disease can behave morphologically, to alter structures in 
the host's body. It can behave biochemically or biophysically to 
affect functions of the body. It behaves clinically, to produce 
symptoms typical for the host's illness, and psychologically as 
the host will counteract the impact the disease will exert on the 
host's life. This classification allows a summary of basic pro-
blems of childhood diabetes. 
Morphologically, the disease is characterized by the destruction 
of specialized cells, producing a crucial hormone for the metabo-
lism of energy sources and other nutrients, insulin {2). The host 
is unable to repair this damage and will need insulin substitu-
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tion (injections) for the rest of her or his life. The mechanisms 
leading to this destruction are presently inaccessible for pre-
ventive intervention. 
Biochemically, failure to completely normalize the metabolism of 
energy sources and other nutrients is a hallmark of the disease, 
despite the availability of highly purified insulin preparations. 
A spectre of chronic metabolic disregulations is still found, of-
ten with remarkably few symptoms (3) . 
After 10 or 20 years the average patient will display an array of 
structural and functional abnormalities. These are called the 
chronic complications of diabetes. They have shortened the life 
expectancy of children with diabetes mellitus by 1/3 in years. 
Clinically, there are presently no means to prevent or even stop 
the irreversible damage to cells producing insulin. 
A classic controversy in medicine (4) has been whether meticulous 
insulin-administration and diet-keeping could alter the behavior 
of the disease in its tendency to develop the incapacitating com-
plications. One of the reasons for this controversy is the lack 
of practical biochemical parameters, to monitor the quality of 
the metabolic regulation as a result of such therapeutic regimens 
(5). 
Psychologically, the child has to grow up with one or two daily 
shots of insulin, dietary measures, to experience regular hospi-
tal-visits, including admissions for unforeseen severe disregula-
tion of the diabetes (6) 
The parents are usually aware of the possibility of chronic com-
plications and have to live with the idea their child's inconspi-
cuous disease is at least partially inherited. The uncertainty 
whether strict following of medical desirabilities, interfering 
with the child's upbringing, would improve the long-term progno-
sis or not, is an embarrassment to health-care professionals as 
well as patients. 
The ramifications of these problems of childhood diabetes provide 
a daunting prospect, if the behavior of this disease cannot be 
modified. 
Although the understanding of the disease is far from complete, 
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advances in knowledge have been made steadily since the discovery 
of insulin in 1921. In the pre-insulin-era diabetes mellitus in 
children meant "melting" away in a couple of weeks or months with 
certain death. The impact of the discovery of Banting and Best, 
that their pancreatic extract saved the lives of these children 
since 1922 was great. The dramatic effect of injected insulin on 
the blood glucose of patients with hyperglycemia undoubtedly led 
to the belief that hyperglycemia, and hence diabetes mellitus, 
was always due to insulin lack, and the more profound the insulin 
deficiency, the higher the glucose concentration. It was not un-
til 1959 that the painstaking studies of Somogyi demonstrated 
that excess insulin could in fact exacerbate the diabetic state 
(7). Just thereafter, in 1960, Berson and Yalow published their 
historic finding that insulin-concentrations could be measured in 
biologic fluids by radio-immuno-assay. This finding was preceded 
by their observation that many patients with diabetes had antibo-
dies against the injected insulin in their circulation (8). 
Early in the 1930's blindness caused by longstanding diabetes, 
treated with insulin, was virtually unheard of. Now it is appre-
ciated that diabetes is the leading cause of new cases of blind-
ness {9) • The rediscovery of an old medical file in the cellars 
of the Hospital for Sick Children in Toronto exemplifies this 
point: it contained an autopsy performed in 1932 on a man who had 
been one of the very first patients ever to receive insulin. A 
full description of abnormalities classic for chronic complica-
tions was in the report, but it was stated publicly the young man 
had died from a motor-cycle accident (10). 
The past decade has delivered an explosion of data on insulin de-
pendent diabetes, as a comparison between the proceedings of 
large meetings of 10 years ago and today would demonstrate: immu-
nology, virology, epidemiology ( 11) , pharmacokinetics ( 12) and 
biochemistry (13) have made steady contributions. 
With the echo of these explosions of knowledge ringing in the 
ears, the clinician selects those topics that would benefit the 
patient most, either directly or indirectly. 
This thesis is the result of the selection and subsequent work on 
such topics between 1978 and 1984. 
14 
It consists of three chapters, each divided into introductory pa-
ragraphs, a selection of papers relevant to that chapter and a 
discussion of its contents, concluded with a summary. Figures and 
tables are numbered by their sequence throughout each chapter, 
excepting illustrations of the reprints of papers. Also, the 
literature references cited throughout each chapter are only gi-
ven at the end of that chapter and do not refer to literature re-
ferences given in the reprints of papers. 
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CHAPTER I ETIOLOGY 
§1. Background 
For I dipt into the future, 
far as human eye could see, 
Saw the vision of the world, 
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and all the wonder that would be. 
Alfred, Lord Tennyson, 1809-1892. 
{From: Locksley Hall 1.119) 
The recognition of thirst and honey-sweet urine in massive 
amounts as signs of the disease is old. In ancient India descrip-
tions have been found in texts on Hindu medicine ( 1) . Diabetes 
mellitus as a term is derived from the greek diabainein (to fall 
through) and mellos (honey-sweet) (2) • 
Today the notion that a variety of genetic and evironmental fac-
tors may lead to diabetic states and sequelae thereof, prompted 
attempts to associate these factors with clinical classifica-
tions. However, etiologic factors may be expressed in several 
clinical forms and putative clinical presentations may involve 
several etiologic factors. Associations are only valid in a "sta-
tistical" manner. What has been learned from such associations? 
A first fundamental point is that insulin-requiring or insulin-
dependent diabetes mellitus (also known as juvenile-onset, keto-
sis prone or labile diabetes) is a distinct disorder from non-
insulin-requiring diabetes mellitus (maturity-onset, non-ketosis 
prone or stable diabetes) . A new classification separating these 
broad categories has been put forward (3,4), distinguishing type-
1-diabetes {insulin-dependent diabetes mellitus IDDM) from 
type-2-diabetes (non-insulin-dependent diabetes mellitus 
NIDDM). This classification has subsequently be refined (5). 
Table 1. 
Type 1 
1 .a. 
l.b. 
Type 2 
2. a. 
2.b. 
* 
Classification of diabetes mellitus (5) 
insulin-dependent diabetes 
genetic susceptibility known 
predominantly young onset 
slight male excess 
transient autoimmune phenomena 
probably initiated by viruses 
* 
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primary association with both HLA -DR3 and HLA-DR4 
predominantly middle age onset - often insiduous 
striking female preponderance 
tendency for persistent autoimmune phenomena 
strong family history for autoimmune disease 
strong association with HLA-DR3 
non-insulin-dependent diabetes 
genetic susceptibility unknown 
strong familial segregation 
associated with obesity 
inheritance of inappropriate metabolic genotype? 
abnormality of centrally mediated control of blood 
glucose? 
abnormalities of insulin receptor concentration and 
affinity on target cells? 
HLA - human leukocyte antigens. 
The relevance of this later classification is, that it distin-
guishes childhood diabetes mellitus in its clinically classic 
form as type-1a-diabetes from other diabetic syndromes with insu-
lin dependency. Diabetes mellitus other than type-la is not the 
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subject of this thesis. There are many unusual, but genetically 
well characterized, childhood syndromes associated with glucose 
intolerance, such as dystrophia myotonica, Werner's syndrome, 
Down 1 s syndrome and lipodystrophies. These syndromes, together 
with the less rare maturity-onset-type-diabetes of the young and 
diabetes associated with cystic fibrosis, have been reviewed by 
Rimoin (6). These unusual syndromes comprise less than 5 percent 
of all diabetic syndromes of childhood, 95 percent or more of the 
children using insulin are considered to have type-la-diabetes 
mellitus. None of the patients described in this chapter had any 
of these syndromes, except the patient reported in the second pa-
per. Therefore all others are considered to have type-la-diabe-
tes. 
The characteristics of type-la-diabetes indicate that the disease 
is possibly related to an environmentally initiated, perhaps vi-
ral (7) perturbation, that causes destruction of the child's own 
pancreatic beta-cells {8) , which normally produce insulin. 
A second fundamental point raised in table 1 is that type-1-dia-
betes per se is not inherited, but it is the susceptibility to 
develop the disease which is transmitted (9). This susceptibility 
is associated with genes of the major histocomptability complex, 
in particular expressed by HLA-DR3 and HLA-DR4. It is unknown how 
these genes cause this susceptibility. 
Table 1 also indicates that the disease is characterized by tran-
sient autoimmune phenomena as a reflection of such involvement of 
the pancreatic beta-cells. These autoimmune phenomena, albeit 
transient, were found to be relatively common in adult patients 
(10). Irvine then developed the following model of the etiology 
of type-1-diabetes, visualized in 1978. 
Fig. 1 
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Fig. 1. The possible interaction between autoinmunity and pancreatotropic 
viral infection in the pathogenesis of type-1-diabetes, based on genetic 
susceptibility to either or to both. Source: Irvine, 1978, Lancet, i, 638. 
Reprinted with peDmission. 
The ultimate goal of any study into the etiology of chronic or 
irreparable disease is its prevention. The Irvine-model combined 
the features related to the etiology of childhood diabetes effec-
tively. It should be noted that Irvine already suspected that 
acute viral infections rarely caused insulin dependent diabetes. 
The primary goal of the studies of this chapter was to identify 
children at risk for the development of insulin dependency, pa-
ving the way for the consideration of future (immuno-)preventive 
measures. 
What sort of preventive measures might be considered is discussed 
at the end of this chapter (paragraph 5). 
The basis for the studies reprinted in this chapter was the fol-
lowing interpretation of the Irvine-model of the natural course 
of diabetes type-la: As the nature of the viruses and hence their 
mode of action is unknown (Chapter II - paragraph 3), interac-
tions of viral infections with autoimmunity leading to pancreatic 
beta-cell destruction may be gradual and repetitive. The disease 
process may evolve insidiously over years in contrast to the im-
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pression the clinician obtains from a history of some weeks of 
diabetic symptoms on admission of a child to the hospital for 
initial treatment. 
The grounds for the idea, that the disease process of childhood 
diabetes might be insidious and asymptomatic, were found in the 
literature on the pathology and the dynamics of insulin secre-
tion, summarized in the next paragraph. 
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§2, Pathology and insulin secretion 
The hallmark of the pathology of childhood diabetes is a selecti-
ve loss of beta-cells of the islets of Langerhans normally produ-
cing insulin ( 11) . 
What loss of beta-cells can be sustained without deterioration of 
glucose homeostasis? Or, conversely, what is the minimum amount 
of beta-cells necessary to prevent diabetic symptoms? 
The studies by Martin and Lacy in 1963, using experimental surge-
ry, indicated that diabetic symptoms do not develop as long as 20 
to 30 percent of the pancreas remains in situ (12). They also 
found that a decrease in total insulin reserve required a paral-
lel decrease in body weight to maintain glucose homeostasis. This 
explains the clinical experience that weight loss may precede 
marked polyuria and polydipsia in children developing diabetic 
symptoms over weeks or months. In children where this sequence of 
events can be documented using previous weights and heights, a 
gradual loss of pancreatic beta-cells is likely, whereas almost 
simultaneous loss of weight with the advent of diabetic symptoms 
would suggest a more acute loss of beta-cells. 
Accordingly, injection of mice with compounds specifically toxic 
to beta-cells, such as streptozotocin, produce graded losses of 
beta-cells. Those studies too revealed that fasting hyperglycemia 
can be prevented until 70-80 percent of the islet-cell mass is 
lost (13). 
The studies by Martin and Lacy (12) indicated in addition that 
remaining beta-cells after major losses may become functionally 
more active, leading to increased synthesis and release of insu-
lin compared to normal beta-cells. That finding is in keeping 
with clinical studies in humans indicating that many newly diag-
nosed children (and adults) have some residual beta-cell-function 
and that improvement of the metabolic state will enhance the 
remnant capacity of the diabetic pancreas to secrete insulin 
(14' 15) . 
An important question then becomes, to what extent beta-cells 
have the ability to regenerate and recover from initial lesions. 
This is essentially unknown. By radio-labelling of islet-cells, 
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including beta-cells, in vivo in animals and in vitro in tissue-
culture, a slow turn-over of intact new islet-cells replacing old 
islets has been documented. It is now generally accepted that 
islet-cells may regenerate, but whether new beta-cells can be 
formed once they are destructed, is unknown {16). To answer this 
question in human patients, serial pancreatic biopsies would be 
required, which is obviously ethically prohibited. Also such 
biopsies may well show different results, depending on the part 
of the pancreas they were taken from (17). 
The islets of Langerhans encornprise about 2 percent of the total 
weight of the pancreas and consist of 65 percent beta-cells, pro-
ducing insulin, C-peptide and pro-insulin, 17 percent alpha-
cells, producing glucagon, 9 percent delta-cells, containing so-
matostatin, 9 percent P.P.-cells, producing pancreatic polypepti-
de (P.P.) (16). In childhood diabetes, the loss of endocrine 
cells is highly selective for beta-cells, whereas alpha-cells, 
delta-cells and P.P.-cells initially remain in amounts similar to 
or higher than those in the normal pancreas. From the few pancre-
atic specimens available from deceased recently diagnosed diabe-
tic patients, it appeared some beta-cells remained and some even 
proliferated (11). Ultimately, however, all endocrine pancreatic 
tissue is lost and replaced by fibrous tissue. The apparently 
temporal proliferation was erratic and had little resemblance to 
the normal architecture of islets of Langerhans: few small 
strands along pancreatic ductuli were found, consisting of mainly 
P. P. -cells. This very partial regeneration does not remind of 
stages of the embryologic development of islets, as one might 
think. 
During normal human embryologic development, the first islet-cell 
to be identified is the more numerous alpha-cell (A2) at 9 weeks, 
shortly followed, at 10~ weeks by beta-, delta- (Al) and P.P.-
cells (16). The alpha- and delta-cells continue to be more nume-
rous than beta-cells throughout fetal life. In the rat, rapid ex-
pansion of beta-cells takes place about mid-gestational, whether 
or when this occurs in humans is unknown (18). 
An important pathologic hallmark of childhood diabetes, was the 
old finding of mononuclear cell infiltrates around the islets of 
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diabetic children (19), designated as "insulitis", later con-
firmed by Gepts and his associates (20). 
About two-thirds of the pancreases of children dying following 
the acute onset of diabetes will have infiltration of granulocy-
tes and monocytes, in particular around the islets. Similar 
changes are almost never seen in adult diabetics ( 20) . A few 
cases of insulitis with an infiltrate consisting of lymphocytes 
have been reported in non-diabetics, all in very young children 
(18) • 
About one-third of the pancreases of diabetic children examined 
shortly after diagnosis showed "hydropic degeneration" accompa-
nied by lymphocytic infiltration. This picture suggests a more 
chronic inflammation (20) . 
Acute inflammation, involving other polymorphonuclear cells, has 
also been noted in diabetic children expiring very shortly after 
an acute onset of diabetes. By contrast, insulitis of the newborn 
child of a diabetic mother will usually show a predominance of 
eosinophils (16). The rather constant finding of lymphocytes in 
and around islets of diabetic children, evidence for cell-media-
ted autoimmune mechanisms, the association with other autoimmune 
endocrinopathies and the presence of auto-antibodies against the 
islets of Langerhans has led to the "autoimmune hypothesis" of 
childhood diabetes (figure 1). Whether such involvement is re-
versible or whether regeneration of islets before the stage of 
clinically manifest diabetes may occur is unknown. 
Can the pre-diabetic state of childhood diabetes be detected by 
partially impaired insulin secretion? There is a lack of long-
term studies of cohorts of children with such impairment, in the 
absence of overt diabetic symptoms. Furthermore there are few da-
ta on standardized insulin responses after oral glucose loading 
with the exception of the classic Rosenbloom-studies (21). Their 
group traced lOS of 140 siblings of children with insulin-depen-
dent diabetes, who had had an oral glucose tolerance test 10-12 
years earlier. Six of these 105 children had developed insulin 
deficiency in the meantime. Nineteen of these 105 children had 
shown 7.8 mMol/L glucose or more, 2 hours after glucose loading 
orally. Five of the six siblings that later developed diabetes, 
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belonged to those 19 children (22). Obviously such data may not 
be reversed: it has been estimated only 0-10 percent of children 
with such defined "chemical diabetes" do develop diabetes (23). 
The simultaneous measurement of insulin or 4 more glucose-values 
up to 4 hours after the ingestion of glucose did not improve the 
predictability of these "prediabetic" siblings. The data implied 
poor sensitivity and poor predictability of oral glucose tole-
rance tests to foretell clinically overt diabetes mellitus, but 
suggested a long latency of diabetic symptoms in some cases. 
The (remnant) endogenous capacity of the pancreatic beta-cells to 
secrete insulin may be estimated in patients already treated with 
insulin by the measurement of "connecting-peptide" (C-peptide). 
Insulin is formed from pro-insulin, which consists of insulin and 
C-peptide. C-peptide is secreted in equimolar amounts to insulin 
by the pancreatic beta-cells into the circulation after cleavage 
of the pro-insulin. C-peptide will not react significantly with 
circulating (exogenous) insulin in suitable radioirnrnunoassays and 
may thus be measured separately. This is mostly done after admi-
nistering one of several suitable stimuli, so that the maximal 
(remnant) capacity of the pancreatic beta-cell to endogenously 
secrete insulin (as C-peptide) is assessed (24) • 
Partial, temporary, remissions of endogenous insulin secretion 
are frequently seen in recently diagnosed children. This episode 
is called the "temporary remission phase" or the "honeymoon-pha-
se" during which low doses or even no insulin substitution may be 
necessary over weeks or months after the initial treatment, re-
quiring higher dosages again thereafter (23). This apparent tem-
porary recovery of the function of pancreatic beta-cells may be 
documented by the measurement of C-peptide, despite the circula-
tion of exogenous insulin (14) . 
Taken together, the literature data suggest that clinical symp-
toms may not develop until some 70-80 percent of endocrine tissue 
of the pancreas is lost. This destruction is accompanied by mono-
nuclear cell infiltrates and selective loss of the pancreatic be-
ta-cells, without signs of organized regeneration of the islets 
of Langerhans. 
Insidious deterioration of glucose-tolerance in sibs of diabetic 
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children, that later developed the disease themselves, did occur, 
but this testing had poor sensitivity in predicting such cases. 
None of these data spoke against a symptom-free, perhaps years 
long, prediabetic phase in diabetes-type-la. 
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§3. Scope of the studies 
When the studies reprinted in paragraph 4 were initiated, the as-
sociation of the susceptibility to the disease and genes of the 
major histocompatibility complex (MHC) appeared the only tangible 
marker. Therefore a detailed analysis of these genes was made, 
described in the first paper of this chapter. The relation be-
tween HLA-antigens and disease in general is reviewed in the the-
sis of B.M. de Jongh (Leiden, 1983). 
It had been found that the relationship between two specific liLA-
antigens (HLA-DR3 and HLA-DR4) and insulin dependency was parti-
cularly strong: some 90 percent of children with diabetes-type-la 
had either of these haplotypes (5). Thus, the absence of either 
haplotype in children with proven total insulin-deficiency may 
point to unusual pathogenetic mechanisms leading to the disease. 
This application is exemplified in the case report given in the 
second paper of this chapter. 
Another purpose of the study on the genetics of HLA in diabetes 
was to answer the question to what extend HLA-identity carries a 
risk to siblings of diabetic children. In other words: what are 
the chances of a child that is HLA-identical to a diabetic sib to 
become diabetic itself over a given period of time, versus the 
chances of a sibling that is only haplo-HLA-identical or non-HLA-
identical? From the data in the reprint of paper 1 the recurrence 
risk for HLA-identical siblings was calculated at 11.6 percent. 
Thus, only 1 in 8 HLA-identical siblings would actually develop 
the disease. 
This was a figure of little predictive value if children at risk 
were to be identified, with the consideration of preventive mea-
sures in mind. Therefore additional associated factors were exa-
mined: the transient autoimmune phenomena. 
The various methods for the detection of such islet-cell antibo-
dies, lacked a definition of their accuracy (25). 
This premise was confirmed in 1981 by comparative studies using 
fresh frozen sections of pancreatic tissue: assay precision and 
reproducibility of islet-cell cytoplasmatic fluorescence were 
such, that a multicentre study revealed only 50 to 60 percent 
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concordant scores of diabetic sera between four different labora-
tories (A. Drash, 1981, at the annual meeting of the Internatio-
nal Study Group of Diabetes in Youth, Les Collons, Switzerland). 
This was not surprising as the control of technical details, such 
as the quality of fluorescent antibodies, microscope lamp and 
filters, was not previously established and the expression of re-
sults in titres rather than "scores" was exception rather than 
rule. A comparison of methods had to be made for this particular 
method. 
In a collaborative study we examined (26) the sensitivity and 
specificity of the assay for islet cell cytoplasmatic antibodies 
in human serum using cryostat sections from freshly frozen pan-
creas. The specificity of the assay was close to 100% while the 
sensitivity was 40%-98% depending on the pancreas used. Inter-ob-
server variation was 12-27%, End-point titres of islet-cell anti-
bodies varied with the sensitivity of each pancreas. End-point 
titration of the antibodies in two different laboratories using 
the same pancreas was significantly correlated (Spearman's test 
p<O.OOl). We concluded that a reliable determination of islet-
cell antibody titres in human serum requires careful characteri-
zation of the sensitivity and specificity of each pancreas used 
as a source of frozen sections, in the indirect immunofluorescen-
ce assay. Given these findings we selected one of the particular-
ly suitable pancreatic specimens (designated "HP" - kindly provi-
ded by the Department of Surgery of the Dijkzigt Hospital, Rot-
terdam) for further studies. 
The rationale for the study of islet-cell antibodies was that 
these were seen at diagnosis, but disappeared thereafter in a few 
years (27) . If one is seeking a marker of children at risk for 
the development of diabetes, it is conceivable that the islet-
cell antibodies might be present before the disease becomes actu-
ally manifest. 
Given an assay-system with known sensitivity and precision for 
the detection of islet-cell antibodies, the accuracy of the pre-
diction of childhood diabetes was explored retrospectively, des-
cribed in the third paper of this chapter. 
In the meantime the late dr. Andrew G. Cudworth and his collabo-
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rators in London reported that one particular property of islet-
cell cytoplasmatic antibodies, complement fixation, appeared to 
be present in circulating antibodies of children that later deve-
loped diabetes. It was suggested that this particular property 
was associated with ~-diabetic stages, as it disappeared rapid-
ly after diagnosis (28). 
Subclasses of IgG fix complement in the order IgG3 > IgG1 > 
IgG2 > IgG4 • 
This suggested that subclasses of IgG - namely IgG1 and IgG3 -
might be preferentially involved in the children's autoimmunity 
towards islet-cells before the disease becomes clinically mani-
fest. Restrictions to certain subclasses of IgG had been found in 
the following diseases: two cases of myasthenia gravis had ex-
clusively IgG3 antibodies to the acetylcholine-receptor; comple-
ment fixing antibodies to epidermal basement membrane in herpes 
gestationis were mainly IgG1 ; in bullous pemphigoid non-comple-
ment fixing antibodies contained only IgG 4 (29). Also preferen-
tially IgG3 was seen in human viral antibody activity (30). As 
the IgG-subclasses by which children • s auto-antibodies reacted 
were unknown, the above suggestion of possible restriction of the 
IgG-subclasses involved was important for two reasons: 
1. IgG-subclasses are isotypes of the heavy chains of immunoglo-
bulins that are coded for by chromosome number 14. The isotypes 
(IgG1 , IgG 2 , IgG 3 , IgG4 ) coded for by the Gm-locus comprise 
different allotypes. Restriction to certain IgG-subclasses might 
suggest the involvement of non-HLA-related genes, which explain 
the inherited susceptibility only partially. Thus the finding of 
additional susceptibility-genes for the detection of children at 
risk might have considerable importance. Even more so, since Gm-
genes were demonstrated to be involved in the susceptibility to 
Graves disease, next to HLA-linked genes (31). 
2. The isolation of IgG-subclasses specifically involved in is-
let-cell autoimmunity might be used to detect subcellular frac-
tions of islet-cells serving as antigens to these auto-antibo-
dies. 
The complement-fixation and IgG-subclasses of children's islet-
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cell antibodies were therefore examined. This is described in the 
fourth paper of this chapter. 
So far the studies were aimed at the identification of children 
in prediabetic-stages, for which stages future techniques for in-
tervention might be considered, that might stall ongoing pancrea-
tic beta-cell destruction. 
It should be mentioned here that the children and their parents 
participating in the investigations into prediabetic stages gave 
their consent if these consisted of single blood-drawings at 
home, which was done outside working hours. It was agreed upon 
beforehand the results of the measurements would not be disclosed 
to them. 
At this point in our studies, we turned to another stage in the 
course of childhood diabetes, namely the first year of treatment 
of the manifest disease. 
After initial treatment, about 2/3 of the children experience a 
temporary remission in their insulin requirements, also named the 
honeymoon-phase, as explained in paragraph 2. This 50 percent or 
larger reduction in insulin dosages, coincides with an apparent 
recuperation of the endogenous insulin secretion ( 3 2) . However, 
the reason for this phenomenon has never been fully elucidated. 
If this partial regeneration of the capacity to secrete insulin 
could be maintained, this might have important consequences for 
the children. It had been suggested type-1-diabetic patients with 
even remnant capacity to secrete insulin had less retinopathy af-
ter 15 years of disease-treatment (33), but this important asso-
ciation has been questioned by others (34). Also, even partial 
endogenous insulin secretion protected against the formation of 
ketone bodies, when insulin treatment was withdrawn (35). 
During a retreat of the Department of Immunohematology of Leiden 
University aboard the "Eendracht", this curious remission in in-
sulin requirements after the initiation of insulin injections was 
discussed. 
With regard to this phenomenon, Prof. I.R. Cohen of the depart-
ment of Cell Biology of the Weizmann Institute referred to their 
finding {36) of the generation of insulin-anti-idiotypes in mice 
as a consequence of the vaccination with insulin. These anti-
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idiotypes were probably antibodies to the insulin-antibodies as a 
part of an idiotype-anti-idiotype regulatory network, put forward 
by Prof. N.K. Jerne in 1974 (37). Prof. Cohen supposed that such 
idiotypic antibodies might also be raised in children by the in-
evitable insulin-substitution. 
Further it was reasoned that some of these anti-idiotypes might 
be internal-image-specific, meaning they would 11 mirror" the 
structure of the original antigen, insulin. In other words: if 
"classic" antibodies to insulin were raised, the anti-idiotypes 
raised against these "classic" antibodies might in turn have the 
structure of the antigen they were originally derived from. Such 
anti-idiotypes, depending on the specific quantities that emer-
ged, might be expected to have effects at the level of the insu-
lin receptor (36). 
The nature of insulin receptor antibodies found in children is 
described in the fifth paper of this chapter. 
The bearings of the findings, reprinted as papers in the next pa-
ragraph, to the consideration of possible preventive intervention 
will be discussed in paragraph 5. 
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Summary 
This report deals with the genetic factors involved in insulin-
dependent diabetes mellitus (IDD) in The Netherlands. 
Twenty-two Dutch multiplex families with IDD were typed for 
HLA-A, -B, -C and -DR antigens, for BF, C2, C4 and GLO polymor-
phisms as well as for GM allotypes of immunoglobulins. In addi-
tion, 53 unrelated IDD children and 31 unrelated patients with 
adult onset IDD were typed for HLA-A, -B, -C and -DR antigens. A 
significant heterogeneity for the frequency of HLA-DR4 related to 
age of onset was observed. A significant deviation of the Hardy-
Weinberg equilibrium was observed for the HLA-DR locus with an 
excess in patients of heterozygotes HLA-DR3, -DR4. HLA-BB and 
HLA-BlS were not only secondary associated, but constituted with 
HLA-DR3 and -DR4, respectively, a haplotype in association with 
IDD. 
Non-random segregation of HLA-haplotypes was observed in multi-
plex families exemplified by an excess of HLA-identical affected 
sibpairs. Cross-overs between HLA-DR and GLO identified the HLA-
DR segment as mainly involved in the association with IDD. Three 
diabetic haplotypes were confirmed to occur frequently among af-
fected sibs: 
a) Al, BB, BFS, C2.l,C4AQO,C4Bl, DR3,GL02 
b) Aw30,Cw5,Bl8,BFFl,C2.l,C4A3, C4BQ0,DR3,GL02 
c) A2,Cw3, BlS,BFS, C2.1,C4A3, C4B3, DR4,GL01 
The segregation of GM allotypes to affected sibpairs was not sig-
nificantly different from random segregation. 
The main conclusions from this study are that significant hetero-
geneity for age of onset exists and that the data are not compa-
tible with simple genetic models including dominant, recessive 
and intermediate models of inheritance. The data do require more 
complex models, involving two different HLA-linked (sets) of sus-
ceptibility genes. 
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Introduction 
The reported association of genes of the Major Histocompatibility 
Complex (MHC) with insulin-dependent diabetes mellitus (IDD, type 
1) and not with non-insulin dependent diabetes mellitus {NIDD, 
type 2) , has enabled considerable progress in studies of the ge-
netics of IDD. 
Singal & Blajchman (l) were the first in showing an increase in 
frequency of HLA-BlS among patients as compared to normal con-
trols. Other investigations confirmed the HLA-BlS association and 
revealed an association with HLA-BB as well (2). Later on, the 
HLA-D and -DR alleles Dw3, Dw4 and DR3, DR4, respectively, were 
shown to have an even stronger association with IDD. Furthermore, 
DR2 was significantly decreased among patients (3,4). Studies of 
families with more than one affected sibling revealed an excess 
of HLA-identical affected sibpairs (5) . 
These data indicated that the susceptibility for IDD was related 
to the HLA system (6) which led to a substantiation of various 
genetic models for inheritance of IDD. These models encompassed a 
dominant (7), recessive (B), overdominant (9) and intermediate 
mode of inheritance (10). 
This variety of models can partly be explained by the fact that 
environmental factors are at least as important as genetic fac-
tors in the development of IDD, as may be inferred from the ob-
servation that less than 50 percent of monozygotic twins are con-
cordant for the disease (11). Our studies focussed on the genetic 
factors involved in IDD in The Netherlands. Three aspects will be 
considered in more detail: 
Genetic heterogeneity in IDD, genetic factors of IDD related to 
the HLA system, and non-HLA genetic factors involved in IDD. 
Regarding the first aspect, several factors involved in genetic 
heterogeneity of IDD have been proposed. An association of IDD 
with other autoimmune diseases, such as thyroiditis and Addison's 
disease, is related to HLA-BB, -DR3 with persistance of islet-
cell antibodies (ICA) , whereas IDD without other autoimmune dis-
eases is characterized by a transient presence of ICA and an as-
sociation with either HLA-B15, -DR4 or HLA-B8, -DR3 (12). Stu-
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dies on genetic heterogeneity associated with the age of onset 
are conflicting. Sibpair analysis in multiplex families showed a 
lack of concordance for age of onset (13). However, HLA-DR4 and 
HLA-BlS are particularly increased in patients with a young age 
of onset (14,15). Thus it appeared worthwhile to investigate the 
association of HLA and IDD with regard to age of onset of the 
disease. 
The second aspect refers to the characterization of HLA related 
markers associated with IDD. To this purpose we investigated 75 
unrelated IDD patients with onset of the disease before the age 
of 17. Among the different tests, to detect associations, we em-
ployed a recently described method to detect haplotype associa-
tions (16). In addition, 22 multiplex families were genotyped for 
HLA-A, -B, -C, -DR, complement factors (BF, C2, C4) and GLO, and 
analysed for HLA haplotype segregation and occurence of specific 
haplotypes related to IDD. The detection of HLA-DR-GLO cross-
overs and a clustering of "diabetic" haplotypes allowed an analy-
sis of the chromosomal segments associated with the susceptibili-
ty for IDD. 
Regarding the third aspect, we investigated whether non-HLA genes 
are involved in IDD. This question was prompted by the observa-
tion of a discrepance in concordance rate for IDD of 50 percent 
among monozygotic twins (11), as compared to 12-14 percent in 
HLA-identical affected siblings (17,18). 
Grn, the allotype of immunoglobulin heavy chains was studied be-
cause this marker was reported to be associated with other HLA-
related immunopathogenic diseases (19,20). 
Subjects and methods 
I. Subjects 
All patients included in this study were diagnosed as having in-
sulin-dependent diabetes, according to criteria of the National 
Diabetes Data Group (21) and were of Dutch Caucasoid extraction. 
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A. Unrelated patients 
The unrelated patients were divided into three groups: 
1. Unrelated patients with age of onset of IDD after 17 years 
In = 31) . 
2. Unrelated patients with age of onset of IDD before 17 years 
In = 53) . 
3. Propositi of multiplex IDD families with age of onset before 
!?years (n=-22). 
Group 2 and 3 (n = 75) were combined in the population analysis. 
ad. 1 The first group comprised 31 unrelated patients with re-
cently diagnosed IDD and age of onset after 17 years, who conse-
cutively entered the adult-diabetic out-patient clinic of the 
University Hospital in Leiden. Of 31 patients, nine were female 
and 22 male (ratio= 2 5)~ the mean age of onset was 30.34 
years, ranging from 17.5 to 63.5 years. 
ad. 2 Group two comprised 53 unrelated children with IDD and age 
of onset before 17 years, attending the out-patient clinic for 
diabetes at the Sophia Children's Hospital in Rotterdam. Of these 
53 patients, 24 were female and 29 male (ratio 4 : 5); the mean 
age of onset was 6.94 years, ranging from 1.25 to 16.75 years. 
B. Multiplex families 
Of 22 Dutch Caucasoid multiplex families, 19 responded to a call 
for families with more than one diabetic patient, at a yearly 
meeting of the Dutch Diabetic Patient Union (DVN) . The remaining 
three families were known at the Sophia Children's Hospital. The 
families originated mainly from the Western part of the Nether-
lands. With the exception of one healthy child the families were 
completely investigated, and genotyped for HLA-A, -B, -C and -DR. 
In addition, most families were typed for BF, C2, C4, GLO and GM. 
In 12 of the 22 families, only two children were affected and in 
six families one parent and two children. In two families, three 
children and in one familiy, four children were affected. 
In one family both members of a monozygotic twin were affected, 
and this family was not included in the haplotype segregation 
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analysis. Arbitrarily, in each family the eldest affected child 
was assigned as the index patient (propositus). In total, we 
found 22 propositi (12 female, 10 male, mean age of onset 7.0 
years, range from 1.3 to 16.8) and 32 secondary patients {12 fe-
male, 20 male, mean age of onset 10.6 years, range from 1.3 to 
44) • 
Marker phenotyping 
The HLA typing was performed by the standard microcytotoxicity 
assay, using peripheral blood lymphocytes. 16 HLA-A, 40 HLA-B and 
6 HLA-C antigens were determined, using a set of 120 well-defined 
alloantisera (22). With the two-colour fluorescence assay 10 HLA-
DR antigens were investigated, using 80 different alloantisera 
(23) • 
Properdin factor B (BF), complement factor 2 (C2), and complement 
factor 4 (C4A and C4B) were determined by electrophoretic techni-
ques (24,25). 
Electrophoretic phenotypes of glyoxalase-1 (GLOl) were determined 
using cellogel techniques (26). 
Allotypes of immunoglobulins (GM, AM and KM) were typed by hae-
magglutination-inhibition assay (27). 
Genetic analysis 
As normal controls, a panel of 1018 local blood donors was used 
for the HLA-A, -B and -C antigens and a panel of 201 randomly se-
lected Dutch Caucasoid individuals for the HLA-DR antigens. The 
HLA antigen frequencies in patients and controls were compared 
using the method given by Woolf as modified by Haldane (28) . If 
mentioned, the P values were corrected for the number of compari-
sons made (29). 
Heterogeneity between estimates of relative risks was analysed 
with a chi-square test (28). Heterogeneity in relative risk for 
HLA-DR3 and HLA-DR4 was investigated among IDD patients with on-
set of the disease before the age of eight, between the age of 
eight and 17, and after the age of 17. The age of 17 was chosen 
because at that age no overlap occurred between the patients from 
the adult Leiden clinic and the childhood patients. 
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As another parameter to determine the strength of an association, 
the etiologic fraction (EF) (30) was estimated for a selected 
group of antigen combinations. Generally speaking, the EF value 
indicates how much of an association is "due to 11 the disease as-
sociated factor, and under certain conditions the EF provides in-
formation about the degree of linkage disequilibrium between a 
marker gene and an assumed disease susceptibility gene. Gene fre-
quencies, used for the Hardy-Weinberg (H-W) expectations were 
calculated by gene counting in the patients and estimated with 
the square-root method in the controls. In comparing subgroups of 
allelic combinations, we employed also the odd's ratio (OR) , as 
defined by Svejgaard and Ryder (31) with the subgroup of pheno-
type (HLA-non DR3, non-DR4 (= HLA-Drx, x)) as reference. 
A striking feature of the HLA system is the degree of linkage 
disequilibrium among alleles of closely linked loci. For this 
reason an association with an allele of one locus often leads to 
a secondary association with an allele of a locus in linkage dis-
equilibrium with the first locus. It is, however, important to 
distinguish whether an association is secondary, due to linkage 
disequilibrium with a primarily associated antigen, or whether 
the association is due to a real haplotype association. In the 
latter case, a third order linkage disequilibrium is implicated 
between an assumed disease locus and two test loci. Recently, 
Porta & McHugh (16) have developed a method to calculate a delta-
value for a third order linkage disequilibrium from population 
data. Two extreme genetic models, rare autosomal dominant (RAD), 
and autosomal recessive (AR) are investigated, based on the as-
sumption of a disease locus with a normal and a disease allele. 
We will refer to the delta-value for a third order linkage dis-
equilibrium as delta-haplotype. 
The occurence of HLA-DR and GLO cross-overs has been analysed in 
affected sibpairs, one of which had a cross-over. The question 
was addressed whether the sibs shared the HLA-DR, or the GLO seg-
ment, thus delineating the "diabetic" segment (32) . 
The haplotypes, determined in the genotyped families, were divi-
ded in three categories, according to a suggestion of J .H. Ed-
wards (personal corrununication) : 
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l. Haplotypes in patients and shared with the index patients 
("hot" diabetic haplotypes), 2. haplotypes in patients but not 
shared with the index patients ("warm" diabetic haplotypes), and 
3. haplotypes only present in normal individuals (non-diabetic 
haplotypes). The "hot" and "warm" diabetic haplotypes were com-
bined and clustered according to HLA specificity (starting with 
HLA-DR) . Analysis of the clusters allows to characterize among 
unrelated "diabetic" haplotypes, those segments which are parti-
cularly conserved in evolution and associated with susceptibility 
for diabetes. Since only those haplotypes are selected that are 
associated with IDD, it is now possible to learn from cross-overs 
that occurred in history: cross-overs and mutations that do not 
alter the predisposing capacity of the chromosome are present in 
the "diabetic" haplotypes and thus may help to delineate the seg-
ment where the factor (s) associated with susceptibility for IDD 
is present. 
Non-random segregation of parental haplotypes to the children was 
analysed with the method of haplotype sharing as given by Thomson 
& Bodmer (8) and with the method given by De Vries et al. (33). 
Because the latter may not be generally known, we will describe 
this method of segregation analysis to affected or normal sib-
lings. 
When the paternal haplotypes are a and b, and the maternal haplo-
types are c and d, D is the absolute value of the number of sibs 
with a minus the number with b (or: the number with c minus the 
number with d). The expected value of D is d, and can be calcula-
ted for each sibship-size and so can the variance of d = ( ad2). 
The sum of the D values (I D) of the various sibships should be 
supposed to be equal to the sum of the d values (l d}. When, how-
ever, an association or linkage would exist I. D would have a 
higher value than that of L d, The difference between the obser-
ved values of I D and of ld can be tested for its statistical 
significance in the following way: 
I D - Id - 0. 5 and the value of P, found in a x 2 table, 
is twice the suitable P value. 
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Results 
We will first describe the results of the analysis of heterogene-
ity related to age of onset. Secondly, we present the data of a 
population analysis of patients with age of onset before 17 years 
and thirdly we report the findings in the multiplex families. 
Age of onset 
Table 1 shows the relation between the age of onset of IDD and 
the frequencies of HLA-DR3 and -DR4. Three categories were com-
pared: onset of IDD before the age of eight, between the age of 
eight and 17, and after 17 respectively. 
Table 1. Frequencies of HLA-DR3 and HLA-DR4 in IDD patients, 
related to age of onset in years. 
Age HLA-DR3 Rel.Risk x2 x2 P' 
of Hetero-
onset pas. neg. geneity 
Controls 58 143 
0- 8 31 18 4.2 18.96 
Patients 8-17 15 11 3.3 8.43 0.20* NS 
>17 13 18 1. 8 2.29 2.87** NS 
HLA-DR4 
Controls 49 152 
0- 8 39 10 11.6 42.14 
Patients 8-17 17 9 5. 7 16.55 1.57* NS 
>17 15 16 2.9 7.64 6.64** 0.036 
* X (1) 
2 
of heterogeneity between RR (0-8) and RR (8-17) 
** X (2) 2 of heterogeneity be""-"'en RR (0-8), RR (8-17) and RR 1>17) 
'P value of the x2 for heterogeneity 
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The frequencies of HLA-DR3 and -DR4 were the highest in the youn-
gest age category and showed a gradual decrease in frequency in 
the middle and oldest age category. The differences among the re-
lative risks for HLA-DR3 were not significant. However, inclusion 
of the oldest age category resulted in significant heterogeneity 
of the relative risks for HLA-DR4 (p = 0.036). Because of the 
latter heterogeneity, we restricted the further analysis in this 
report, to the patients with onset of IDD before the age of 17. 
Population analysis 
7 5 Unrelated patient.s with onset before 17 years were analysed 
for HLA, and compared to the results of normal controls. The re-
sults are shown in table 2. 
Table 2. HLA antigen distribution in IDD patients (n 75) and 
normal controls. 
Phenotype Patients Normal Rel. x2 P value Etiologic 
(n ~ 75) controls Risk fraction 
(n ~ 1018) 
HLA! pos. (%) pas. (%) 
B7 9 (12) 282(27.7) 0.4 8.142 0.005 
B8 33 (33) 133 (24.0) 1.4 14.426 0.000* 0.118 
B12 11 (15) 260 (25. 6) 0. 5 3.950 0.044 
B15 23 (31) 173(17.0) 2.2 8.934 0.003 0.169 
B18 12 (16) 73 (7. 2) 2. 5 8.059 0.005 0.095 
Bw22 0 (0) 48 (4. 7) 0.1 3.952 0.044 
Cw3 36 (48) 351 (34. 7) 1.7 5.460 0.018 0.200 
Cw4 7 (9) 215 (21. 2) 0.4 5.425 0.019 
(n ~ 201) 
DR1 10 (13) 40(19.9) 0. 6 1. 466 0.224 
DR2 2 (3) 56(27.9) 0.1 15.785 0.000* 
DR3 46 (61) 58(28.8) 3. 9 23.297 0.000* 0.457 
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Table 2 continued. HLA antigen distribution in IDD patients 
(n = 75) and normal controls. 
Phenotype Patients Normal Rel. 
Risk 
HLA! 
DR4 
DRS 
DRw6 
DR7 
DRw8 
DRw9 
DRwlO 
(n = 75) controls 
(n = 1018) 
pas.(%) 
56 (75) 
3 (4) 
11(15) 
4 (5) 
2 (3) 
2 (3) 
0 (O) 
pos. (%) 
49(24.4) 8.9 50.933 
35(17.4) 0.2 7.417 
59(29.4) 
50(24.9) 
5 (2. 5) 
5 (2. 5) 
10 (5. 0) 
0.4 6.827 
0.2 11.575 
1.2 0.073 
1.2 0.069 
0.1 3.661 
P value 
0.000* 
0.007 
0.009 
0.001* 
0. 777 
0.782 
0.053 
Etiologic 
fraction 
0.665 
HIA-A, -B, and -c antigens included if significant before cor-
rection for number of comparisons 
* Significant after correction for 40 comparisons 
The frequencies of HLA-DR3 and -DR4 were significantly increased 
in patients with a relative risk of 3.9 and 8.9, respectively. 
The corresponding values of the etiologic fraction confirmed the 
strong positive association with HLA-DR3 and especially with HLA-
DR4, and indicated a weaker association with B locus antigens, 
-88, -BlS and -Bl8. HLA-DR2, -DRS, -DR7 and HLA-B7 were decreased 
among the patients. Taking into account the associations with DR3 
and DR4, only DR2 appeared to be decreased significantly (data 
not shown) . 
Table 3 shows the analysis of H-W equilibrium among patients and 
controls. It must be noted that the patients sample is not a true 
population in the genetical sense, and that within the present 
patient .group heterogeneity might still exist, as some patients 
come from simplex and others from multiplex families. That this 
ascertainment difference is not critical as far as the HLA-DR 
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frequencies are concerned, may be seen from the separate figures 
shown in table 3. 
Table 3. Analysis of Hardy-Weinberg equilibrium in IDD patients 
(n = 75) and controls (n 201) 
Patients Controls 
(0-E) 2 (0-E) 2 
OBS. EXP. E OBS. EXP. E 
Mult.Simpl. Total 
DR3/x (0+ 8) 8 12.48 1. 61 48 45.06 0.19 
DR3/3 (3+ 3) 6 9.01 1. 01 5 4.98 0.00 
DR3/4 (9+23) 32 21.49 5.41 5 8.25 1. 28 
DR4/4 (2+ 4) 6 12.81 3.61 3 3.41 0.05 
DR4/x (5+13) 18 14.87 0.66 41 37.33 0.36 
DRx/x (3+ 2) 5 4.32 010 99 101.96 0.09 
(22+53) 75 74.98 11.95 201 200.99 1. 97 
X(3) 2 11.95 X(3) 2 1. 97 
p 0.0075 p NS 
Gene frequency patients Gene frequency controls 
DR3: 52/150 0.3467 DR3 0.1574 
DR4: 62/150 0.4133 DR4 0.1304 
DRx:36/150 0.2400 DRx 0. 7122 
The gene frequencies of HLA-DR3 and -DR4 did not differ between 
simplex and rnul tip lex propositi (maximal difference 2 percent) , 
and also the frequency of HLA-DR3/4 propositi is remarkably simi-
lar (43 and 41 percent, respectively) for these two categories. 
Therefore, we pooled the propositi for analysis of H-W equilibri-
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urn. Whereas the control population did not deviate significantly 
from H-W equilibrium, the distribution of the allelic combina-
tions in patients was significantly different from the expecta-
tion of H-W equilibrium (X2 = 11.95, p = 0.008). The homozygous 
DR3 I 3 and DR4/4 combinations were relatively decreased in fre-
quency. The heterozygote DR3/4 combination was increased in fre-
quency and contributed with 5.41 most to the chi-square value. It 
must be noted that these calculations are conservative, because 
in the homozygous DR3/3 and DR4/4 subgroups, the phenotypes with 
a possible blank allele were included. 
Table 4 presents a comparison of HLA-DR phenotypes in patients 
and controls. A significant increase was found in relative risk 
for DR3/4 heterozygotes (RR = 26.7) and for DR3 and DR4 homozygo-
tes (RR ~ 3.3 and RR = 5.3, respectively). The highest odd ratio 
(OR), as defined by Svejgaard and Ryder (31) , among the possible 
allelic combinations was observed for heterozygote DR3/4. 
Table 4. HLA-DR allelic combinations in IDD (n 75) 
patients and controls (n = 201) 
Phenotype Patients Controls Rel.Risk x2 Etiologic Odd's # 
DR3/x* 
DR3/3 
DR3/4 
DR4/4 
DR4/x 
DRx/x 
(75) (201) 
pos. (%) pos. (%) 
8 (11) 
6 (8) 
32 (43) 
6 (B) 
18(24) 
5 (7) 
48(23.8) 0.4 
5 (2.5) 3.3 
5 (2.5) 26.7 
3 (1.5) 5.3 
41(20.4) 1.2 
99(49.3) 0.08 
75 201 
x* denotes non-DR3 , non-DR4 
5.54 
4.42 
47.99 
6.75 
0.48 
31.71 
fraction 
0.057 
0.412 
0.066 
0.045 
# Cdd's ratio, calculated according to Svejgaard (31), using 
DRx/x as reference group 
ratio 
3.3 
23.8 
126.7 
39.6 
8.7 
1. 
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In comparing the different OR's, the OR (DR3/4) vs OR (DR4/4) can 
be calculated as (32 x 3)/(5 x 6) = 3.2 (exact P = 0.17). Simi-
larly, the OR (DR3/4) vs OR (DR3/3) equaled 5.3 (exact P 
0.036). In addition, the OR (DR3/3) vs (DR3/x) was 7.2 and OR 
(DR4/4) vs (DR4/x) was 4.6. The latter two values differed signi-
ficantly from unity with P exact values of 0.01 and 0.04, respec-
tively. 
A strong association with DR3 and DR4 and a lower, but signifi-
cant association with B8, B18 and BlS had led us to consider the 
question whether the B locus association was part of a r·eal hap-
lotype association, or was rather an association secondary to 
HLA-DR, due to linkage disequilibrium. To investigate the pre-
sence of a haplotype association, we employed the method des-
cribed by Porta and McHugh (16). 
Table 5. Test of HLA-B8-DR3 and HLA-Bl5-DR4 haplotype association 
with IDD 
Haplotype Genetic Estimate 
model Delta =I= 
haplotype 
B8-DR3 RAD 0.1485 
AR 0.0775 
Bl5-DR4 RAD 0.1782 
AR 0.1054 
RAD = Rare autosanal dcminant 
AR = Autosomal recessive 
of S.E. 0 Z* 
0.0587 2.5310 
0.0336 2.3065 
0.0513 3.4756 
0.0205 3.7016 
# = Delta refers to value of third order linkage disequilibrium 
0 SE = Standard error 
*Z = Denotes the value on the abscis of a nonnal distribution 
P value 
0.02 
0.02 
0.01 
0.01 
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We selected two antigen combinations with a positive association 
in IDD and known to occur in linkage disequilibrium, namely HLA-
BB, -DR3 and HLA-Bl5, -DR4. Both HLA-B8, -DR3 and HLA-BlS, -DR4 
haplotypes revealed a significant haplotype association in IDD 
patients, tested in the RAD and the AR model (table 5). 
Multiplex families 
Twenty-two multiplex families were genotyped for HLA-A, -B, -c, 
-DR and most families for BF, C2, C4, GLO and GM. 21 Informative 
families were investigated for segregation analysis of HLA haplo-
types. 
Table 6 presents the HLA segregation data and it compares the 
number of HLA haplotypes of the index patient shared in affected 
and normal siblings. Assuming random segregation, the expected 
Mendelian ratio is 1 : 2 : 1 for sibs sharing both one or no hap-
lotype with the propositus. A departure of the observed from the 
expected ratio can be analysed with a chi-square test with two 
degrees of freedom. 
The families were divided in three groups: group A: families with 
two affected siblings; group B: families with more than two af-
fected siblings; group C: families with two affected siblings and 
one affected parent. 
Affected siblings in group A shared both haplotypes with the pro-
positus significantly more often than expected (X2 22). In 
group B the relative proportion of sharing one haplotype was in-
creased (X2 = 4.7) and in group C the observed ratio was not sig-
nificantly different from the expected {X 2 = 0.33). The normal 
sibs in group A showed also a significant departure in the other 
direction from the 1 : 2 : 1 ratio in sharing haplotypes with the 
propositus {X2 = 6.8; P = 0,034). 
Another observation relates to the occurrence of cross-overs be-
tween HLA-DR and the GLO locus, which is located centromeric of 
HLA-DR at 4 percent of recombination in males (34). Cross-overs 
in one of an affected sibpair suggest that the gene segment pre-
disposing for IDD is located to the telomeric, HLA-DR side of the 
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chromosome (32). We observed in our families from a total of 91 
informative meioses, six HLA-DR/GLO cross-overs. Two occurred in 
normal siblings and three in HLA-identical affected sibpairs. One 
cross-over in a haplotype-identical sibpair was of undetermined 
parental origin. 
Table 6. HLA haplotype sharing with propositus in 21 multiplex 
families with IDD 
Families with No of haplotypes shared with propositus 
IDD in 
affected sibs normal sibs 
total 2 1 0 total 2 1 0 
A. Two sibs (n=2) (12) 10 2 0 (30) 2 16 12 
B. More than two 
sibs (n=3) 171 4 3 0 (9) 1 6 2 
+ + 
Subtotal (19) 14 5 0 (39) 3 22 14 
c. Two sibs, one 
parent (n=6) I 61 2 3 1 (9) 2 6 1 
+ + 
TOTAL (25) 16 8 1 (48) 5 28 15 
affected sibs normal sibs 
X2' p X2' p 
A 22 0.01 6. 8 0.03 
B 4. 7 0.09 0.9 NS 
c 0.33 NS 1. 22 NS 
A + B 24.89 0.01 6.85 0.03 
A + B + c 21.24 0.01 5. 5 0.06 
ox
2 
= chi-square with tvJo degrees of freedom 
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The fact that three affected sibpairs were HLA-identicalt but 
different for GLO, confirmed that the "hot" segment for IDD was 
located towards the HLA-DR side of the chromosome. 
Another way of characterizing the HLA-haplotypes associated with 
IDD is shown in table 7. The unrelated haplotypes encountered in 
patients {"diabetic" haplotypes) are clustered according to their 
HLA specificities. In the meantime the same approach has been re-
ported in families from France (35). Three haplotypes were con-
firmed to occur frequently among the IDD patients. 
a} Al, BS, BPS, C2,1, C4AQ0, C4Bl, DR3, GL02 
b) Aw30, Cw5, Bl8, BFFl, C2.1, C4A3, C4BQ0, DR3, GL02 
c) A2, Cw3, BlS, BFS, C2.1, C4A3, C4B3, DR4, GLOl 
In addition to this observation, the haplotype clusters showed 
that "historical 1' cross-overs at the GLO side and the HLA-A side 
of the haplotypes occurred. Apparently these cross-overs did not 
change the diabetogenic properties of the haplotypes and inspec-
tion of the clusters seems to confine the diabetogenic segment of 
the B-DR segment. 
The gene frequencies of HLA-DR3 and -DR4 (counted from table 7) 
were lower in the 11 warm" haplotypes than those in the "hot" hap-
lotypes, but these differences were not significant. 
Table 7. Diabetic ("hot" and "warm") haplotypes, in 22 multiplex 
families, with IDD in two or more IDD patients 
FAM HAPL H/W HLAA HLAC HLAB BF C2 C4A C4B DR LB LBE GLOI 
011 a w 33 14 s 1 2 2 1 12 2 
003 d H 24 39 NA 1 1 12 
025 a H 2 39 F 1 3 QO 1 12 2 
012 b w 24 4 35 F 1 1 12 2 
013 c H 2 7 s l (3) (1) 2 12 2 
013 a w 2 44 (12) s 1 3 1 2 12 2 
010 c w 3 4 35 s 1 3 1 2 12 1 
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Table 7 continued. 
FAM HAPL H/W HLAA HLAC HLAB BF C2 C4A C4B DR LB LEE GLOI 
005 
019 
021 
022 
022 
009 
002 
027 
025 
026 
024 
012 
004 
009 
017 
002 
015 
019 
015 
018 
013 
026 
026 
004 
003 
001 
011 
015 
001 
024 
012 
027 
a 
b 
c 
a 
c 
c 
d 
c 
c 
c 
a 
a 
a 
a 
d 
c 
a 
c 
b 
b 
b 
a 
b 
c 
b 
b 
c 
c 
d 
d 
c 
a 
H 
H 
H 
w 
H 
H 
w 
H 
H 
H 
H 
w 
H 
H 
H 
w 
w 
H 
w 
w 
w 
w 
w 
H 
H 
H 
H 
H 
H 
H 
H 
H 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
3 
30 
30 
2 
2 
31 
31 
3 
24 
24 
3 
2 
2 
2 
2 
2 
3 
2 
11 
2 
3 
3 
5 
5 
5 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
6 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
NA 1 
s 1 
s 1 
(S) 1 
s 1 
s 1 
8 s 1 
1 39 (16) s 
18 
18 Fl 
18 Fl 
35 
60 
60 
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7 
7 
7 
14 
62(15) 
s 
s 
F 
s 
s 
s 
1 
1 
1 
1 
1 
1 
1 
1 
62 (15) NA 1 
62(15) s 1 
62(15) s 1 
62(15) s 1 
62(15) s 1 
62(15) s 1 
1 
3 
3 
3 
3 
3 
QO 1 3 
QO 1 3 
QO 1 3 
QO 1 3 
QO 1 3 
QO 1 3 
3 
3 
3 QO 3 
3 QO 3 
3 
3 
1 3 
1 3 
3 
17 
17 
17 
17 
17 
17 
17 
17 
17 
17 
17 
3 QO 4 4 13 
4 4 13 
3 QO 4 4 13 
3 1 4 4 13 
QO 1 4 4 13 
4 
4 
3 3 4 
(3) (1) 4 
3 3 4 
3 3 4 
3 QO 4 
4 
4 
4 
4 
4 
4 
4 
13 
13 
13 
13 
13 
13 
13 
4 13 39 (16) s 
57(17) s NA 6 1 4 4 13 
2 
2 
2 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1 
1 
2 
1 
1 
1 
1 
1 
2 
2 
1 
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Table 7 continued. 
FAM HAPL H/W HLAA HLAC HLAB BF C2 C4A C4B DR LB LEE GLOI 
017 a H 25 18 s 1 3 1 4 4 13 1 
006 b H 2 2 27 4 4 13 1.2 
022 b H 2 2 27 4 4 13 
021 a H 3 2 27 4 4 13 1 
002 b H 3 6 37 F 1 3 1 4 4 13 1 
005 c H 24 6 37 NA NA 4 4 13 2 
023 d H 31 3 60 (40) s 1 3 1 4 4 13 1 
023 a H 2 44 (12) s 1 3 1 5 5 13 1 
001 a w 24 18 s 1 3 1 5 5 13 2 
018 c w 2 3 62 (15) 6 12 1 
018 a w 33 3 58 (17) 6 12 1 
011 b H 24 3 55 (22) s 2 4 5 6 12 2 
010 a H 11 4 35 s 2 3 1 6 12 1 
024 c w 2 3 60 (40) s 1 QO 2 6 12 2 
006 c H 2 3 60 (40) 6 12 1.2 
018 d w 2 6 50 (5) 7 7 17 1 
010 d H 3 13 s 1 3 1 7 7 17 1 
Legend to table 7 
HAPL = haplotype LBE =defined by serum MO which 
H/W = "hot" and "wann" recognizes MB2 + DR3 
LB = subtypes of HLA-DR. See for definition of LB and 
LB4 and LBlO are LBE reference 44. 
defined as a split NA = no activity 
of DR4, LB5 and LB58 = not tested 
of DRS and LB7 and QO = Quantity zero = null 
LBll of DR7 allele 
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Table 8 shows an analysis of non-random segregation for GM to af-
fected siblings. In none of the three families we found evidence 
for non-random segregation of parental GM haplotypes. Thus, these 
data do not provide evidence for a predisposing gene for IDD re-
lated to genes coding for immunoglobulin heavy chains. 
Table 8. Segregation of GM haplotypes to affected children in 
21 multiplex families with IDD 
Segregation of 
parental haplo-
types in fami-
lies with 
A. Healthy parent, 
No of No of 
families informa-
tive pa-
rents 
two affected sibs: 12 7 
B. Healthy parent, 
three affected 
sibs: 3 4 
c. Affected parent, 
two affected sibs: 6 3 
NS = Not significant 
Discussion 
SD 
8 7 7 0.036 NS 
3 5.5 3.25 1.231 NS 
2 3 
A + B 
A + B + C 
3 0.083 NS 
0.098 NS 
0.3 NS 
p 
Our study describes the role of immunogenetic factors in insulin-
dependent diabetes as detected in unrelated patients and multi-
plex families with IDD in The Netherlands. 
52 
We will consider the following aspects in more detail. 
1. Genetic heterogeneity related to age of onset of IDD. 
2. Associations in unrelated patients. 
3. Genetics in multiplex families with regard to liLA-segregation, 
occurrence of cross-overs and haplotypes. 
4. Segregation of GM. 
Age of onset. 
1. We have investigated the frequencies of HLA-DR3 and HLA-DR4 in 
IDD patients with regard to age of onset. Comparing three age 
groups, we found that the frequencies of both HLA-DR3 and -DR4 
decreased with older age of onset and that the relative risk 
of HLA-DR4 was significantly heterogenous. Whereas in patients 
with onset at adult age, IDD may be diluted with NIDD, we fa-
vour another explanation for the observed heterogeneity. 
Because IDD is a disease caused by a mixture of genetic and 
environmental factors, one might expect that at younger age, 
where the exposure time to environmental factors is shorter, 
the genetic factors are more prominent. 
Evidence for this hypothesis was recently reported in a study, 
which showed an increased recurrence of IDD in sibs of propo-
siti with onset of IDD before the age of ten as compared with 
that in sibs of probands with onset after the age of ten {36). 
To make a genetic analysis more meaningful, we excluded for 
further study the patients with onset of the disease after the 
age of 17. Although the cut-off point of 17 may be arbitrari-
ly, it coincided with excluding patients from the adult cli-
nic. 
2. The patient and control sample were investigated for the pre-
sence of H-W equilibrium and the data of the patients were 
compared with those expected under various genetic models. As 
stated before, this analysis requires the sample to be chosen 
randomly from a large random mating population. A priori this 
assumption may not be fulfilled. 
However, we considered our patient and control population to 
be fairly homogeneous with regard to ethnic background, be-
cause only individuals of Dutch Caucasoid extraction were in-
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eluded. Moreover, we reduced heterogeneity within the patients 
by confining the analysis to patients with onset of the dis-
ease before the age of 17. Although the ascertainment was not 
the same for all the patients, it appeared that the observed 
gene frequencies and allelic combinations of HLA-DR were very 
similar in the population and multiplex family sample. 
Under the assumption of a single recessive susceptibility gene 
in linkage disequilibrium with HLA-DR3 and -DR4, the expected 
proportions of allelic combinations are in H-W equilibrium 
(37). However, the observed proportions deviated significant-
ly from expected, providing evidence against a single reces-
sive model. 
Moreover, the excess of observed over expected HLA-DR3/4 he-
terozygotes is incompatible with a single dominant or inter-
mediate model {37). In a different approach we compared the 
odd's ratio's (OR) of the different allelic combinations, em-
ploying the method of Svejgaard and Ryder (31). They showed 
that the OR of the heterozygote DR3/4 would fall between the 
two homozygote OR's, if the disease were due to a single sus-
ceptibility gene acting as recessive, dominant or intermediate 
gene. 
The observed excess of the OR (DR3/4) over OR {DR3/3), provi-
ded in another way evidence against a simple recessive, inter-
mediate or dominant model. 
Information in determining the mode of inheritance can be also 
derived from the haplotype segregation in families. 
3. Without considering the allelic combination of HLA-haplotypes, 
the multiplex families demonstrate an excess of sharing both 
HLA-haplotypes among pairs of affected sibs. The observation 
that the families with an affected parent less often demon-
strate HLA identity among affected sibs than families with two 
normal parents, can be explained by an increased conditional 
probability of observing susceptible genotypes in the children 
of affected parents, as compared to genotypes segregating from 
normal parents (32). Thus, also the high frequency of sharing 
both haplotypes in affected sibpairs indicates that a dominant 
model of inheritance can be ruled out. Moreover, the combined 
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data of the allelic combinations in unrelated patients and of 
the haplotype segregation in multiplex families, do not fit a 
simple recessive or intermediate mode of inheritance. There-
fore, more complex genetic models seem to be required to des-
cribe the relationship between the HLA system and IDD ade-
quately. 
We considered the possibility that HLA-haplotypes rather than 
a particular antigen were associated with IDD. Based on popu-
lation data we found evidence that HLA-B8, -DR3 and HLA-BlS, 
-DR4 haplotypes manifested a third order linkage disequili-
brium under a RAD and AR model. This observation seems compa-
tible with a susceptibility gene between HLA-B and -DR or with 
a set of genes with an additive or interactive effect. Al-
though the conclusion of a haplotype association should be ta-
ken with some caution, because the patient population is not a 
true population in genetical sense and the assumptions of the 
mode of inheritance are only partially valid, the difference 
of linkage disequilibrium of these haplotypes in patients as 
compared to normal controls, seems worthwhile in considering 
the genetics of IDD. 
The occurrence of cross-overs between HLA-DR and GLO in one of 
an affected sibpair enabled us to localize the diabetic seg-
ment towards the HLA-DR segment of the chromosome. We cannot, 
however, determine at present what the distance is of the 
11 hot" diabetic segment to GLO. Markers between GLO and HLA-DR 
would allow to answer this question, and the newly discovered 
SB locus (38) may turn out to be a very good candidate for re-
solving this question {39) . 
Another way of further characterizing the chromosomal segment 
associated, is the analysis of haplotypes occurring in affec-
ted sibs as shown in table 7. 
Sorting of diabetic haplotypes reveals clusters of chromosomal 
segments selected for being diabetogenic. Inspection of these 
clusters indicates that "historical" cross-overs have occurred 
both on the GLO and the HLA-A side of the haplotypes, and that 
the identity of the segments concentrates around the HLA-B-DR 
region. Three clusters have been delineated, that previously 
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were reported to occur in IDD patients (35) . Considering that 
these haplotypes are unrelated, it is striking to see that in 
these three clusters the identity even seems to extend from 
HLA-A to GLO. Because, at present we have no appropriate data 
on control genotypes, the significance of the latter observa-
tion remains to be determined. 
However, our population data suggest that indeed an increased 
linkage disequilibrium occurred in patients as compared to 
normal controls, with regard to the haplotype HLA-B8-DR3 and 
HLA-Bl5-DR4. 
4. In a search for genetic factors in IDD, not related to HLA, we 
investigated GM as a marker system, because GM has been impli-
cated in other HLA-associated diseases such as chronic active 
hepatitis and myasthenia gravis {19,20). In the present fami-
lies we found no evidence for non-random segregation of GM 
haplotypes. 
This observation may not be generalized to all families with 
IDD, because a recent study demonstrated that non-HLA factors 
may only be prominent in families with a propositus negative 
for HLA-DR3 and DR4 ( 40) . 
Taken together, the results of this study suggest that the HLA 
system is associated with a major susceptibility effect for IDD. 
Moreover HLA-DR4, or a susceptibility gene in linkage disequili-
brium with it, is associated with age of onset. In addition, the 
data provide strong evidence against a single recessive, inter-
mediate or dominant mode of inheritance of the susceptibility 
genes. Therefore more complex models are required to account for 
the data (40). 
With regard to more complex models, it is relevant to consider 
some molecular aspects of the MHC system. The HLA-DR or class II 
molecules consist of an alpha and beta chain that are encoded by 
two closely linked loci (41). In the MHC of the mouse it has been 
shown that these class II molecules are the products of the immu-
ne response genes {42). These alpha and beta loci act in comple-
mentation and hybrid alpha-beta molecules of both cis- and trans-
complementation can be formed. 
In addition to the creation of "new" hybrid molecules as the re-
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sult of transcomplementation, it has been shown that preference 
for cis- or transcomplementation is dependent on the allelic com-
bination of haplotypes (43). This preference is reflected in an 
immune response gene effect (43). 
By analogy, one could suggest that in humans both HLA-DR3 and 
-DR4 are associated with susceptibility for IDD, and that in a 
heterozygote DR3/4 a preferential transcomplementation leads to 
an even increased susceptibility for IDD. However, because this 
possibility does not easily explain the observed B-DR haplotype 
association, one should also consider the possibility, that a 
gene interaction between alleles coding for class I and class II 
(and perhaps even class III) HLA molecules might be involved in 
the susceptibility for IDD. 
Thus recognition of fine specificities of the HLA-region has also 
implications for the study of the molecular mechanisms underlying 
the susceptibility of IDD. 
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Summary 
Neonatal onset permanent diabetes mellitus is extremely rare and 
pathogenetic mechanisms are suspected to differ from those des-
cribed in childhood diabetes developing at later ages. The pre-
sent child had other HLA-types than mostly seen in childhood dia-
betes, lacked islet-cell auto-immunity but did have features of 
the fetal alcohol syndrome. Other (genetic) syndromes associated 
with diabetes at very young ages were excluded. 
Introduction 
Since the fetal alcohol syndrome was rediscovered in 1973 (1) a 
variety of associated anomalies have been reported, including ex-
trahepatic biliary atresia, and renal anomalies (2). We report 
ketotic diabetes mellitus starting the seventh day of life in a 
child with features of the fetal alcohol syndrome. 
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Case report 
A 2200 g boy was born in another hospital to a 29 year old mother 
after an unknown duration of gestation. Although length and head-
circumference were not recorded at birth, a "small-for-date ap-
pearance" was noted. The pregnancy was complicated by the daily 
ingestion of unknown quantities of beer and wine, and by the in-
gestion of half a litre or more of dutch gin per day intermit-
tendly in the third month of pregnancy, during a summer vacation. 
Previously two healthy children had been born. The mother thought 
she had taken less alcohol during those pregnancies. Two years 
before the mother had an oral glucose tolerance test with normal 
result. This was only done because her mother had developed glu-
cose intolerance at age 60 and the mother herself had complaints 
of thirst at that time. In the last trimester of this and previ-
ous pregnancies no glucose was found in the urine. Except for am-
pillicin for a urinary tract infection no medication was taken by 
the mother, as evidenced from her pharmacy 1 s record. She smoked 
20-40 cigarettes daily. Lues was excluded. The placenta weighed 
400g. Microscopy revealed the partial presence of a single layer 
of trophoblast-cells, but no other abnormalities. 
At birth fetal alcohol syndrome was not suspected. Maximal bili-
rubin was 65 jlMol/1 at the fourth day of life. On the seventh 
day of life mild glycosuria was detected, without ketonuria. This 
gradually increased up to 20 g per 24 hrs and the child was re-
ferred to our hospital at the age of 13 weeks. 
At that time weight was 3400 g (lOth percentile), length 53 em 
( < -2 SO), headcircumference 34.2 em ( < -2 SD). On physical exa-
mination features of the fetal alcohol syndrome were found {1). 
These are tabulated in table l. 
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Table 1 
SYMPTOMS IN INDEX CASE COMPARED TO THE FETAL 
ALCOHOL SYNDROME (FAS) 
SYMPTOM: 
GROWTH: 
prenatal length 
postnatal length 
adipose tissue 
CNS-DYSFUNCTION: 
mental deficiency, 
mild-moderate 
microcephaly 
poor coordination/ 
hypotonia 
irritability 
hyperactivity 
FACIAL/HEAD: 
~plO 
~plO 
short palpebral fissures 
short nose 
hypoplastic philtrum 
maxillar hypoplasia 
thin upper vermillion 
retrognathia 
ptosis/strabismus 
eye abnormality 
ear malposition 
prominent palatal ridges 
small teeth 
CARDIAC: 
defects 
INDEX CASE 
? 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
** 
+I-
+ 
+ 
+ 
% PAS-PATIENTS 
SHOWING SYMPTOMS 
80 
80 
50 
80 
80 
50 
80 
50 
80 
50 
80 
50 
80 
50 
26-50 
26-50 
26-50 
26-50 
1-25 
26-50 
* 
Table 1 continued. 
URINARY TRACT: 
hypospadia's 
small kidneys, 
hydronephrosis 
CUTANEOUS: 
* 
** 
hemangioma's 
hirsutism 
data from reference 
+ is present; - is absent 
+ 
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1-25 
1-25 
26-50 
1-25 
Initial laboratory results included: an oral glucose tolerance 
test (1.75 g/kg) with glucose rising from 8 to 25.4 mMol/1, all 
insulin values below 1 mU/1, glucagon 36-98 ng/1 (normal up to 80 
ng/1), growth hormone elevated ranging from 10 to over 40 mU/1. 
Pre-treatment random blood-glucoses varied from 9-38 mMol, urina-
ry ketones were only present in minor amounts. A 24 hrs urine 
analysis for amino-acids and oligosaccharides were normal, except 
for glucose. The diurnal rhythm for cortisol was normal. Chromo-
some-analysis using trypsin-Giemsa banding was normal male ( 4 6, 
XY) • Epiphyseal dysplasia, cystic fibrosis, exocrine pancreas 
dysfunction, and coeliac disease were excluded. Thyroid function 
was low normal, TSH never elevated. Tests for liver and kidney 
function, blood gases, electrolytes and hematology were unremark-
able. 
Insulin substitution was initiated at the age of 15 weeks in 
single or multiple dosages not exceeding 0.7 U/kg, using mixtures 
of short- and intermediate-acting insulin. Despite the careful 
administration of these little amounts of insulin, blood glucoses 
bounced from 1.8 up to 25 mMol/1 in an erratic fashion. Glycosy-
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lated hemoglobins varied from 10-14% (6-8% in normal children) 
and urinary ketones (2+ or more) were found twice weekly on the 
average. Frank hypoglycemia occurred two times, the child quickly 
recovering on oral glucose administration. Keto-acidosis 
(pH< 7 .2) was first seen at the age of 6 months during an upper 
respiratory tract infection. Respiratory tract infections recur-
red, requiring adenotonsillectomy, ear-tubes for chronic otitis 
and antibiotics for Haemophilus and Proteus bacteria. Keto-acido-
sis requiring admission occurred two times thereafter. Recovery 
with intravenous insulin and electrolyte solutions was normal. 
Diaper-dermatitis was present, requiring almost chronic local 
treatment mostly for Candida. Staphylococcus folliculitis was 
seen four times. Immunoglobulins, including secretory IgA and 
complement-factors were normal for age. Islet-cell cytoplasmatic 
antibodies, thyroid antibodies, adrenal antibodies and gastric 
antibodies were first tested at 8 months, subsequently with year-
ly intervals. No positive results were obtained, neither in the 
family. The patients' HLA-D-genotype was HLA-DRl and HLA-DRS. Hy-
perrea_cti vi ty and irritability were almost constantly present. 
Fine-motor seizures and athetotic movements lasting 5-10 minutes 
became apparent during the second year of life. Electroencephalo-
graphy revealed aspecific epileptic activity, for which phenobar-
bital and phenytoin were prescribed. At present the child is 4 
years and 10 months old, has severe growth and mental retarda-
tion, and stays in an institution for handicapped children. 
Comment 
Diabetes mellitus has not been recognized as a symptom of the fe-
tal alcohol syndrome; however, the present case suggests the pos-
sibility of such an association. 
Permanent insulin dependent diabetes developing before the age of 
six months is extremely rare. In a recent nation-wide incidence 
study over three years time only 3/1271 newly diagnosed children 
from 0-19 years of age became permanently insulin dependent be-
fore the age of six months (3). One was the present patient, the 
other two had multiple congenital malformations, other than seen 
67 
in the fetal alcohol syndrome. The term congenital diabetes has 
been used to indicate failure of fetal development of islets of 
Langerhans (hypoplasia or aplasia of islets) . Only one well docu-
mented case is known to have been delivered alive, and it is be-
lieved that congenital diabetes is essentially non-existent (4). 
As glucose-intolerance developed gradually some days after birth 
in the present case, it may be presumed the neonatal pancreatic 
response was sufficient during the first week of life to prevent 
diabetic symptoms. Insulin dependency was documented by hypergly-
cemia, ketonuria, absolute insulin deficiency, relative hyperglu-
cagonemia and elevated growth hormone levels. These endocrine 
findings are compatible with selective insulin deficiency. No au-
toantibodies to islet-cells were found within one year of the 
clinical onset of insulin deficiency in this patient and his HLA-
DR-type was neither HLA-DR3 nor HLA-DR4. These immunologic fin-
dings speak against the autoimmune involvement of the islets seen 
in childhood diabetes: 80% of the newly diagnosed children at ol-
der ages have such antibodies at diagnosis and 60% after one year 
of treatment (5). 
Almost all children with an age of onset below 8 years studied in 
the Netherlands had HLA-DR3 and/or HLA-DR4 haplotypes as well as 
90% or more of children studied elsewhere with older ages of on-
set (6, 7). The present patient's HLA-genotype comprised neither 
of these haplotypes. Other etiologic factors may be supposed in 
this highly unusual presentation of childhood diabetes, but the 
known genetic syndromes in which diabetes mellitus concurs were 
excluded. 
The amounts of alcohol ingested during gestation were probably 
not as high as those reported in cases of children with the fetal 
alcohol syndrome in which cases permanent alcohol consumption 
throughout gestation is believed to occur (2). It has been sug-
gested that 90 ml of absolute alcohol per day (equivalent to some 
six hard drinks) constitutes a major risk to the fetus (7). The 
present history contained an intermittend alcohol consumption, 
far exceeding this quantity during the third month of pregnancy 
by history and there appears enough descriptive evidence (table 
1) to at least suppose fetal alcohol effects. 
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The time sequence as well as the quantities of the gestational 
alcohol ingestion may be related to the partial expression of the 
fetal alcohol syndrome of the present case. Hitherto, insulin de-
pendency has never been seen in the full syndrome. This does not 
preclude interference with the development of the functions of 
islet-cells during fetal life to a lesser extent than leading to 
frank insulin dependency: insulin levels in the full fetal alco-
hol syndrome have not been reported although it is known many of 
such children brought in at later ages were referred for "being 
too skinny" and there are no follow-up data with regard to this 
clinical feature (2). 
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Summary 
In three children (patients 1, 2 and 3) insulin-dependency was 
predicted 28, 32 and 4 months before the disease became clinical-
ly manifest, respectively, by the finding of islet-cell antibo-
dies at that time. 
These retrospective findings confirm the evidence for a long pre-
diabetic phase in childhood diabetes, marked by the presence of 
islet-cell antibodies, as well as the linkage of HLA-antigens to 
the susceptibility to this disease. 
The possibility to detect pre-diabetic states in children before 
the endogenous insulin secretion decreases to the point of clini-
cal symptoms, supports efforts by basic scientists to develop 
techniques for immunologic intervention early in the course of 
this disease. 
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Introduction 
It is well known that diabetes mellitus shows a familial tenden-
cy. However, attempts to assess modes of inheritance failed, be-
fore it was realized type-1 (insulin-dependent) diabetes mellitus 
(IDDM) is a distinct disorder from type-2 (non-insulin-dependent) 
diabetes mellitus (NIDDM) ( 1) . 
From the Pediatric Register of the British Diabetic Association 
it has been estimated that 5. 7% of the siblings of diabetic 
children will develop insulin dependency themselves by the age of 
16 years (2) . In the Pittsburgh studies (3) the recurrence risks 
for siblings in families already having a type-1-diabetic child 
by the age of 20 years was 3.3% to 6.0%, depending on the calcu-
lation methods. 
In the past decade two factors have been associated with the re-
currence risk for siblings of diabetic children: one is HLA iden-
tity, on the basis of the fact that the genetic susceptibility to 
the disease is strongly HLA-linked (4); the other is the presence 
of islet-cell cytoplasmatic antibodies (ICCA), found in 80% of 
the newly diagnosed children with IDDM (S) • 
The question to what extent these two factors might predict fu-
ture type-1-diabetes in families of affected children has been 
investigated in the Barts-Windsor Family study (6) . 
They found that sibs HLA-identical to the already diabetic child, 
would have a 100 times greater risk of developing the disease 
themselves, whereas non-HLA-identical sibs would have the same 
risk as the general population. In that prospective study each of 
the six siblings that did develop diabetes in the course of their 
follow-up (up to 4 years at the time of the report) did have ICCA 
from the moment they entered the study, whereas in a control po-
pulation 1% positives for the presence of ICCA were found. The 
study indicated that type-1-diabetes in children has a long pre-
diabetic period and carries implications for future research into 
preventive measures before the disease becomes clinically mani-
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fest. 
The present report describes three children retrospectively (pa-
tients 1, 2 and 3), in which diabetes mellitus was predicted 28, 
32 and 4 months before the disease became clinically manifest, 
based on the finding of islet-cell antibodies. 
Patients 
Patient 1 
Patient 1 participated in a study on genetic markers in families 
with two or more children having type-1-diabetes, described in 
detail elsewhere (7) . Blood was also drawn for the determination 
of ICCA. This study included 22 families, selected from all over 
the Netherlands on the basis of their willingness to cooperation. 
It was agreed upon beforehand with each of the 22 families that 
single blood drawings would be done and that the results of the 
tests would not be disclosed. The 22 families had 111 children in 
total, aged 2-20 years {average 11.6 years), 51 of the children 
were already treated for insulin-dependent diabetes, 60 sibs had 
no diabetes. Of these 60 sibs patient 1 was the only child, that 
did have ICCA (titre 1:64), without any sign of clinical diabe-
tes: a random bloodglucose at the moment he participated in the 
study {fig. l) was 5.4 mmol/1, his percent glycosylated hemoglo-
bin (HbA 1 %) was 6.3% {normal range 6-8%). His disease became cli-
nically manifest 28 months later at age 19 years, with a -retro-
spective- history of increasing lassitude, thirst and hunger of 
three months. He was then admitted to another hospital with mild 
keto-acidosis (blood pH 7.2, urinary ketones 2+, blood glucose 25 
mmol/1). 
The HLA-segregation of his family is depicted in figure 1, inclu-
ding the titres of (complement-fixing-) islet-cell cytoplasmatic 
antibodies {CF-ICCA). Islet cell surface antibodies (ICSA) were 
not measured in this family. The ICCA found in patient l, indica-
ted by a half-open square, fixed complement in a titre of 8. His 
already diabetic brother, born in 1964, had a remnant ICCA-titre. 
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The HLA (-A-B-C-DR) haplotypes are indicated by A1 /B 1 for the 
father and c1;n 1 for the mother. Patient 1 is haplo-identical 
(shared c 1 only) to his older sister and younger brother, alrea-
dy having IDDM, and HLA-identical (sharing both A1c 1 ) to his 
brother born in 1961, who did not develop IDDM to date and did 
not have ICCA positivity either. 
With regard to the family-history of patient 1, no second degree 
relatives had IDDM, but his father had undergone an operation for 
hyperthyroid thyroidism 15 years earlier. 
Fig. 1 liLA-segregation, islet-cell antibodies and glycosylated 
hemoglobins found in the family of patient 1 in January 
1980 (legend see text). 
A1/B1 Cl/01 
D 0 
I I 
I I I I I 
• D D .. .. 
0 
year of 1958 1961 1962 1963 1961.J 1965 
birth 
year of 1960 1982 1978 
lOOM 
HLA- A1Cl B1/C1 Bl/01 B1/C1 A1/C1 BtfDt 
antigens 
ICCA- 0 0 0 64 4 0 
titre 
CF-ICCA 0 0 0 B 0 0 
titre 
HbA1 % 12.9 6.1 7.4 6.3 15.1 6.8 
,. patient 1 
• female lOOM 
.. male lOOM 
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Legend to figure 1. 
IliA 
A B c DR 
~ 2 8 3 
Bl 11 W35 W4 1 
cl 2 Wl5.2 W3 4 
Dl 2 W40.1 W3 W6 
None of the other 59 non-diabetic siblings of this multiplex fa-
mily study~ all being negative for (CF-)ICCA, developed IDDM over 
a three year time span, from the moment each child entered the 
study. The bloodsarnple of patient 1, obtained 28 months prior to 
his insulin dependency and another sample obtained one month 
thereafter, showed no significant difference in virus-titres for 
mumps, measles, german measles, cytomegalia, adenoviruses, reovi-
ruses, no tests were done for titres against coxsackie-virus. 
Patient 2 
Patient 2 is a girl of 14 years old when IDDM developed clinical-
ly. She is the cousin of two IDDM children that took part in the 
multiplex family study aforementioned. However, neither she her-
self nor her first degree relatives had diabetes, but it so hap-
pened her father's sister was the mother and her mother's brother 
was the father of her two IDDM cousins (figure 2). Because of 
this relationship it was decided to draw blood of her family too, 
the HLA-haplotypes found in these two families are in table 2. 
Patient 2 had no (CF-)ICCA in March 1979 (fig. 2) but 32 months 
later, at the clinical onset of her disease, an ICCA-titre of 8 
was found, that fixed complement with a titre of 2. Because of 
the absence of ICCA in March 1979 this serum was assayed for is-
let-cell surface antibodies (ICSA) on beta-cells obtained by 
cell-sorting techniques from rat-islets (8). Islet cell surface 
antibodies (ICSA) were 3+, in the absence of cytoplasmatic anti-
bodies (ICCA) . Two years after treatment the ICCA, present in a 
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titre of 8 at diagnosis, had increased to 16. Her HLA-identical 
cousin, born in 1961 had "persisting-ICCA", not usually seen af-
ter a duration of IDDM for ten years (5) . 
As indicated in figure 2 her uncle also had IDDM. He developed 
the disease at age 29, but no other more distant relatives were 
insulin-dependent nor had other endocrine autoimmune diseases, 
been reported. The same virus-titres as in patient 1 were ob-
tained, but the results were unremarkable. 
Fig. 2. HLA-genotypes, islet-cell antibodies and glycosylated 
year of 
birth 
year of 
lOOM 
HLA-
genotype5 
ICCA-
titre 
CF-ICCA 
titre 
ICSA 
HbA1 % 
hemoglobins, found in patient 2 and her relatives in 
March 1979 (legend, see text) . 
Cz/P A2/Q A2/82 GztD2 
; l 0 D I ; l l 
1961 1966 1967 1963 1965 1966 
1972 1969 1982 
A2/C2 C2/Q A2/C2 A2/02 B2/C2 A2/C2 
16 0 0 0 0 0 II :Bl 
4 0 0 0 0 0 11 :2] 
+ 
13.2 6.0 11.3 5.6 5.7 6.0 
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Legend to figure 2. 
HLA-haplotvpes found in patient 2 and her relatives 
HLA. types 
A B c DR 
~ 1 8 W3 3 
B2 11 44 W2 3 
c2 2 27 W2 4 
02 29 18.4 W3 5 
p 2 8 W2 3 
Q 3 7 W2 2 
Patient 3 
Patient 3 is a boy, aged 3 3/12 years, when insulin was first 
administered. He is the only son of a type-1-diabetic mother who 
had developed the disease herself at age 27 years. This patient 
came to our attention because of glucosuria and hyperglycemia 
( ~13 mmol/1) without ketonuria, seen only during corticosteroid 
treatment for severe bouts of asthma. For this he received 2 
mg/kg prednisone per day as well as 20 mg/kg aminophylline per 
day. Such bouts lasted 4-7 days, after withdrawal of the cortico-
steroid treatment he became normoglycemic. 
Three days after the first episode an oral glucose tolerance test 
{OGTT) was done, yielding a peak glucose of 9.7 mmol/1, peak in-
suline of 13 mU/L and C-peptide increasing from 0.2 nmol/1 to> 
2 nmol/1. Glucagon and cortisol were 9-14 ng/1, respectievely 
0.27-0.41 iJ.mol/1. Five non-diabetic children between 3 and 5 
years of age had 6.3-7.8 mmol/1 peak glucose, 10-24 mU/1 peak in-
sulin and> 2 nmol/1 C-peptide on OGTT, also with 1.75 g glucose/ 
kg as the glucose load, with a maximum of 50 g. 
Three months later (with the aminophylline treatment continued at 
5 mg/kg/day, without corticoste:-oid treatment in between) the 
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OGTT was repeated, also three days after corticosteroids for an-
other asthmatic attack were stopped. This time the peak glucose 
on OGTT, performed as above, was 23.8 mmol/1, peak insulin 
1 mU/1, peak C-peptide 0.28 nmol/1. This time normoglycernia did 
not return: home made glucose measurements varied 4.4 till 22.2 
mmol/1 despite a diet avoiding oligosaccharides, but ketones were 
not found in the urine, Three weeks thereafter another asthmatic 
episode followed, necessitating insulin administration on the ba-
sis of hyperglycemia, ketonuria and thirst in the absence of cor-
ticosteroid treatment. 
The clinical and biochemical data, including the findings on ICCA 
in this patient are summarized in fig. 3. In addition to the ICCA 
found when first tested, ICSA could be demonstrated at the same 
time. Virus tests, made at every time point ICCA were measured 
(fig. 3), were unremarkable as in patients 1 and 2. 
Figure 3 Time-course and biochemical findings in patient 3 
PREDIABETIC 
cJ" 4 YEARS OLD 
DIABETIC 
Insulin respons N. L. slightly 1 0 
to GTT 
HbA1 % 
(N.L.fi-6%) 
ICCA-titre 
CF ICCA-titre 
Asthma attacks 
7.6 9.2 11.3 9.0 6.6 10.0 
B 16 
-l.J -2 
no increase in 
-viral antibodies 
B 6 
-I +2 +4 months 
insulin dependent-
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As patient 3 is an only child, his HLA-type cannot be compared to 
that of sibs. His mother had HLA-DR3/DR3, his father HLA-DR2/DR4, 
patient 3 himself had HLA-DR3/DR4. 
Apart from his mother's IDDM since the age of 27, his father had 
slight asthmatic symptoms as a youth, declining when he became an 
adult. There were no other family-members with known (auto-immu-
ne) endocrine disease. 
Methods 
The HLA-typing was performed by the standard microcytotoxici ty 
assay, using periferal lymphocytes: 16 HLA-A, 40 HLA-B and 6 
HLA-C antigens were determined, using a set of 120 well defined 
antisera (9). With the two-coloured fluorescence assay 10 HLA-DR 
antigens were investigated, using 80 different allosera (10). 
Intra-HLA cross-overs were not observed, 
Islet-cell cytoplasmatic antibodies (ICCA) were measured by indi-
rect fluorescence on fresh frozen human pancreas sections (11), 
complement fixation of ICCA was determined in addition in each 
sample (5). Islet-cell surface antibodies (ICSA) were estimated 
on dispersed islet-cells from rodents, as described by Lernmark 
et al. (12). In patient 2 this assay was performed after separa-
ting the pancreatic beta-cells of rodents by cell sorting techni-
ques (8). 
Virus-titres were estimated by standard serologic technique, glu-
cose by specific enzymatic reaction (GOD) , hormones by radio-im-
muno-assay, (stable) glycosylated hemoglobins (HbA1 ) by a modifi-
cation of the microcolumn (IsolabR -Akron (Ohio) USA) chromato-
graphy, drawing the blood in excess buffer prior to assay, the 
normal range is 6-8% HbA1 . 
Discussion 
Patient 1 illustrates that recurrence of IDDM may occur in haplo-
identical sibs and that the other healthy sib to which this pa-
tient was HLA-identical in turn, did not have islet cell antibo-
dies. Further, patient 1 was the only healthy participant in the 
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multiplex family study that did have ICCA and did develop IDDM. 
Thus standardized ICCA ( 11) may be a good screening agent for 
prediabetic states of IDDM (12) . 
Patient 2 had no ICCA 32 months before she came down with IDDM, 
but she did have ICSA. When her disease became manifest she had 
low titres of (CF-)ICCA, suggesting that ICSA developed previous 
to ICCA. This is consistent with the view (14) that cytoplasmatic 
antibodies (ICCA) would not react with intact pancreatic islets, 
but only after they have been previously damaged by surface anti-
bodies ( ICSA) . To the best of our knowledge, this is the first 
patient in which this supposed sequence of events has actually 
been documented. The opportunity to study the HLA-segregation in 
her family, with her parents married to each others brother and 
sister, demonstrates the association between the susceptibility 
to IDDM in childhood and HLA-antigens in another way than by con-
currence of HLA-antigens in affected siblings. Yet, only 12% of 
the healthy sibs that are HLA-identical to affected children in 
the same family, will develop IDDM before the age of 20 (15). 
Patient 3 indicates that ICCA may be used in clinical instances 
where the development of IDDM is suspected. It has been suggested 
before that corticosteroid-treatment may precipitate the develop-
ment of IDDM ( 16) , which is in contrast to reports indicating 
that corticosteroid-treatment, initiated as soon as the diagnosis 
is made, may have a preservative effect on the residual capacity 
of pancreatic beta cells to secrete insulin (17). 
This contrast exemplifies the necessity to elucidate first patho-
genetic mechanisms leading to IDDM, before immunosuppressive the-
rapies are considered in individual patients. Alternatively, the 
maintenance aminophylline treatment of this patient (5 mg/kg/day) 
may have stimulated his declining capacity to secrete insulin to 
some extent: theophylline, by in vitro studies on islet-cells in 
culture, is a known pancreatic beta-cell secretagogue. 
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The reports of these children confirm that pre-diabetic states 
can be detected by the presence of islet-cell antibodies and that 
the susceptibility to the disease is HLA associated. However, the 
pathogenetic significance of neither association has been estab-
lished. 
Recently two protein-fractions have been isolated from human is-
let-cells, reacting with immuno-reactive serum components of dia-
betic children {18). These protein-fractions may be used to deve-
lop more sensitive radio-immune-assays for the detection of 
islet- cell antibodies. Also hybridoma techniques, after dissec-
ting the DNA of the HLA-DR4 region with suitable endonucleases, 
yielded DNA-sequences which may lead to a better understanding of 
the role of the HLA-genes in the pathogenesis of IDDM in child-
hood (19). 
With these novel approaches the nature of islet-cell antibodies 
and the genetic mechanisms of the susceptibility may be further 
elucidated. If so, prospective studies in sibs of diabetic child-
ren may be considered exploring possibilities for preventive im-
munologic measures, on the basis of defined abnormalities to be 
corrected. In particular, the recently described techniques to 
vaccinate against animal-disease models for encephalitis, rheuma-
toid arthritis and thyroiditis should be explored with respect to 
IDDM (20). 
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Summary 
Circulating islet-cell antibodies (ICA) were present in high 
frequency (80%) early after diagnosis and decreased in the time 
course of childhood diabetes mellitus. The complement fixing 
ability of islet-cell antibodies (CF-ICA) in the course of the 
disease appeared· to depend on the titre of ICA: the coefficient 
of correlation between ICA and CF-ICA titres was 0. 79 and all 
ICA's with a titre over 16 were complement-fixing. Incubating 
fresh-frozen human pancreatic sections thrice rather than once 
with the children's sera, increased the detectability of comple-
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ment fixation by a factor 1.4 in all ICA-positive sera. Thus tes-
ted, the detection of complement fixation per se did not appear 
to have a separate pathogenic significance, as the fraction of 
complement fixing ICA's was almost constant throughout the clini-
cal course. The presence of ICA-IgG subclasses also was dependent 
on the ICA titre: above a titre of 16 mostly all four subclasses 
could be detected. Incubating the pancreatic tissue thrice rather 
than once with rCA-positive sera resulted in enhanced detectabi-
lity of ICA-IgG1 . Early in the course of childhood diabetes, in-
cluding two prediabetic children, most of the IgG subclasses 
could be detected in ICA, but after a duration of one year IgG 1 
alone was mainly seen. In two other children, having a family 
history of insulin-dependency, restriction to the IgG2 subclass 
was found. 
Introduction 
It has been demonstrated that complement-fixing islet-cell anti-
bodies CF-ICA) relate more closely to the clinical onset of 
childhood diabetes mellitus than non-complement fixing islet-cell 
antibodies (ICA) , Importantly, CF-ICA have been found in siblings 
of diabetic children, up to 4 years before their disease became 
manifest (1). There is evidence that CF-ICA encomprise beta-cell 
cytotoxic antibodies (2), thereby explaining the closer relation-
ship of CF-ICA, rather than ICA, with the actual onset of the 
disease, Also, CF-ICA tend to disappear more quickly than ICA in 
the course of the disease (3) However, the ICA-IgG from sera not 
fixing complement may react with fewer epitopes in the islet-
cells, so that the IgG bound would be too far apart to fix suffi-
cient complement components, especially c 3 . To test this hypo-
thesis, fresh-frozen human pancreatic sections were incubated 
once or thrice with the patient's sera, to augment the amount of 
IgG-antibodies reacting with antigens in the islet-cells. Subse-
quently, the ability to fix complement as well as the presence of 
IgG subclasses in the bound ICA was tested after single or triple 
serum incubation. 
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Previously, we compared our methods of detecting ICA between two 
laboratories (4) , 
We now report our findings on the occurence of complement fixa-
tion and IgG subclasses during childhood diabetes, including fin-
dings in two children who had CF-ICA-28 and 4 months before the 
clinical onset of diabetes. 
Patients and sera 
Sera were obtained from consecutive referrals to the Sophia Chil-
dren 1 s Hospital of newly diagnosed children (1980-1982) and in-
cluded follow-up samples (Tables 1, 2 and 4). Figure 1 and Table 
3 include samples of recently diagnosed children from other pae-
diatric units (1982). All samples were spun immediately after 
clotting, frozen at -20°C and assayed within 72 h for ICA. For 
all other studies, sera were stored up to 3 years before assay. 
None of the children had thyroid or adrenal disease. 
The 25 newly diagnosed children (Tables 1 and 2) had an average 
age of 9.2 years (range 3-17 years), the male:female ratio was 
1:1. On first referral, stable glycosylated haemoglobin levels 
(HbA1 ) averaged 14% (range 10%-17%); 17 children had ketonuria 
and three had ketoacidosis. 
Two patients (1, 2, Table 4) were CF-ICA positive 28 and 4 months 
respectively before the diagnosis of clinically overt diabetes, 
necessitating the administration of insulin. The data from these 
patients are omitted from Tables 1, 2, 3. 
Patient 1 (aged 17 years) participated in a study on genetic mar-
kers, involving 22 families with two or more children (in total 
51) with treated diabetes. These families also had 60 siblings 
without diabetes. This patient was the only sibling with CF-ICA 
without any sign of diabetes, a random blood glucose was 5.4 
mmol/1, HbA1 6.3% (normal range 6%-8%), the disease becoming ma-
nifest only 28 months later. None of the other healthy siblings 
developed diabetes over a 3-year time span. 
Patient 2 is a boy, aged 3 years 3 months when insulin was first 
administered. He is the only son of an insulin-dependent diabetic 
mother, coming to our attention because of hyperglycaemia 
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( >13.3 mrnol/1) during corticosteroid treatment for severe bouts 
of asthma. Such bouts lasted 4-7 days and after withdrawing cor-
ticosteroids he was normoglycaemic. Three days after the first 
episode, an oral glucose tolerance test (1.75 g glucose/kg) yiel-
ded a peak glucose of 9.7 mmol/1, a peak insulin of 13 mU/1 and 
an increased C-peptide > 0. 2 nmol/ 1. Glucagon and cortisol were 
9-14 ng/1 and 0.27-0.41 ~mol/1, respectively. Five non-diabetic 
children in this age group had 6.3-7.8 rnmol/1 peak-glucose, 
10-24 mU/1 peak insulin and >2 nmol/1 peak C-peptide during an 
oral glucose tolerance test. Three months later the oral glucose 
tolerance test was repeated 3 days after the last corticosteroid 
dose: by that time peak glucose was 23.8 mmol/1, peak insulin 
1 mU/1, peak C-peptide 0.28 nrnol/1. This time normoglycaemia did 
not recur: home-monitored glucose levels varied from 4.4 to 
22.2 rnmol/1, despite a diet avoiding oligosaccharides. Three 
weeks later he had another asthmatic episode, necessitating insu-
lin administration since then. 
Glucagon, cortisol, insulin and C-peptide were measured by radio-
immunoassay, glucose by GOD, glycosylated haemoglobin by microco-
lumns (Isolab, Akron, Ohio, USA), with the blood drawn in excess 
saline or buffer prior to assay. 
Methods 
Assay procedure for ICA 
For all studies one pancreas specimen was used (designated as 
"HP" in the study by Marner et al (4)). The preparation and sto-
rage of the pancreas and the method of assessing ICA in terms of 
titres (defined as the maximal dilution at which fluorescence 
can be detected) has been described (4). Fluorescence readings 
were made by two observers, discounting very weak ( ±) fluores-
cence. In cases of doubt, involving < 2% of all readings, the 
vote of a third observer was sought. All measurements were car-
ried out as single determination, unless otherwise indicated. 
ICA was determined with fluorescein-isothiocyanate (FITC) -label-
led rabbit anti-human IgG, IgA and IgM sera specific for the 
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heavy chain, purchased from the Central Laboratory of the Blood 
transfusion Service, Amsterdam, the Netherlands (anti-IgG, batch 
number: KH-16-105-FOl, anti-IgA, batch number: KH-14-17-FOl, an-
ti-IgM, batch number: KH-15-21-FOl) . A Leitz Orthoplan microscope 
(Wetzlar, FRG) with epi-illumination (100 Watt lamp) and dichroic 
mirror RKP 510 with filter LP 515 (Wetzlar, FRG) were used. 
In two out of 46 samples IgG-rheumatoid factors were found (5) • 
Those samples were excluded from the study. 
Complement-fixing ICA 
Since complement binding to IgG is dependent on the close proxi-
mity of IgG molecules, the occurrence of CF-ICA was tested under 
two different conditions, i.e. pancreas sections were incubated 
once (complement-fixing-titre) and thrice (complement-fixing-pro-
perty) with preheated (30 min, 56°C) patient sera (50 Ill) for 
30 min. The sections were washed with phosphate buffered saline 
(PBS, pH=7. 2) and incubated with human serum as a complement 
source (fresh serum, blood group AB, stored -80°C, diluted 1:5). 
After another washing procedure the presence of c 3 was demonstra-
ted by incubation with FITC-conjugated rabbit anti-human c 3c 
(1:80 dilution, Dakopatts A/s, Copenhagen). Fluorescence was eva-
luated as decribed above. 
The conjugate did not react with human IgG, nor could fluorescen-
ce be demonstrated under the above conditions, if ICA-positive 
samples (titres 8-64) were incubated thrice with tissue in the 
absence of c3. 
ICA-IgG subclass detection 
For the determination of IgG subclasses in ICA, specific rabbit 
anti-human IgG subclass sera were used. The principle of the pre-
paration of thes·e sera has been described (6): they were made 
specific in agglutination and subsequently in indirect immuno-
fluorescence by adsorption with a panel of relevant isolated IgG-
paraproteins and tested against IgG subclass-paraproteins bound 
to erythrocytes by tannin. When applied to bone marrow smears ob-
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tained from multiple myeloma patients, these subclass antisera 
appeared suitable for use by indirect immunofluorescence. The 
sensitivity and specificity of these anti-sera (anti-IgG1 , 
batch number: KH 161-02-A1 ; anti-IgG 2 , KH 162-19-A6 ; anti-IgG3 , 
KH 163-0l-A1 ; anti-IgG4 , KH 164-05-A3 , obtained from the Central 
Laboratory of the Blood Transfusion Service, Amsterdam) was found 
adequate in immunofluorescence, as well as in an enzyme-linked 
immunosorbent assay (Elisa) in two other studies (7,8). 
To demonstrate the occurrence of a particular IgG-subclass, rCA-
positive sera were incubated once or thrice with pancreatic tis-
sue and subsequently tested for the subclasses. Anti-IgG subclass 
sera were used at 1:20 dilution (excepting anti-IgG2 , 1:40) and 
were applied in a double layer method in conjunction with FITC-
labelled swine anti -rabbit Ig ( 1:8 0 dilution, F205, Dakopatts, 
Copenhagen). The latter did not cross-react with human IgG, as 
demonstrated by the absence of fluorescence when tested directly 
on bone marrow cells of 10 multiple myeloma patients or when tes-
ted on pancreas sections bound with ICA. Finally, extensive ab-
sorption of the conjugate with human IgG did not affect in IgG 
subclass detection. 
Results 
Table 1 indicates the prevalence of ICA and CF-ICA during child-
hood diabetes. Each sample assayed came from a different child. 
At the onset of disease the prevalence of ICA was 80%, but after 
a duration of 4 years or more, only 11% of the children had cir-
culating ICA. All positive sera contained ICA of the IgG class. 
In addition, two sera contained ICA-IgA. ICA-IgM were not found. 
If the sera were incubated once with pancreatic tissue, comple-
ment fixation was found in 46% (19/41) of the samples (Table 1), 
but triple incubation of the same sera increased the percentage 
fixing complement by a factor 1.4 (to 27/41). Of 100 healthy 
adult blood donors one sample was weakly positive for ICA and 
none for CF-ICA. 
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A significant linear correlation could be demonstrated between 
the fluorescence intensity score observed with undiluted sera and 
the ICA titre of 32 samples tested (p<O.OS). Thirteen samples 
with a titre ¢8 were CF-ICA positive after single incubation. 
Only two of the 20 samples with an ICA titre ( 8 were CF-ICA po-
sitive on single incubation, the standard procedure. Triple incu-
bation resulted in four additional CF-ICA positives among these 
20 samples with ICA titres ~B. 
None of the sera with CF-ICA activity on single incubation lost 
this capacity by triple incubation. 
Table 1. Prevalence of islet-cell cytoplasmatic antibodies (ICA) 
in the sera of diabetic children in relation to the duration of 
diabetes. 
Months Number ICA- ICA-fixing complement 
after of posi-
diag- patients tive After one After three 
nos is studied serum in- serum incu-
bat ion bations 
0- 3 25 20/25 (80%) 12/20 (60%) 15/20 (75%) 
4-12 13 8/13 (62%) 1/8 (13%) 4/8 (50%) 
13-24 12 2/12 (17%) 1/2 (50%) 1/2 (50%) 
25-48 19 7/19 (37%) 3/7 (43%) 4/7 (57%) 
48 37 4/37 (11%) 2/4 (50%) 3/4 (75%) 
Total 106 41/106 19/41 27/41 
Healthy 100 1/100 (1%) 0/1 (0%) DID (=%) 
records 
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Table 2. Follow up of islet-cell antibody (ICA) and complement-
fixing islet-cell antibody (CF-ICA) titres 0-12 months after 
diagnosis. 
Patient 
a 
no. 
ICA/CF-ICAb titres 
0 months 0-5 months 5-10 months 8-12 months 
1 
2 
3 
4 
5 
6 
7 
8 
a Eight 
Table 1); 
32/210) 32/413) 
2/0 10) 2/0 12) 
8/010) 0 (0 12) 
64/210) 64/412) 
8/110) 8/112) 
32/210) 16/213) 
16/415) 
16/413) 16/213) 
64/1617) 
0/0 15) 
16/1 15) 
16/4 17) 
8/1110) 
16/8 18) 
8/2 16) 
2/0 Ill) 
0(0 18) 
16/1 19) 
8/0 112) 
8/4111) 
patients (randanly selected fran the 25 (0-3 
b CF-ICA titres obtained after single incubation of the 
months) 
sera follow the corresponding ICA-IgG titre and the exact number 
of months after diagnosis is shown in parentheses 
of 
Of ten samples that lost their complement fixation by dilution 
1:3, the complement fixing property reappeared in nine of them 
after triple incubation. In the sera of 25 healthy adult blood 
donors no complement fixation could be detected after triple in-
cubation with the pancreatic tissue. 
The sequential titres of Table 2 show a gradual decrease of ICA 
as well as CF-ICA titres during the first year of diabetes treat-
ment. A strong correlation was found between ICA and CF-ICA tit-
res obtained after single incubation (Spearman's rank correlation 
gave a rho of 0. 79, p < 0. 0001). The CF-ICA titres were mostly 
much lower than those of ICA-IgG. 
Table 3 shows the relationship between ICA titres and IgG sub-
class detection. The first samples of 44 recently diagnosed 
diabetic children (0-12 months after diagnosis) were tested for 
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ICA-IgG subclasses after single or triple incubation of the tis-
sue with the serum. 
Firstly, we considered samples that fixed complement after single 
incubation and in which ICA-IgG subclasses were determined by 
single incubation. In this category samples with an ICA-IgG tit-
re >16 had most IgG subclasses detectable. Secondly, of the 27 
samples with ICA-IgG titres ~ 8, the number of IgG subclasses 
detected exceeded two in only three samples, all of which fixed 
complement on single. incubation. 
Finally, the 17 samples that either did not fix complement at all 
or only after triple incubation all had an ICA titre of ~ 16 and 
in six of these sera no IgG subclass was detectable, regardless 
of the incubation procedure. 
The above findings raise the question whether the detectability 
of specific IgG subclasses may be enhanced or suppressed by sin-
gle or triple serum incubation. IgG subclasses were detected in 
37 of the 44 ICA-positive samples of Table 3, after single or 
triple incubation. Of those 37 sera, 34 contained IgG 1 , 17 IgG2 , 
18 IgG3 , 10 IgG4 • 
ICA-IgG1 was detected in 9/27 sera with ICA-IgG titre ~ 8, 
while triple incubation resulted in the detection of 20/27 ICA-
IgG1. Only in one sample of this category ICA-IgG1 was lost by 
triple incubation. The chi square test for paired observations 
gave p < 0.05 for this comparison. Thus, IgG 1 detectability was 
enhanced by triple incubation in CF-ICA. In CF-ICA negative sam-
ples, however, ICA-IgG1 detectabili ty appeared in 3 I 10 samples 
by triple incubation and disappeared in 2/10. 
With the other IgG subclasses no significant suppression or en-
hancement of detectability was found by single or triple incuba-
tion. 
Seven patients were followed up from before their diagnosis up to 
20 months thereafter (Table 4) . Despite variability in the detec-
tion of IgG subclasses caused by single or triple incubations, 
consistency of IgG subclasses was found in parts of the clinical 
course. Changes in subclasses were seen in patients 1, 2 and 5 
where a 16-fo1d decrease in ICA-IgG titre was found. 
In all patients, excepting patient 6, IgG 1 was the predominant 
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ICA-IgG subclass detected in the time course of their disease. 
This result is in agreement with the quantitative distribution of 
IgG subclasses found in the sera of 50 normal children, aged 8-12 
years, using the same antisera (IgG 1 :IgG2 :IgG3 :IgG 4 = 70:20:8:4). 
Ten randomly selected children with treated diabetes had a simi-
lar IgG subclass distribution to that found in the sera of normal 
children {data not shown) . 
Patient 6 (encircled in Table 4) with ICA-IgG 2 alone and another 
patient (encircled in Table 3) having ICA-IgG 2 only on single as 
well as triple serum incubation, had family histories of insulin-
dependency. The maternal grandfather of the first patient was in-
sulin-dependent at age 27 years and his maternal uncle developed 
diabetes at age 10 years. The other patient had two maternal 
grand-uncles with insulin-dependency as of ages 36 and 49 years. 
The sera of these two patients, however, contained normal quanti-
ties of IgG subclasses. 
Table 3 The distribution of IgG subclasses (1, 2, 3, 4) in rela-
tion to ICA-IgG titre and complement fixation in sera of newly 
diagnosed diabetic children. 
Number 
of in-
cuba-
tions 
ICA-IgG 
titre 
256 
128 
64 
CF-ICA nega-
tive 
One Three 
Overall 
result 
CF-ICA positive 
on triple incu-
bat ion only 
One Three 
Overall 
result 
CF-ICA positive on 
single incubation 
One Three 
Overall 
result 
4 1+2+4 1+2+4 
1+3 1+3 
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Table 3 continued. 
Number CF- ICA nega- CF-ICA positive CF- ICA positive on 
of in- tive on triple incu- single incubation 
cuba- bation only 
tions 
One Three One Three One Three 
ICA- IgG Overall Overall Overall 
titre result result result 
32 0 0 0 
2+3 1+2+3+4 1+2+3+4 
1+2+3+4 1+2+3+4 1+2+3+4 
1+2+3+4 1+2+3+4 1+2+3+4 
1+2+3+4 1+3+4 1+2+3+4 
1+2+3+4 1+3+4 1+2+3+4 
16 1 1 1 1+2+3 1 1+2+3 
2 1+2 1 +2 1+3 1 1+3 
1+2 1 1+2 
1+2+3+4 1+2+3 1+2+3+4 
1+3 1+2+3 1+2+3 
1+4 1 1+4 
1 1 
8 1 1 1 1 
1 1 
1+4 1+4 
4 
Legend to Table 4 
nd = not detectable 
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a Five patients (3-7) were randomly selected from the 25 of 
Table 
fore 
1 and children 1, 2 were those 
the disease became clinical! y 
in whan ICA 
manifest; b 
was rreasured be-
IgG subclasses 
are given as the overall result of their detection by single and 
triple incubation; c titres are those obtained after single incu-
bation of the sera with the tissue, All measurements were done in 
triplicate 
was always 
only 
Discussion 
and the 
within one 
average 
titre 
titre reported. The reproducibility 
difference; d after triple incubation 
The complement fixing nature of ICA may be particularly relevant 
for the pathogenesis of childhood diabetes as this variety of ICA 
has been detected in children before the disease becomes clini-
cally manifest (1). This association is confirmed by two more ca-
ses in the present study. In clinically overt childhood diabetes, 
no complement fixation was found if the ICA-IgG titre was 4 or 
lower, whereas the correlation between ICA-IgG and CF-ICA titres 
was high, suggesting a limited sensitivity of our system for the 
detection of CF-ICA titres. 
The fixation of complement depends on the proximity of IgG-anti-
bodies bound to the islet cells of the pancreatic sections. Trip-
le incubation resulted in the detection of 1.4 times as many com-
plement fixing ICA as single incubation (Table 1) , primarily be-
cause samples with ICA-IgG titres of 4 or lower appeared to fix 
complement by this procedure (Fig. 1). If CF-ICA-positive samples 
were diluted until the complement fixing detectability disappea-
red and were subsequently incubated thrice at that dilution, the 
complement fixing property reappeared. This finding raises the 
question whether the complement fixing nature of ICA has any sig-
nificance other than that it is more likely to be seen in samples 
with higher ICA-IgG titres. 
As in other studies, ICA decreased with the duration of the dia-
betes. However, our fraction of ICA's fixing complement remained 
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50%-75% (Table 1). Therefore, we do not feel the detection of 
complement fixation per se has a separate significance. 
Dean et al. (9) recently investigated ICA-IgG subclasses and 
found 50% of the ICA-positive sera showed a restricted response, 
with 12% reacting only with the IgG 2 subclass. We too found an 
uneven distribution of IgG subclasses, however some apparent res-
trictions were clearly dependent on the ICA-IgG titre on which in 
turn the CF-ICA titre depended. Dean et al. found the restric-
tions to be independent of CF-ICA titres, although their reported 
CF-ICA titres were much higher than those in the present study. 
We used triple incubation of the pancreatic sections to enhance 
the detectability of complement fixation and if samples demon-
strating all four ICA-IgG subclasses were diluted, IgG1 was the 
last subclass to disappear. Conversely, triple incubation signi-
ficantly enhanced the detectability of IgG1 . In addition, the 
IgG1 subclass appeared predominant in 13 rcA-positive sera not 
fixing complement, which suggests again that the IgG1 subclass 
was relatively more abundant in ICA, than in whole serum. The ab-
sence of detection of any IgG-subclass in seven sera of lower 
ICA-IgG titre could be due to the limited number of epitopes pre-
sent in ICA which are specific for the relevant subclasses. The 
finding that ICA with lower titres did not fix complement may be 
due to the low density of ICA bound from those sera. The discre-
pancies indicated may be resolved with the availability of mono-
clonal IgG subclass-specific antisera and sensitive enzyme-la-
belled or radiolabelled assays (10) , now that two human ICA-reac-
tive islet-cell protein fractions have been separated (11). 
In conclusion, indirect immunofluorescence carried out on one 
single fresh-frozen human pancreas, with a previously established 
specificity and sensitivity for the detection of ICA (4) , yielded 
variable results for the detection of complement fixation and IgG 
subclasses, depending on ICA-IgG titres and incubation procedu-
res. The present data suggest the occurrence of a non-restricted 
IgG subclass response early in the course of childhood diabetes. 
However, IgG2 subclass restriction in ICA was seen in two child-
ren having a family history of insulin-dependency. 
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Summary 
Insulin-dependent diabetes mellitus 
childhood or early adulthood, and its 
(IDDM) usually begins in 
aetiology is thought to in-
valve autoimmune damage to the islet-cells that secrete insulin 
(1). To investigate an additional target of autoimmunity in IDDM 
we examined sera for antibodies to insulin receptors. Such anti-
bodies were defined by their ability to compete with insulin for 
binding to insulin receptors and by their capacity to behave like 
insulin in activating lipogenesis in adipocytes. We now report 
the occurrence of anti-insulin receptor antibodies of the IgM 
class in the sera of 10 of 22 IDDM patients obtained before their 
treatment with exogenous insulin. Furthermore, two of five IDDM 
patients who were initially negative developed anti-insulin re-
ceptor antibodies during treatment with human or pork insulin. 
These findings suggest that autoimmunity to the insulin receptor 
may contribute to the pathophysiology of IDDM. 
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Results and discussion 
The population of IDDM patients we examined comprised children 
who were referred consecutively to the Department of Endocrinolo-
gy of the Sophia Children's Hospital. Sera were obtained from 22 
patients before treatment and from 5 of them also after they be-
gan to receive insulin. Control sera were obtained from healthy 
volunteer blood donors at the Blood Bank of the Leiden University 
Hospital and from the investigators. We surveyed the sera by as-
saying 0.5-5 ~l for insulin-like activity in stimulating lipoge-
nesis in rat adipocytes measured by incorporation of radiolabel-
led glucose into lipid (2,3). 
Table 1 shows that the insulin-like activity in a representative 
serum could be identified as anti-insulin receptor antibody of 
the IgM class by fractionating the serum and testing the various 
fractions for lipogenic activity. For example, 75% of the lipoge-
nic activity found in the whole serum could be eluted from an an-
ti- ~-column that specifically binds IgM. The effluent which con-
tained the non-IgM material had relatively little lipogenic acti-
vity. Filtration through Sephacryl 300 to separate IgM from IgG 
confirmed that the lipogenic activity was a property of the frac-
tion containing IgM, while the fraction containing IgG was inac-
tive. Dissociation of possible insulin-insulin antibody complexes 
by acidification and separation of serum fractions on Sephadex 
G-100 showed that the lipogenic activity remained intact and re-
sided in the insulin-free, high-molecular weight fraction (2) . 
The low-molecular weight fraction did not contain sufficient in-
sulin to activate lipogenesis. The lipogenic activity of the po-
sitive sera was not inhibited by adding antibodies to insulin, 
illustrating by another method that the lipogenic activity was 
not due to insulin itself. In contrast, goat antibodies to human 
IgM inhibited about 95% of the lipogenic activity in the positive 
sera. Lipogenic IgM did not bind to immobilized insulin (not 
shown). These results taken together indicate that the lipogenic 
activity could be assigned to IgM molecules and not to free insu-
lin or insulin-insulin antibody complexes. The lipogenic IgM was 
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identified as anti-receptor antibody as it specifically competed 
with radiolabelled insulin for binding to insulin receptors. 
Table 2 illustrates that increasing amounts of IgM purified on an 
anti- ~-column increasingly inhibited the binding of insulin to 
the insulin receptors of adipocytes, Control IgM isolated from 
the serum of an IDDM patient without lipogenic activity had no 
effect on the binding of insulin to its receptor. 
Normal human IgG stimulates lipogenesis in rat adipocytes in vi-
tro (4). Although the IgM anti-receptor antibodies described here 
also caused lipogenesis, the two lipogenic effects differ with 
regard to both ligand and receptor. The stimulatory effect of IgG 
is exerted through the non-variable Fe portion of the molecule 
(4,5) and normal IgG does not compete with insulin for binding to 
the insulin receptor (P. Dandona, personal communication). 
Table 1. Anti-insulin receptor antibodies in serum of IDDM pa-
tient are IgM 
Treatment of serum 
None 
Anti- j..l-column 
Sephacryl 300 
Dissociation of 
complexes, 
Sephadex G-100 
Antibodies to 
insulin* 
Antibodies to 
IgM! 
Serum fraction 
Whole 
Effluent (not IgM) 
Eluate (IgM) 
Large (IgM) 
Small (IgM) 
Large (Ig) 
Small (insulin) 
Whole 
Whole 
% Relative lipogenesis 
of adipocytes 
100 
15 
75 
100 
0 
90 
0 
100 
5 
105 
Legend Table 1. 
Sera were fractionated (2) using columns of goat antibodies to 
human 1.1.-chain (Dako Im:nunoglobulins), bound to Sepharose (Pharrra-
cia (1)), Sephacryl 300 (Pharrnacia (12)) or Sephadex G-100 (Phar-
macia). Antigen-antibody complexes were dissociated by acidifica-
tion (0.01 M HCl, pH 2. 7) of serum (2) before gel filtration. 
Control serum or fractions for each procedure were obtained fran 
healthy donors and from an IDDM patient whose whole serum was ne-
gative for 
was canputed 
serum (100%). 
pad of male 
anti-receptor antibody activity. 
relative to that found in 1 ~l 
Adipocytes were obtained from 
Lipogenic activity 
14 D(U- C)glucose 
as described 
equivalent to 
insulin (10 ng 
ne::l without added 
Wistar rats {90-120 g) 
(4-7 nCi mol-1 ; NEN") 
previously (2,3). Max:inal 
and 
into 
of the unfractionated 
the epididymal fat 
the incorporation of 
lipid was measured 
lipogenesis (100%) was 
that produced by incubation of the adipocytes with 
rnl-11 and was 300% of control lipogenesis obtai-
insulin. 
* Guinea pig anti-insulin antisennn (Miles-Yeda; titre 10-S) 
was added (2 !Jl) to the lipogenic assay. 
Goat antiserum to IgM (Miles-Yeda) was adde::l (30 
lipjgenic assay. 
1111 to the 
Table 2. Purified IgM receptor antibody competes with insulin for 
binding to insulin receptors on rat adipocytes 
Affinity-purified 
IgM ( 11gl 
5 
10 
20 
% Inhibition insulin binding to adipocytes 
Test serum 
29 
48 
72 
Origin of IgM 
Control serum 
9 
4 
0 
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Legend Table 2. 
Affinity-purified IgM eluted fran an anti- j..L column (see Table 1) was added in 
the indicated arrounts to rat adipocytes (105 cells) in plastic tissue 
culture tubes containing 0.35 ml KRB buffer (pH 7.4)-0.3% bovine serum albumin 
and 125r-insulin (35,000 c.p.m.). The tubes were incubated at 25°C for 40 
min and the adipocytes were then separated from unbound insulin on a Millipore 
filter (EGWP, 0.2 j..Lffi), washed with ice-cold buffer and counted for radioac-
tive content (13). Extent of binding was 1.7 pmol per 105 adipocytes of Which 
70% was specific (displaced by 1 !lM cold insulin) . Per cent inhibition was 
computed relative to the binding obtained in the absence of added IgM. 
Table 3 documents the presence of anti-insulin receptor antibo-
dies in the sera of IDDM patients before and after treatment with 
exogenous insulin. Ten out of 22 patients had these antibodies in 
their sera at the time they first presented, before they had been 
treated with exogenous insulin. We have had the opportunity to 
examine serial bleedings obtained after treatment of five pa-
tients who had been negative at the outset. Two of these patients 
became positive within 4 months of receiving treatment with exo-
genous insulin, one having been given human and the other porcine 
insulin. 
The investigation described here was prompted by the observation 
that mice developed anti-insulin receptor antibodies spontaneous-
ly after immunization to insulin (2). These receptor antibodies 
were identified as anti-idiotypes to insulin antibodies, sugges-
ting that they might have arisen as components of an idiotype-an-
ti-idiotype network {6). The anti-idiotypes probably functioned 
as receptor antibodies by mimicking the conformation of the anti-
gen insulin (7). We reasoned that humans might possibly develop 
similar anti-idiotypic insulin receptor antibodies in response to 
their own insulin antibodies produced by accidental immunization 
to exogenous insulin used for treatment. However, a large number 
of the pretreatment sera which we had believed would serve as ne-
gative controls were found to be positive for anti-receptor anti-
bodies (Tabel 3). Therefore, we must conclude that autoimmunity 
to insulin receptors, rather than resulting merely from an iatro-
genic accident, may be generated during the pathological process 
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intrinsic to IDDM. Moreover, the prevalence of these antibodies 
in an unselected group of patients suggests that their presence 
is neither sporadic nor infrequent (Table 2). We have no evidence 
to indicate whether or not the anti-insulin receptor antibodies 
in the IDDM patients are anti-idiotypes to insulin antibodies. 
Table 3. Anti-insulin receptor antibodies in sera of IDDM pa-
tients before and during treatment with exogenous in-
sulin 
Serum donors Anti-insulin receptor antibodies 
Normal controls 
IDDM patients 
Before treatment 
After treatment 
0/20 
10/22 
2/5 
Anti -receptor antibodies in each serum were identified by two or 
rrore of the assays described in Table 1 . Sera of 22 patients were 
obtained before they were treated >vith injections of insulin. Se-
ra were obtained serially fran five patients treated with injec-
tions of insulin after being negative for receptor antibodies be-
fore treatrrent. Two patients becarre positive for anti-receptor 
antibodies during 4 rronths of observation. 
Insulin receptor antibodies have been found in a few dozens of 
patients with acanthosis nigricans and severe diabetes (8). It 
seems, however, that IDDM and the acanthosis nigricans diabetic 
syndrome are diverse entities with distinct anti-receptor antibo-
dies. Unlike IDDM, the anti-receptor antibodies in the acanthosis 
nigricans patients are mostly IgG rather than IgM (8), the dis-
ease is extremely rare, the resistance to treatment with insulin 
is marked and the patients seem to have a primary structural de-
fect of their insulin receptors (9). 
Patients with IDDM, with or without IgM receptor antibodies, do 
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not have the degree of insulin resistance characteristic of the 
acanthosis nigricans syndrome. The disparate clinical entities 
associated with these anti-receptor antibodies may be attributed 
to the diverse biological effects of IgG and IgM receptor anti-
bodies, to differences in the fine specificities of the receptor 
antibodies, to the intrinsic state of the insulin receptors and/ 
or to the presence or absence of additional pathological proces-
ses. 
Regardless of the mechanism of insulin receptor antihody genera-
tion, their presence indicates that autoimmunity in IDDM is not 
limited to islet-cells (1). The clinical consequences and theore-
tical implications of these anti-receptor antibodies may be im-
portant. What is their role, alone or together with viral infec-
tion and islet-cell antibodies, in the pathogenesis of IDDM? Do 
they influence the response to treatment or the development of 
late complications? Can they be used to identify degrees of risk 
or immune response genes? Are they a factor in the subclinical 
insulin resistance that is a prominent feature of IDDM (10)? 
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§5. Discussion 
The etiology of childhood diabetes can be represented as pancrea-
tic beta-cell destruction as a function of time {figure 2) . 
Fig. 2 Pancreatic beta-cell destruction 
Pancreatic beta cell destruction 
Percent of the beta cell mass left 
l 00 +------, ,-------,------------------------------ --
I 
1 
I? 
II 
onset 
of 
symptoms 
m 
The gradual destruction of pancreatic beta-cell with ti.rre, 
clinical symptoms not developing before 70-80 percent of the 
original beta-cell mass has been destructed (paragraph 2) . 
Question marks indicate putative phases of beta-cell regeneration. 
Raman numbers on the horizontal axis indicate time spans of: 
I. genetic susceptibility (HLA-related) 
II. subclinical expression of the disease (islet-cell antibodies) 
III. the clinical! y overt state (when insulin is administered) . 
Time 
The papers presented in the previous paragraph can be assigned 
each to one the three phases of the time-course of childhood dia-
betes depicted in figure 2. The purpose of the following discus-
sion is to present the findings in as much as they contribute to 
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the consideration of possible immune-intervention of childhood 
diabetes. 
This fascinating new field of clinical research has very recently 
received much attention, but only preliminary data are available 
(to be discussed in the final section of this paragraph). 
To clarify the connection of the studies presented to this new 
field of research it must be understood that all investigations 
hitherto into immunosuppression of childhood diabetes dealt with 
possible prolongation of the remission-phase {paragraph 2) , once 
the disease became clinically manifest. In other words: immuno-
suppressive measures were only tried in phase III of figure 2. 
This discussion attempts to demonstrate that present findings in 
the other phases of the clinical course of childhood diabetes 
have consequences for the interpretation of the possible finding 
of prolongation of the remission-phase by virtue of immuno-sup-
pressive measures, after insulin treatment is initiated. Further-
more new approaches are mentioned that will contribute to an im-
proved understanding of each of the phases of the clinical course 
of childhood diabetes depicted in figure 2. 
1. HLA-antiqens as genetic markers for the susceptibility to 
childhood diabetes. 
From twin studies it is known identical twins have a concordance 
rate of 50% or less (38,39). Gm-markers were not associated with 
diabetes-type-1a generally (paper 1) , but they may still be in a 
small subgroup of children (paper 3) , as far as the IgG-subclas-
ses of their islet-cel1-cytoplasmatic-antibodies are concerned. 
Limiting this discussion to HLA: 
From the multiplex families of paper 1 it was calculated that in 
our multiplex type-la-diabetic families HLA-identity with an af-
fected sib would carry a 11.6% risk for that sib to become diabe-
tic himself. This is the same figure (12%) as calculated by Platz 
et al., who studied 51 multiplex young onset diabetic families 
and 212 monoplex families, meaning that only one sib had treated 
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diabetes (40). This figure is too low to employ HLA-identity as a 
practical guide for prospective studies finding children that la-
ter will develop diabetes, as will be demonstrated below. 
Using this data the question can be asked: how many HLA-identical 
siblings ( x ) to newly diagnosed diabetic children should be 
followed to find 10 new cases in a two year period, if the ages 
of those siblings for practical reasons are limited from 10-19 
years? This can be calculated from the following equation (41) : 
number of new cases (10) 
X 
(observation period (years)) x (corrected risk) 
10 X 100 X 20 
X 346 
2 X 11.6 X 1.60 X 1.66 
The corrected risk is arrived at as follows: 
2 duration of follow-up in years 
1. 60 
11.6% risk of development of diabetes in HLA-identical 
sib. 
increased risk for the age-cohort 10-19 years over that 
of the age-cohort of 0-19 years (chapter II - the ascer-
tainment corrected annual incidences per 100.000 are 303 
and 486, respectively. 
1. 66 
20 
113 
correction for the finding that one third of all sib-
lings to diabetics become diabetic themselves within two 
years after their already diabetic sibling, according to 
a large study in England (42). 
correction to annual rates for the use of risks for the 
age-cohort of 0-19 years. 
More than 300 HLA identical sibs would have to be identified to 
be followed prospectively for two years in order to detect 10 
children of 0-19 years becoming clinically diabetic in that 
time-span. The ascertainment corrected incidence per year for 
that age-span in the Netherlands is 486 (Chapter II) and only one 
in four sibs will be HLA-identical as there is no evidence of se-
lection against or for HLA-combinations in families with type-1-
diabetes ( 5) . 
Thus, 346 x 4 = 1384 healthy siblings would have to be HLA-typed, 
which would involve 659 (1384 : 2.1 (the average dutch kindred)) 
families, which represents a formidable task against the back-
ground of the dutch total annual incidence. 
In what way did the study of HLA by serology contribute to the 
understanding of the mechanism of the genetic susceptibility? 
The mode of inheritance of susceptibility is complex and the "two 
or more gene concept", linked to HLA-DR3 and/or HLA-DR4 seems to 
fit the data best. This is in agreement with other studies, sum-
marized by the late Dr. Andrew G. Cudworth et al. (5). They also 
described haplotype-clusters, involving genes over the whole of 
the major histocompatibility complex in association with suscep-
tibility to type~l-diabetes. This finding suggests common ances-
tor haplotype-clusters among the patients, but, more importantly, 
lends support to the hypothesis of sets of interacting genes to 
act in concert within these clusters. 
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In another study (42), we found that the SB-locus, situated be-
tween the HLA-D locus and GLO (hence centromeric from HLA-D), 
shared no allotypes with type-la-diabetes. 
The cross-overs observed in our family-study, suggested that the 
HLA-A locus contributed more likely by linkage-disequilibrium to 
diabetic clusters than by truly being part of them. Thus, two lo-
ci situated between HLA-A and SB, were selected for their possi-
ble involvement, namely HLA-B and HLA-DR. Two haplotype-combina-
tions, HLA-B8/HLA-DR3 and HLA-B15/HLA-DR4 were tested for third 
order disequilibrium with type-la-diabetes. The indication found 
of the genes of two loci acting in concert, involving different 
classes of gene-products, namely HLA-B antigens (class I histo-
compatibility antigens) and HLA-D antigens (class II histocompa-
tibility antigens) 1 may have important consequences for the un-
derstanding of the immunologic pathogenesis and hence the consi-
deration of future immunologic interventions. What these would be 
is at present unclear, as the interactions of the multiple anti-
gens coded for by genes of the major histocompatibility complex 
(MHC) are only beginning to become elucidated. 
The merit of the described suggestion of third order linkage-dis-
equilibrium, arrived at by "classic" genetic analysis, is, that 
it can be tested by novel techniques, known as "fine genetics". 
This implies the use of DNA-probes on segments of chromosomes 
dissected by endonucleases. 
Recently, D. Owerbach and associates at the Hagedorn Institute 
(43), described two such fragments, relevant for the association 
between HLA-DR4, the commonest haplotype in our childhood diabe-
tic population, and insulin dependency. It is known class !!-an-
tigens (HLA-D related) show a marked genetic polymorphism asso-
ciated with the beta-chains of these molecules (44). This poly-
morphism appears to be associated with several MHC genes, eviden-
ced from hybridization studies (45). Thus, differences in hybri-
dization pattern between DNA from healthy individuals and diabe-
tic patients, using the beta-chain c DNA probe (p DR- p -1) after 
digestion with certain restriction endonucleases may be highly 
relevant. They found an increased frequency of one fragment among 
HLA-DR4 I HLA-DRx individuals as well as among HLA-DR4 I HLA-DR3 
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individuals, that were insulin dependent. They also described an-
other fragment, occurring in 30-40% of controls, but in only 0-2% 
of the diabetics. Other probes, suitable for the examination of 
the HLA-B locus could yield similar results, perhaps supporting 
the proposed "two or more loci concept". 
Should relevant DNA-fragments be found, monoclonal antibodies to 
their gene-products {membrane antigens) may be generated, facili-
tating the detection of cells carrying such antigens. 
For the detection of children with a genetic risk for type-la-
diabetes, the accuracy using the above techniques could be higher 
than presently possible with serologic typing. 
In what further way may the study of HLA contribute to better un-
derstanding of childhood diabetes? 
The MHC-complex in humans (as well as genes of the H-2-complex in 
mice) encomprises a large variety of functions pertinent to pre-
sentations of type-1-diabetes. 
With regard to insulin-dependent-diabetes it is relevant to men-
tion biologic functions that have so far been associated with 
HLA-genes or their products: the HLA-antigens on the cell-membra-
ne. Table 2 summarizes such functions, in mice (of the H-2-com-
plex) and in humans (of the HLA-complex) , contrasted to their 
possible relevance for all stages of childhood diabetes. 
Table 2. 
Function 
1. Production of humoral 
antibodies 
2. Production of killer T-
cells and helper T-cells 
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Relevance for diabetes-type-! 
1. Islet-cell antibodies, 
thyroid, adrenal, parietal 
cell and other prevailing 
auto-antibodies (46). Anti-
bodies to injected insulin. 
2. Pancreatic beta-cell cyto-
toxicity (47) 
Impaired suppressor T-cell 
function (48). 
3. Regulation of immune response 3. Ibidem including mode of ex-
pression of autoimmunities. 
4. Biosynthesis of some comple- 4. 
ment components 
5. Regulation of embryogenesis 5. 
6. Regulation of synthesis of 6. 
some steroid hormones 
7. Regulation of ligand-membrane 7. 
interactions of some protein 
hormones 
Ibidem 
Unknown 
Unknown 
Insulin action (49) also mo-
dified by insulin antige-
nicity. 
With present serologic HLA-typing sub-groups of type-la-diabetic 
patients cannot be separated easily in view of the already men-
tioned haplotype-clusters that contain genes in linkage to each 
other rather than to disease-states. Fine-genetics, referred to 
above, may detect and hence predict highly relevant entities 
within type-la-diabetic patients. Such entities might include: 
1. differences of islet-cell antibody occurrence in particular in 
pre-diabetic-states; 
2. differences in velocity of loss of remnant endogenous insulin 
secretion; 
3. differences in sensitivity to injected insulin. 
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2. Islet-cell antibodies as markers for childhood pre-diabetes 
The second tool investigated for the evaluation of the predicta-
bility of diabetes-type-la were antibodies to the islets of Lan-
gerhans (ICA). One human pancreatic specimen with previously es-
tablished specificity and sensitivity for the assay of ICA was 
used for this purpose. The prevalence of ICA in newly diagnosed 
children was 80% with this system (paper 4), in the same order of 
magnitude of other studies, using fresh-frozen, rather than Bouin 
fixed pancreatic specimens. In controls, only 1% was weakly posi-
tive, indicating a better specificity in this respect than found 
in other studies. 
Subsequently, the question was asked to what extent these ICA 
might be present before the diagnosis is made. 
Two years before the study reprinted as paper 5 was started, the 
London group lead by the late Dr. A.G. Cudworth and Dr. G.F. Bot-
tazzo set up a prospective study into the predictability of 
childhood diabetes by ICA. This study became known as the Barts-
Windsor study. It involved 154 healthy brothers, 134 healthy sis-
ters from 160 families having a diabetic child. ICA were assayed 
every 1-4 months with a mean follow-up of 2 (1.1-2.5) years at 
the time point the study reprinted as paper 4 was initiated. In 
their preliminary report (SO) it was indicated six subjects of 
these families had developed insulin-dependency. Four of these 
six subjects had been ICA-positive from the moment they entered 
the study and had remained positive on repetitive testing until 
the disease became clinically manifest. The two other subjects 
had become positive during their follow-up. Of these six subjects 
two were HLA-identical sibs, two were haplo-identical sibs and 
two were parents. 
In total, that study involved 473 healthy siblings and parents. 
In their final report (51) seven developed diabetes in two years 
and 54 of these subjects had ICA positivity without the develop-
ment of clinical diabetes. If one assumes all these subjects 
(children and parents) would become diabetic eventually, the re-
currence risk would be 54/473 = 11.2 %. 
It is difficult, to compare this figure with the recurrence risk 
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derived from epidemiologic studies. Very few epidemiologic sur-
veys have taken the recurrence risk in parents into account and 
only one corrected for incomplete ascertainment, the study from 
the Pittsburgh group (52). Another difficulty with the Barts-
Windsor data is that several pancreas specimens were used for the 
assay of ICA and that the fluorescence was not expressed in 
titres. 
Provided pancreatic tissue with defined sensitivity and precision 
for the detection of ICA would be used, this tool appears to have 
a high accuracy screening for pre-diabetic states in childhood 
(papers 3 and 4). A practical advantage of this method as an en-
try to identify pre-diabetes of childhood is that minute quanti-
ties of serum can be used. In positive cases, only 50 microliters 
of serum is needed for a reliable assay. As demonstrated in paper 
3 and 4 the titres of prediabetic children as well as of newly 
diagnosed children were usually 4 or higher, if positive. Such 
quantities would be obtainable by fingerprick, a technique most 
families with diabetic children are used to, so that the partici-
pation of children younger than 10 years of age may be conside-
red. 
It should be noted that 20% of the newly diagnosed children did 
not have ICA. The one patient (paper 3) that developed ICA only 
after diagnosis did have 3+ islet-cell surface antibodies (ICSA) 
only, three years before her disease became manifest. This data 
and the sequence of the islet-cell antibodies developing in this 
particular patient, suggests that next to ICA, ICSA should be 
used as screening tools for prediabetes of childhood. For this 
method 1 milliliter of serum is presently required and the fluor-
escence assay involved is much more difficult. 
At the moment we initiated our own survey of rCA-positivity among 
healthy sibs and parents of 22 multiplex families, we only knew 
of 4 children that had become diabetic in the Barts-Windsor study 
forementioned, with ICA positivity from the moment they entered 
that study. We agreed with our participants we would make the 
HLA-data available only to their family physicians, but would not 
disclose the - to us at that point uncertain - meaning of rcA-po-
sitivity in a healthy family member. We decided to look for ICA 
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in sibs and parents on the basis of single bleedings (with the 
above preliminary findings of the Barts-Windsor study on the per-
sistence of ICA in mind). The 22 multiplex families, only 3 co-
ming from our own clinic, participated voluntarily, in full know-
ledge of our own uncertainties to the meaning of HLA and/or ICA 
with respect to their future health. 
With the data on the accuracy of predicting childhood diabetes by 
ICA (described in paper 3) , one might feel less insecure about 
the prospect of a sib of a diabetic child having ICA without any 
signs o'r symptoms and this represents major problems. It was re-
ported (the late Dr A.G. Cudworth, personal communication) that 
some participants of the Barts-Windsor study did resent their 
non-diabetic child becoming diabetic during those prospective 
studies. This experience holds an important warning if such stu-
dies are to be repeated. Participation of children not becoming 
diabetic may generate an undue awareness of the child and its 
family that the child may still become diabetic after an unknown 
number of years. The burden of this "partially inherited" life 
long disorder cannot be overestimated and causes numerous inter-
actions in the families of children with treated diabetes (Chap-
ter III - paragraph 1) • Similar interactions may be projected by 
parents on healthy sibs by their mere participation in a screen-
ing program of childhood diabetes, that has no therapeutical con-
sequences. Possible interference with the upbringing of these 
sibs cautions for a repeat of such studies on ethical grounds. 
Before considering any screening program for pre-diabetes of 
childhood, more needs to be known on the nature of islet-cell-an-
tibodies as predictors of childhood diabetes. Both islet-cell cy-
toplasmatic - and surface fluorescence-techniques are qualitative 
in nature, and the following three principle shortcomings (a-c) 
remain: 
a.children with mumps infection (but not with Coxsackie, Measles, 
Rubella or Influenza) may have temporary ICA, not persisting for 
more than 2-4 months and without developing insulin-dependency 
subsequently (53). Beside this problem there are other limits to 
the immunologic specificity of ICA. 
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Islet-cell cytoplasmatic antibodies, usually not reacting with 
intact cells, are measured as islet-cell flurorescence on pancre-
atic slices. The antigenicity of the whole pancreatic beta-cell 
is assessed and the antigens of the whole islets they react with 
have not been specified to date. The complement fixing ICA appea-
red a fairly good screening agent for the pre-diabetic state of 
children. In view of the absent definition of their immunologic 
functions and biochemical nature they have been compared to "the 
crowd gathering around the accident". However, it happens with 
criminal accidents that "the criminals hide within this crowd to 
secretely enjoy the effects of their act" and the problem to 
identify them remains. Even the number of protein-isolates acting 
as antigens of the pancreatic islets was undefined until recent-
ly. S. Baekkeskov et al. (54) isolated two protein-fractions from 
cultured pancreatic islets, that reacted with a panel of ICA po-
sitive samples obtained from several institutions, including our 
own. They used detergent-solubilized radiolabelled islet-cell an-
tigens from cultured human and rodent pancreatic islets, com-
plexed these to antibodies isolated from the sera of diabetic 
children (obtained by plasmapheresis) and detected the two reac-
ting protein-fractions by gel electrophoresis after specific ab-
sorption to protein A-sepharose. Their findings that ICA reacted 
with at least a limited number of (two, thus detected) protein-
fractions raises hopes to the further elucidation of the nature 
of these fractions. 
Further, it is unknown where the relevant antigens reside within 
the islets. Studies with human-human hybridoma systems, where pe-
riferal lymphocytes of a diabetic child were fused with a human 
myeloma line, yielded one clone reactive with human pancreatic 
islets by fluorescence. Further analytical studies indicated that 
the target antigen was possibly situated in the cytosol of gluca-
gon-, rather than insulin-producing cells of these islets (25). 
The significance of this experiment (the first to employ this no-
vel technique with regard to childhood diabetes) remains unclear. 
ICA react with the cytoplasmatic contents of islet-cells as mea-
sured on fresh-frozen pancreatic sections. One would expect that 
cytotoxicity to intact islet-cells is mediated by islet-cell-sur-
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face-antibodies ( ICSA) . These have been found to react with is-
let-cells of rodents. ICSA appeared to be organ-specific, but not 
species-specific. ICSA react mainly with pancreatic beta-cells 
and they can mediate a complement-dependent cytotoxic reaction 
(55) . One would expect ICSA to react first with pancreatic beta-
cells, destructing their membrane. Consequently the contents of 
the pancreatic beta-cells are exposed, which subsequently results 
in the generation of ICA. As forementioned, this sequence of 
events was actually documented in patient 2 of paper 3. In this 
view ICSA would be "the criminal" and ICA "his accomplice". 
b. A second enigma, with possible immunogenetic implications, is 
exemplified by the detection of IgG-subclass restriction of ICA 
in a few diabetic children as described in paper 4. Early after 
diagnosis as well as in two pre-diabetic children (patients 1 and 
2 of paper 4) mostly all four IgG-subclasses were present and no 
IgM-ICA was found. The absence of IgM-ICA suggests that auto-im-
munity towards the islets must have been going on for some time, 
because at the onset of auto-immune reactions antibodies of the 
IgM-class generally predominate. The presence of mostly all four 
IgG-subclasses early in the course of childhood diabetes suggests 
that there was no restriction of B-lymphocyte clones producing 
these multiple classes of antibodies. Of course, this absence of 
restriction does not exclude switching of such B-lymphocyte 
clones. Two children were found to have IgG 2-rcA restriction, 
despite relatively high (complement-fixing} ICA-titres. Admitted-
ly, the demonstration of the IgG2-subclass appeared to be more 
difficult than that of other IgG-subclasses. Hence, a dilution of 
1:40 was used to demonstrate this subclass in ICA, as opposed to 
the dilution of 1:20 for the demonstration of the other subclas-
ses, IgG1 , IgG3 and IgG 4 (paper 4). These two children had 
11 Ver-
tical transmission" of insulin dependency in their families. Al-
though the family histories of these two children have not been 
compared to those of the other 42 studied with regard to IgG-ICA-
subclasses, such family history is exception rather than rule in 
childhood diabetes. Although IgG-ICA-subclass restriction appears 
"a characteristic of an accomplice", this feature hints to a par-
ticular kind of 11 criminal act 11 in the comparison used before. 
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c. A third problem with ICA that needs to be considered is that 
ICA may encomprise idiotypic as well as anti-idiotypic antibodies 
against human islets. The relevance of this feature has been re-
viewed elegantly by C.H. Brogren and A. Lernmark {25): "The hy-
bridoma technology provides a novel approach for investigating 
the network theory of Jerne, which implies that the antibody res-
ponse is regulated through negative and positive feed-back mecha-
nisms. Let us imagine that a monoclonal antibody able to induce 
diabetes has been isolated. According to Jerne's theory these an-
tibodies, injected into syngeneic recipients will induce the for-
mation of anti-antibodies (or so called anti-idiotype antibo-
dies) . We speculate that these anti-idiotype antibodies have a 
specific immunosuppressive effect, when administered to the dia-
betic recipient. A suppressive effect may be achieved by those 
anti-idiotypic antibodies depicting the antigenic determinants as 
the target molecules (internal image) which are expressed on is-
let-beta-cells. Anti-idiotype antibodies reactive with acetylcho-
line receptor antibodies have been produced after syngeneic mouse 
spleen cells were "educated 11 with acetylcholine receptors. Mono-
clonal anti-idiotype antibodies may thus prove to be useful re-
agents in studies of immune response regulation". 
Human-human and human-mouse hybridomas have been produced from 
patients with auto-immune polyendocrine disease, including diabe-
tes-type-lb (paragraph 1 of this chapter), thyreoiditis and some-
times adrenalitis (55). These hybridomas synthesize auto-antibo-
dies that react with multiple normal human tissues, pituitary, 
gastric mucosa, endocrine pancreas and thyroid, at least partial-
ly explaining the multiorgan autoimmunity both in animals (25) 
and humans. The availability of large quantities of such monoclo-
nal antibodies will aid in raising anti-idiotypic antibodies for 
the abovementioned purpose. 
This specific example is relevant for "diabetes-type-1a" (para-
graph 1) as well. In our own clinic (with presently 136 children 
of 0-19 years followed annually for 0-14 years, 4 years averaged) 
10%-20% had antithyroid-, 4% anti-gastric-mucosa- and 1% anti-
adrenal-antibodies, next to other varieties of auto-antibodies. 
If the organs involved in these cases could be demonstrated to be 
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antigenic by the sharing of common antigens to the pancreatic be-
ta- cell, the generation of monoclonal.anti-idiotypes may be use-
ful to elucidate immune response regulation. The nature of this 
supposed common auto-antigen is still unknown. "Heterogeneity" of 
monoclonal antibodies, however, may still ensue, as these may re-
act with still other constituents of the body, only sharing mole-
cular substructures with relevant antigens. 
A different problem with the interpretation of the significance 
of islet-cell antibodies deals not so much with their nature or 
specificity (a-c) but with their possible effects: it has been 
suggested immunoglobulins of diabetic children, that react with 
islet-cells, interfere with the islet's capacity to secrete insu-
lin. In the presence of complement, the children's antibodies 
blocked the insulin release of rat islets (56) . Cytotoxic antibo-
dies markedly slowed down the insulin release of human islets in 
a system where the cultured islets were peri-fused (57). This ef-
fect casts doubt on tests assessing the secretory capacity of is-
let-cells as a measure of their (remnant) quantity: in the pre-
sence of islet-cell antibodies, interfering with insulin release, 
the C-peptide stimulation by for instance glucagon may well be 
hampered. During the first years of insulin treatment, when is-
let-cell antibodies prevail (paper 4) , C-peptide reserve testing 
may "underestimate" the number of islets with functional poten-
tial, as this may be blocked by the potential of islet-cell anti-
bodies abovementioned. This potential of islet-cell antibodies 
may seriously hamper the interpretion of beta-cell saving immuno-
suppressive therapies, reviewed in the last section of this para-
graph. 
Taken together, islet-cell antibodies in the course of childhood 
diabetes may become more heterogeneous as the disease-state pro-
gresses. Auto-antibodies towards islet-cells may or may not com-
prise reactivities with antigens that served as recipients for 
initial lesions of pancreatic beta-cells along the course of 
childhood diabetes: the heterogeneity of auto-antibodies in 
childhood diabetes is further expressed by the generation of an-
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tibodies to insulin and to its receptor, discussed in the next 
section. 
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3. Insulin antigenicity 
The one antigen that may be involved in the immunopathology of 
childhood diabetes and that has a known structure is insulin 
(paper 5). The concept that insulin antigenicity may be part of 
the disease process, evidenced by insulin-receptor-antibodies 
perhaps emerging as insulin-anti-idiotypes, suggests that the 
hormonal contents of damaged pancreatic beta-cells may also 
become involved in the auto-immunity of childhood diabetes. 
Dr. W. G. Reeves very concisely summarized present knowledge on 
insulin antigenicity (58} as follows: 
"The insulin molecule is of modest seize: 5600 daltons, the num-
ber of antigenic sites is limited, accordingly sera of treated 
patients have insulin-containing immune complexes of modest sei-
ze, which suggests that only one or at most two antibodies are 
able to combine with a single insulin molecule in these circum-
stances. Larger, precipitating complexes can be produced when bo-
vine insulin is injected into guinea pigs: the insulins of these 
two species have 18 different sequences. 
Insulins hitherto used for the treatment of human diabetics (bo-
vine, porcine) show up to three amino-acid sequence differences, 
but the antibody produced in response to these injection is usu-
ally not specific for these variant residues, but reacts with de-
terminants shared by the endogenous insulin molecule, Similar 
findings have been demonstrated in other species. Very little is 
known about the topography of these antigenic determinants on the 
surface of the molecule, but it is likely that they occur in suf-
ficient proximity to each other to cause steric hindrance between 
the respective antibodies". 
Next to species differences, the source of insulin preparations 
may be important: very highly purified porcine insulins and semi-
synthetic human insulins are derived from pancreas extractions, 
r-DNA-insulins from E-coli pools. Minute but repetitive contami-
nations from any of these preparations with molecular forms other 
than native circulating insulin may still contribute to antibody 
formation after subcutaneous injection. Further it is of note 
that all insulin preparations for conventional treatment contain 
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complexed forms of native insulin, to slow down subcutaneous ab-
sorption. Complexed insulins may have different irnmunogenicity 
from crystalline insulin. 
Many investigations have been done into the significance of anti-
bodies to insulin in treated patients. Generally, these antibo-
dies do not cause clinical insulin-resistance, but they can alter 
the molecule's pharmacokinetics (59). 
Importantly, their presence may modify the duration of the remis-
sion-phase (60), further complicating the interpretation of pro-
longations thereof by virtue of immunosuppressive measures. 
The insulin-receptor antibodies of the IgM-class described in pa-
per 5, may or may not be related to the sub-clinical insulin re-
sistance that is a prominent feature of treated insulin-dependent 
patients. It has been known for some time (61) that insulin-re-
ceptor antibodies have a paradoxical insulin-like effect on the 
metabolism of adipose tissue, namely lipogenesis. Therefore the 
bio-activity of the IgM insulin-receptor antibodies described was 
tested both in terms of lipogenic activity in the rat epidydimis 
fat-pad assay and in terms of specific displacement of radio-la-
belled insulin from isolated adipocytes (see paper 5 for methodo-
logy) . It appeared relevant to search for clinical expressions of 
the IgM insulin-receptor antibodies in the two patients in which 
these IgM insulin-receptor antibodies emerged after the initia-
tion of insulin therapy, compared to three patients in which 
these were not found. With regard to the ten of twenty-two child-
ren in which IgM lipogenic activity was found before insulin 
therapy: the specificity for insulin-receptors of their IgM has 
not been tested yet conclusively in insulin radioreceptor assays. 
The two patients referred to above, in which this specificity was 
documented (paper 5), are described next and are called patient 1 
and patient 2. 
Patient 1 is of negroid extraction, born in the Netherlands to 
parents from the Cape Verde-isles. At age 12.4, she was admitted 
with a severe keto-acidosis and dehydration with a history of 
thirst, hunger, weight loss of three weeks. She had been mildly 
obese as of age 4, her weight 2 kg above the 90th percentile for 
weight for height on the dutch growth chart (fig. la). Her health 
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history was otherwise unremarkable. 
Before intravenous therapy was initiated her blood glucose was 
32.2 mMol/1, glycosylated hemoglobin 18.6% (the presence of Hb-S 
and Hb-F were excluded) , insulin ( 1 mU/L. IgG-antibodies 
against the islet-cells were positive {titre 32) and fixed com-
plement. Also titres of antibodies against mitochondria and 
smooth muscle were present but not against thyroid, adrenal or 
parietal cells. Her family history revealed no diabetes mellitus, 
both her parents had normal weights for height. Her HLA-D-geno-
type was HLA/DR3, homozygous. 
During the first four months of treatment (fig. 2a) she used 0.7 
- 0.9 U human semisynthetic human insulin/kg after initial stabi-
lization also with human insulin (Monotard HMR in two daily dosa-
ges) . Between 3 and 6 months glucosuria did not exceed 30 grams 
per day, stable glycosylated hemoglobin varied from 7 - 9 %. A 
diet of 1500 cal. per day was prescribed, her weight stabilized 
during that same period at the 90th percentile (57 - 58.4 kg 
weight) • Her chief complaint remained hunger and her weight in-
creased until 70 kg two years later. 
Patient 2 is of caucasoid extraction. She was 10 years old when 
her general practioner found glucosuria by coincidence. She was 
obese (like her mother) . Between age 3 and 10 her weight had been 
4 to 6 kg above the 90th percentile for weight for height on the 
dutch growth chart (fig. 1b). Her mother was also obese, but not 
her father. A 1000 cal. diet was prescribed without any other me-
dication as her general practioner did not think of childhood 
diabetes. During the five months thereafter she lost 13 kg of 
weight and in the sixth month she developed mild complaints typi-
cal for insulin deficiency. Except for obesity, her health histo-
ry was otherwise unremarkable. 
A month later glucosuria increased until 75 gm/day, ketones ap-
peared, and porcine- insulin was administered (MixtardR in twice 
daily dosages) on referral to our hospital. During the second 
year of treatment her daily dosage was increased from 36 U to 44 
u (fig. 2b). 
Her family history revealed diabetes to be present in members of 
her fathers side: his mother used "tablets" as of age 69, her 
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sister was insulin-dependent as of age 40, the son of this sister 
became diabetic at age 9. On the side of the mother the family 
history was unremarkable, except for obesity. 
The patient•s HLA-D-genotype was HLA-DR3/HLA-DR4, islet-cell an-
tibodies were present (titre 8) without other relevant auto-anti-
body titres. 
She was classified as a "slow-onset" diabetes-type-la. In a se-
ries of 44 children she was the only child that had IgA-islet-
cell antibodies next to IgG at the clinical onset of diabetes 
(paper 4) • During the first eight months of treatment 0. 4 U of 
insulin/kg was used, glucosuria did not exceed 30 gm per day and 
glycosylated hemoglobin did not exceed 10.2% (fig. 2b). No hypo-
glycemia was documented with a diet of 1500 - 2000 cal. per day 
and her weight increased from 45 to presently (44 months after 
the beginning of insulin therapy) 81 kg. Also her chief complaint 
remained hunger. 
After one year of treatment islet-cell antibodies were still de-
tectable (titre 4) , after two years not any more. 
Three other children, that had no significant (paper 5) lipogenic 
activities either before or up to one year after the initiation 
of insulin therapy, were two girls and one boy. They had no obe-
sity beyond the 90th percentile for weight/height of figures la/ 
lb, neither before or after the initiation of insulin therapy. 
(data not comprised in fig. la or fig. lb). 
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The time-course of patient 1 and patient 2 is depicted in figure 
2a and figure 2b, respectively. Apart from the lipogenic activity 
of the IgM insulin-receptor antibodies, the lipogenic bio-activi-
ty of the IgG isolated from their sera was plotted. One reason 
for doing so was the recent observation of Khoker and Dandona 
(personal communication) that human IgG has a powerful lipogenic 
effect by itself (also see paper 5), 
Patient 1 developed high lipogenic activities, first IgM, subse-
quently IgG before high affinity "classic" insulin antibodies had 
been detected, kindly measured by Prof. Dr. J.H.H. Thijssen of 
the Endocrine Chemistry Department of the Utrecht University 
School of Medicine. In that time period her insulin dosage (36 U 
per day) was lower than before and after and also her glycosyla-
ted hemoglobin levels were lowest then. Her urinary C-peptide 
excretion as well as her C-peptide reserve suggested remnant en-
dogenous insulin secretion, synchronous with a temporary reduc-
tion in insulin requirements. 
Patient 2 developed also high lipogenic activities, but in her 
these consisted primarily of IgM up to a year, before high affi-
nity insulin antibodies were detected. In this time period her 
insulin was gradually increased until 50 U per day, but, in con-
trast to patient 1, her stable glycosylated hemoglobins were ne-
ver lower than 11.2%. Her weight increased from 45.5 until 74.6 
kg, presently (5 years after the beginning of insulin therapy) 
81 kg. Her urinary C-peptide was lower from the onset of insulin 
treatment, compatible with the absence of a temporary remission 
in insulin requirements. 
As illustrated in figure 1a and figure lb both patient 1 and 2 
had previous obesity prior to the onset of type-1-diabetes, in 
contrast to five other type-1-diabetic children of the same age, 
not depicted in these figures. 
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These preliminary observations have clinical and pathophysiologi-
cal implications with respect to the role of immunoglobulins in 
the regulation of the metabolism of adipose tissue. 
Clinically, these activities may be related to the experience 
that degrees of obesity in treated childhood diabetes are not a 
simple function of insulin dosages, diet and/or physica·l exerci-
se, but that body weight attained under treatment may also be me-
diated by these immunoglobulins. This is in keeping with the cli-
nical experience that it may be very difficult in very obese ado-
lescent girls {as patients 1 and 2) to loose weight by changes in 
the usual therapeutic regimen of their diabetes. Pathophysiologi-
cally, the significance of the IgM insulin-receptor antibodies 
was discussed in paper 5, The lipogenic activity of IgG, that ap-
peared to predominate in patient 1 over that of IgM, may be rela-
ted to the non-suppressible insulin-like-activity-P, described by 
Froesch and colleagues to account for 90% of the insulin-like ac-
tivity of human serum. NSILA-P has a molecular weight of about 
150,000 Daltons like human IgG, whereas IgM is a pentamer, with a 
molecular weight of about 900,000 Daltons. The lipogenic effect 
of human IgG appeared to be mediated by the (non-variable) F c 
part of the IgG molecule and was not exerted via the insulin re-
ceptors of fat-cells (62). On a recent symposium (63) Khoker, 
Taylor and Dandona expressed the need for a critical reassessment 
of the observations that 1) insulin-receptor antibodies induce a 
paradoxical stimulation of adipocytes in vitro; 2) their finding 
that human IgG stimulated adipocytes in vitro; 3) the findings of 
paper 5, that IgM isolated from newly diagnosed diabetic children 
contained specific insulin receptor antibodies, that might be an-
ti-idiotypic antibodies to the insulin injected, 
The present observation of clinically expressed obesity in pa-
tients 1 and 2 implies that the sera of treated diabetic children 
may be very useful for such critical reassessment. 
The findings further exemplify the complexity of functions of 
(auto-)antibodies involved in early stages of childhood diabetes, 
either emerging spontaneously or as a consequence of insulin in-
jections, depicted in figure 3. 
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Figure 3. 
The etiology of childhood diabetes mellitus, a schematic repre-
sentation of findings (arrows) and concepts (question marks) of 
the roles of humoral antibodies. 
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4. Immune-intervention in childhood diabetes 
At the beginning of this discussion it was noted that centres 
have recently begun to investigate the effects of immuno-suppres-
sion in newly diagnosed patients. The important animal experi-
ments (71) that lead to these clinical trials will not be re-
viewed here. Table 3 summarizes the methods used in humans and 
their possible side-effects. 
Table 3. Studies of immuno-suppression in childhood diabetes. 
Immuno-suppression used. 
Plasmapheresis 
(Ludvigsson, Sweden) (64) 
Prednisone 
(Ellis, New Zealand) {65) 
Cyclosporin A 
(Stiller, Canada) (6 6) 
Monoclonal anti-T cell 
antibody-T12 
(Eisenbarth, U.S.A.) (67) 
Possible side-effects. 
thrombosis, hepatitis. 
growth retardation 
insulin-resistance, a.o. 
hirsutism, gingival 
hypertrophy, anemia, 
hepato-/nephro-toxi-
city. 
mild transient rash 
anaphylaxis? 
The effects of immuno-suppression in the clinically manifest dis-
ease were expressed as prolongations of the remission in insulin 
requirements after the initiation of insulin therapy. Also, the 
preservation of the capacity to secrete insulin endogenously has 
been assessed. Prednisolon was also tried on a pilot basis in li-
mited numbers of children with disappointing results after two 
years of follow-up (68). With regard to the other means of 
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immuno-suppression abovementioned, formal studies are underway 
and the results mentioned here are preliminary. It should also be 
mentioned most trials involve older children and young adults. 
Stiller et al (66) used cyclosporin in a dosage of 10 mg per kg 
per day, adjusted to serum levels ranging from 100-200 ng per rnl 
and found considerable side-effects. At the time of last observa-
tion {48-114 days, the cyclosporin initiated within 6 weeks after 
diagnosis) three of seven patients were receiving no insulin. 
In another group of patients, initiated on cyclosporin two or 
more months after diagnosis, none had a reduction in insulin do-
sage of 50% or more and there was no significant increase in 
C-peptide levels. 
Eisenbarth et al. (67) using monoclonal T12 antiserum in a simi-
lar study, concluded that none of the pilot studies on immunothe-
rapy of type-1-diabetes so far gave clear beneficial results. 
In other studies (without applying immunosuppression) intensi-
fied conventional treatment during the first year of disease was 
associated with prolongation of remission-phase (14), although 
not as markedly as seen in the patients referred to above. 
At present, the preliminary findings on the effects of immuno-
suppression raise the following questions: 
1. why did some patients appear to react much more favorably than 
others? 
2. to what extend was the prolongation of the remission-phase due 
to the immunosuppression applied? 
3. what relevant humoral antibodies were suppressed? 
Some pathophysiological difficulties interpreting the clinical 
phenomenon of a remission-phase were discussed in the previous 
sections. 
It seems to the author these important questions can only be 
answered clinically by previous stratification of patients, with 
regard to already known characteristics of remission-phases in 
sub-groups of patients. Such stratification would include con-
trolling for the following factors: 
1. the age of the patients as young children {below age 5 in par-
ticular) as these very young children have shorter remission-
phases (if any) compared to their older peers on conventional 
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treatment (69); 
2. the quality of metabolic control during the follow-up of 
trials; 
3, velocity and ferocity of pancreatic beta-cell loss prior to 
diagnosis. 
The weight of the first two variables, with respect to their in-
fluence on remission-phases, may be established by age selection 
and by choosing optimal treatment-modalities in defined age-
groups. Having done so, it may be less difficult to evaluate ef-
fects on remission-phases by virtue of immunosuppression, 
The third factor is dictated by circumstances prevailing on re-
ferral of a newly diagnosed child and can only be controlled for 
by screening programs of pre-diabetic states of childhood diabe-
tes. One might envisage the identification of children at risk by 
"refined" HLA-typing 1 defined islet-cell antibodies 1 followed by 
intensive treatment alone or in combination with immunosuppres-
sive therapy in a randomized prospective study, as soon as "early 
phase" glucose-intolerance (70) developed. The ethical legitimi-
city of such a trial, that has potential therapeutic consequen-
ces, should be discussed with platforms of parties involved, no-
tably ethical committees of medical faculties and patient orga-
nizations. 
In view of the daunting prospects of children suffering from the 
disease, it is hoped for that such trials can be considered in 
the not too distant future: along with expected progress in 
screening methodology, improved specificity of immune-interven-
tion and defined means to assess its effects. 
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6. Summary 
The findings reported in this chapter may be summarized as fol-
lows: 
1. The strong association between childhood diabetes and HLA-DR3/ 
HLA-DR4 is confirmed. 
2. The recurrence risk for a sib of a diabetic child being HLA-
identical to that child is about 12%. 
3. The susceptibility to childhood diabetes may be mediated by 
two or more loci, one associated with HLA-B8/HLA-DR3, the 
other with HLA-Bl5/HLA-DR4, in third order linkage disequili-
brium. 
4. Generally, childhood diabetes is not associated with Gm-mar-
kers. 
5, Absence of cytoplasrnatic islet-cell antibodies at the clinical 
onset of the disease occurs in 20% and absence of either 
HLA-DR3 or HLA-DR4 in less than 10%. Absence of these immuno-
logic parameters may be found in unusual syndromes with child-
hood insulin-dependency. 
6. The accuracy of islet-cell antibodies, measured by immunoflu-
orescence, to detect pre-diabetic states in childhood is pro-
bably high, although their pathogenetic significance is un-
clear. 
7. Restriction to single IgG-subclasses in islet-cell fluores-
cence suggests linkage to Gm-markers for the small subgroup of 
diabetic children in which this was found, with regard to the 
expression of this auto-antibody. 
8. Besides islet-cell autoimmunity, autoimmunity towards fat-cell 
insulin receptors may develop spontaneously. 
9. IgM insulin-receptor antibodies arising after treatment with 
insulin may be associated with obesity. 
10. Before the consideration of "immunoprevention" of childhood 
diabetes, more needs to be known about the pathophysiology and 
the immunology of the disease and disease states in which im-
mune-intervention is applied. 
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CHAPTER II EPIDEMIOLOGY 
"for Art and Science cannot exist 
§1. Introduction 
but in minutely organized Particulars" 
(Blake) 
The fourth year medical student lectures at the Erasmus Universi-
ty, taught by Prof. Dr. H.A. Valkenburg and his associates contain 
a quotation from Francis (1954): 
"Epidemiology provides a third dimension to the understanding of 
disease by creating awareness of the nature of the environment in 
which disability arises, of the factors in the community which 
contribute to its causation and, in turn, its effect upon the 
community". 
The retrospective investigation of the incidence of childhood dia-
betes in the Netherlands (paragraph 2), was the result of a colla-
borative effort of the "Working Committee on the Epidemiology of 
childhood diabetes" established in 1978 through the initiative of 
Prof. Dr, W. H. H, Tegelaers, chairman of the Department of Pedia-
trics at the University of Amsterdam Medical School.* 
With regard to the methods of epidemiologic studies it is interes-
ting to review the minutes of the committee: first, the testing 
for urinary glucose in healthy school children was considered as a 
method to detect children in which insulin-deficiency might be de~ 
veloping. A pilot-study was carried out by two school-physicians 
M, Wirix-Nagelsmit and J.M. van der Ros, demonstrating nil positi 
ves among 450 healthy children. 
* The members to the working cannittee, other than the authors of 
the paper reprinted, in alphabetic order, were: 
Prof. Dr. J.L. van den Brande, Dr. H.F. Dankrreyer, Dr. M.H. 
Gons, Drs. M. Jansen, Prof. Dr. G.A. de Jonge, Prof. Dr. 
W.H.H. Tegelaers, Dr. H.P. Verbrugge, Drs. A.A.M. Vloemans 
and Drs. F. Wafelbakker. 
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This approach was prompted by the clinical observation, impres-
sion rather, that relatively more children, compared to former 
years, presented with asymptomatic glucosuria, when first seen 
clinically, than with keto-acidosis. Indeed, in our own hospital 
we found in retrospect 12 (10-20) percent of 55 newly diagnosed 
children with diabetes mellitus presented with keto-acidosis 
(blood pH< 7.2.) between 1975-1980, whereas 36 (30-40) percent 
of 71 newly diagnosed children did so between 1970-1975 (1}. 
The rejection of urinary glucose as marker for beginning diabetes 
of childhood coincided with the formal acceptance (1979) of dia-
betes-type-2 being different from diabetes-type-! by authorities 
as the NIH and the WHO: in diabetes-type-2 glucosuria may be a 
marker by virtue of its slow onset; in diabetes-type-1 (childhood 
diabetes} the clinical onset is much more sudden, so that glycos-
uria would only be present weeks or months at most before its on-
set (Chapter I - paragraph 1). 
Subsequently this approach was abandoned and a retrospective ana-
lysis of newly diagnosed children was considered by the committee 
of which the author of this thesis had the honour to become 
chairman. 
The first question raised was what criteria should be used for 
diabetes-type-1 in childhood. 
In the epidemiologic sense, it is an advantage of diabetes in 
childhood that patients are either insulin dependent or not. Tem-
porary use of insulin is occasionally seen in neonates (2), but 
such cases can be excluded by checking on reported cases of neo-
natal diabetes, expected to be rare. In contrast to type-2-diabe-
tes, the incidental administration of insulin, for example around 
operations in elderly patients, does not occur in youth. 
Mild glucose intolerance, usually not accompanied by glucosuria, 
may be seen in obese (pre-) adolescents, but these children never 
require insulin (3) , nor do most of the genetically determined 
mild cases referred to in paragraph 1 of chapter I. 
It is of course possible that children with mild glucose-intole-
rance are inadvertently treated with insulin. In such case one 
would suppose that either hypoglycemia would develop or that such 
low dosages were needed that specialists - who invariably treat 
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children with insulin dependency in the Netherlands - would doubt 
the necessity thereof. In incidence studies, assessing newly 
diagnosed children retrospectively only, the contribution of such 
cases was felt to be low, if any. 
One exception should be made: the insulin-dependency that concurs 
in up to 8 percent of the patients with cystic fibrosis (4). In-
terestingly, the HLA-DR3 and HLA-DR4 haplotypes predominated mar-
kedly in the cystic fibrosis patients on insulin over cystic fi-
brosis patients without fasting hyperglycemia (5). Up to 8 per-
cent of all living cystic fibrosis patients under the age of 19 
years in the Netherlands would represent 80 or less cases (Dr. 
L.P. ten Kate, Institute for Anthropogenetics, University of Gro-
ningen, personal communication). Compared to an expected preva-
lence of 4,000 for all minors under age 19 with insulin-dependen-
cy this subgroup of children with cystic fibrosis would represent 
too small a fraction to be considered separately. 
With these considerations in mind it was felt "insulin-dependen-
cy" as a criterion would encomprise "classic" type-1-diabetic 
children. The committee decided to conduct a retrospective survey 
of the incidence of childhood diabetes under age 19 all over the 
Netherlands, using this simple, but practical criterion, by a 
questionnaire to all dutch pediatricians and internists. 
The second question raised was how to ascertain the data obtained 
from a retrospective survey among dutch pediatricians and inter-
nists. 
Methods used in Scandinavian countries (drug-registry or hospi-
tal-file checking) were either impossible or very difficult in 
the dutch health-care system. On the other hand the Netherlands 
are unique in having the largest relative membership of the Dutch 
Diabetes Association (Diabetes Vereniging Nederland- D.V.N.) in 
the world, with 35.000 members in a country of 14.3 million inha-
bitants. With the help of the medical advisor to the D.V.N., Dr. 
H.F. Dankmeyer, it was decided to separately conduct a retrospec-
tive survey on the incidence of childhood diabetes by a question-
naire to the members of the D.V.N., as an ascertainment procedu-
re. 
The report of the investigation, conducted by the Netherlands In-
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stitute for Preventive Health Care under direction of Dr. G.J. 
Vaandrager, is reprinted in the next paragraph. 
Other data forthcoming of this epidemiologic study were published 
in a monograph in the dutch language ("De incidentie van insuli-
ne-afhankelijke diabetes mellitus bij 0-19 jarigen in Nederland 
1978-1980" - G.J. Vaandrager, F.J. Veenhof, M.M. van der Klaauw-
published by the Nederlands Insti tuut voor Preventieve Gezond-
heidszorg (NIPG-TNO) Leiden, 1984). 
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§2, Addendum 
The incidence of childhood diabetes in the Netherlands. 
A decrease from north to south over north-western Europe? 
1 . . 2 1 3 G.J. Vaandrager G.J. Bru1n1ng F.J. Veenhof , N.M. Drayer 
Netherlands Institute for Preventive Healthcare/ TNO, Leiden1 , 
Dept. of Pediatrics, Division of Endocrinology, Erasmus Universi-
ty and University Hospital Rotterdam/Sophia Children's Hospital, 
Rotterdam2 , Dept. of Pediatrics, Endocrine Unit, State Universi-
ty of Groningen, the Netherlands 3 • 
Accepted for publication by Diabetologia (1984), reproduced with 
permission. 
Introduction 
In the past decade incidence-rates of childhood diabetes (0-14 or 
0-19 years of age) were determined in all Scandinavian countries 
(1-4) and parts of the United Kingdom (S). In these studies high 
percentages of ascertainment were possible by virtue of the 
health-care system: drug-registry and hospital files could be 
used. In the Netherlands there is no nationalized health-care 
system, therefore such methods for ascertainment cannot be used. 
However there is an effective registration system. We decided to 
conduct a retrospective survey on the incidence of insulin depen-
dency among all diabetic children in the Netherlands from 0-19 
years of age, during 1978, 1979 and 1980. 
The Netherlands national register counted 4.46 million youngsters 
from 0-19 years at that time, of whom 6.1 percent were born to 
first generation immigrants. In the health-care system only pae-
diatricians and internists would treat insulin dependency in mi-
nors and both types of specialists act as registered consultants. 
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Methods 
A questionnaire was sent to all consultant paediatricians and 
consultant internists to obtain data on newly diagnosed children 
between 1978 and 1981. The questionnaire contained only questions 
regarding the initials of the child's name, sex, age, date of the 
first insulin injection and residence at that time (no attempt 
was made to identify children of immigrants or of non-caucasoid 
background). The same information was obtained separately from 
the Dutch Diabetes Association, to ascertain the data obtained 
from the questionnaire sent to the specialists. 
The questionnaire was sent to the 660 consultant internists and 
the 263 consultant paediatricians in the 181 general hospitals 
and to a contact person in each of the 8 internal medicine and 7 
paediatric university clinicsf including residential care cen-
ters. After one or two calls 100 percent of the paediatricians 
and residential care centres responded between February and Sep-
tember 1981. 
Patient-members of the Diabetes Association were requested to 
submit the same information after a call to do so in their month-
ly periodical, sent to all 35.000 members, 2.44 per 1000 inhabi-
tants, with a range from 1.87-3.26 per thousand over the eleven 
provinces in the Netherlands. The membership of the Diabetes As-
sociation is high as members can obtain treatment materials for 
retail prices at local offices of the Association. The request to 
the members was published at a time point that 80 percent of the 
specialist responses had been obtained. In addition to the above 
mentioned questions the members were also asked who was their 
child's doctor: all answers contained either a consultant paedia-
trician or a consultant internist, confirming the premise that 
all diabetic children were treated by either one of these consul-
tant specialists. Also, all treating doctors thus reported were 
present on our mailing lists. 
The paediatricians reported 856 children, the internists 415, to-
gether 1271 youngsters from 0-19 years of age in whom insulin 
substitution was initiated and continued in 1978-1980. 
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From the Diabetes Association 305 complete responses were obtai-
ned of which 268 could be found also in the specialist's respon-
ses. This implied a reporting percentage of 21 from the Diabetes 
Association and an ascertainment percentage of 88 of the total 
number of patients found by the questionnaire among the specia-
lists. For 1978 the ascertainment percentage was 85 percent, for 
1979 84 percent and for 1980 93 percent, not statistically diffe-
rent. The method used for the estimation of the corrected number 
of new patients and its confidence limites {expressed as s 0 in 
table 2) was based on the capture-recapture census described by 
Bishop et al. (6) and by Sekar and Deming (7). A premise with 
this method is that the response of the patients/members of the 
Diabetes Association was independent of that of the specialists. 
The homogeneity of each file (physicians and patient/members of 
the Diabetes Association) was tested by comparing ascertainment 
percentages found for answers with regard to age, sex, kind of 
specialist, grade of urbanization (8) of living place, month of 
the first insulin injection and province of living at that time. 
The two-sided chi-square test was used, no differences were found 
below the 5 percent level except for "age" and "kind of specia-
list". If however a distinction was made between paediatricians 
and internists this relation was no longer present: both the de-
gree of completeness of the files and the age of the patients 
were related to the factor "kind of specialist". The ascertain-
ment of the paediatricians 1 data (94 percent) was considerably 
higher than that of the internists (75 percent) (table 1). For 
the age-groups 0-4, 5-9, 10-14 and 15-19 the paediatricians as-
certainment percentages were respectively 98, 90, 97 and 100 per-
cent, of the internists -, 67, 70 and 77 percent. The material 
was split-up according to the two subgroups of specialists. The 
incidence rate was then calculated: the two sets of data were 
multiplied by the reciproce of their ascertainment percentages 
and subsequently added. Statistical calculations for geographic 
distributions and for degree of urbanization were done by the 
two-sided chi-square test, deviations from uniform distribution 
over the months of the year were tested by a modification of the 
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Kolmogorov/Smirnov test (9). The level of significance chosen was 
p < o.os. 
Figure 1 
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Figure 1 depicts the incidence by age at the first insulin injec-
tion, separated for the two sexes. The male to female sex ratio's 
in the different age groups were: 0-4 years: 1.18, S-9: 1.18, 
10-14: 0.94, 15-19: 1.34, for 0-14: 1.05 and 0-19: 1.12. 
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Table 1 shows the ascertainment percentages were 94 percent for 
paediatricians and 75 percent for internists, while this percen-
tage decreased also with age: a significant (p ~0.02) progressi-
ve decrease was found between five year intervals. 
Table 1 
Insulin dependency reported by type of specialist, patient/mem-
bers of the Diabetes Association, age in years and ascertainment 
percentage. 
Specialist Patient/ Both Ascertainment 
members files percentage 
Paediatrician 856 206 194 947p<0.001 
Internist 415 99 74 75 
0- 4 179 50 49 987p<0.02 
5- 9 323 90 80 89 
10-14 463 99 87 887 p<O .02 
15-19 306 66 52 79 
Table 2 indicates the incidence rates found with a distinction 
between sex and age, and the standard deviation (SD) of the me-
thod of estimation. The ascertainment corrected incidence was 
10.95/100.000 per year for 0-19 years and 11.10/100.000 per year 
for 0-14 years. The 95 percent confidence intervals were 
10.47-11.43 and 10.64-11.56 respectively for these age groups. 
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Table 2. The three-year incidence and the incidence per 100.000 
inhabitants per year according to sex and to age group 
(1978-1980); after correction for ascertainment. 
sex 
age 
(years) 
boys 
0- 4 
5- 9 
10-14 
15-19 
0-19 
girls 
0- 4 
5- 9 
10-14 
15-19 
0-19 
number s0 
102 
202 
261 
228 
790 
82 
164 
266 
163 
676 
3.4 
11.9 
11.2 
16.5 
22.8 
(-) 1 
5.9 
15.9 
16.8 
24.3 
1 Ascertainment 100 % 
mean population incidence per 
per year (Central 100.000/yr 
Bureau for Sta-
tistics, 1979-1982) 
456.327 
564.636 
625.878 
633.133 
2.279.974 
434.746 
539.960 
597.359 
605.746 
2.177.811 
7.45 
11.91 
13.88 
11.98 
11.55 
6.29 
10.11 
14.84 
8.95 
10.35 
0.25 
0.70 
0,60 
0.87 
0,33 
(-)1 
0.36 
0.89 
0.92 
0.37 
The range of the differences between the Netherlands provinces 
was 8.9-13.7/100.000 children from 0-19 years of age. These dif-
ferences were not statistically significant. 
"Countryside", "urbanized municipalities" and "large municipali-
ties" had incidence rates of respectively 11.61, 10.52 and 
11.14/100.000 per year, not significantly different. 
The distribution of the months of the year in which the first in-
sulin injection was administered revealed no statistically signi-
ficant differences for 0-4 nor for 5-9 year old children. In the 
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age groups 10-14 and 15-19 years a seasonal influence was present 
with the incidence rates higher in the winter months than in the 
summer months (p < 0. 05 respectively p < 0. 01, for these age 
groups) • When the seasonal varation was studied for the three 
years separately, these differences were significant for 1978 and 
1980, but not for 1979. 
Discussion 
The annual incidence found in the present study over the whole of 
the Netherlands (14.3 million inhabitants) was lower than that 
found in any other ascertained survey in western Europe conducted 
in the same time period. The trends in age of initiation of insu-
lin treatment and the distribution over the sexes were very simi-
lar to those found in other studies. The present survey found no 
seasonal variation in the onset of clinical diabetes in children 
younger than 10 years of age. No significant differences in inci-
dence were found with regard to the distribution over the provin-
ces of the Netherlands, neither in the degree of urbanization. 
This latter finding is perhaps not surprizing as truely rural 
areas are rare in the densely populated Netherlands. 
Given the limits of the Netherlands health-care system to employ 
drug-registry for ascertaining the data, the capture-recapture 
census method was chosen to calculate the confidence limits of 
the incidence found by two separate questionnaires. The advantage 
being that the largest childhood population so far could be exa-
mined relatively simply, the disadvantage being that an ascer-
tainment percentage of only 79 percent was found for the children 
aged 15-19 years. For children younger than 14 years of age al-
most all responses were obtained before the survey among members 
of the Dutch Diabetes Association was initiated an the ascertain-
ment percentage for that age-cohort was 94 percent. It is likely 
that the difference in ascertainment percentages found between 
paediatricians and internists was associated with the much higher 
"density" of newly diagnosed children seen by paediatricians than 
by internists. Over the three years of the study 3.25 cases were 
per reporting paediatrician (856/263) and 0. 62 cases per inter-
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nist (415/660). 
It was found that 837 newly diagnosed children from 0-14 years 
were reported by consultant paediatricians (94 percent) and 287 
children from 14-19 years by consultant internists (87 percent). 
These percentages indicate a referral pattern sharply distinct by 
the age of the newly diagnosed diabetic children in the dutch 
health-care system. 
The incidence found for children 0-14 years of age was almost 
threefold lower than that found in Finland (1) almost two-fold 
than in Sweden (2) or Norway {3) and also lower than that repor-
ted from Denmark, excepting children from 0-5 years old {4), As 
emphasized by Christau et al. (10) it is very difficult to compa-
re incidence rates even with high percentages of ascertainment as 
long as different methods were used. Yet, it is hard to conceive 
the magnitude of these differences would be only due to differen-
ces in ascertainment methods. Genetic differences are not a like-
ly explanation as childhood diabetes was associated with the same 
genotypes of the major histocompatibility complex in the Nether-
lands as in other north-western European countries (11). Over 
time, by comparing yearly incidence rates, remarkable changes in 
incidence rates have been noticed as well as two-fold differences 
between regions of the same country have been reported (1-5). 
However the numbers of newly diagnosed children involved in such 
breakdowns were small (10). 
In north-western European countries the incidence of childhood 
diabetes (0-14 years) appears to have increased over the past de-
cades (1, 5, 12). In the Netherlands the prevalence of diabetes 
among army conscripts at age 18 increased gradually from 0.99 per 
thousand in 1960 to 1.72 per thousand in 1980, indicating a simi-
lar trend. The incidence found in the present survey adds another 
suggestion: that of a possible north-south gradient over north-
western Europe. This suggestion is by no means proven but rein-
forces the importance of exogenous factors involved in the clini-
cal onset of childhood diabetes. 
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§3. Discussion 
The purpose of this discussion is two-fold: 
1. to give an estimate of the prevalence from the incidence data 
and to compare these data to findings elsewhere; 
2. to review data on viruses as exogenous factors in the etiology 
of childhood diabetes, as epidemiologic data have often been 
used as circumstantial evidence in this respect. 
1. Prevalence estimated from incidence. 
With certain provisos, one might attempt to estimate a prevalence 
from the incidence data, reprinted in the previous paragraph. If 
it is assumed the incidence of childhood diabetes did not change 
between 1959 and 1981 (the years in which the children encompri-
sed in the incidence study were born) and if corrections for 
changes in mortality and migration are omitted, the calculated 
incidences per year cohort may be added. This summation repre-
sents cumulated yearly incidences rather than a true prevalence, 
and includes the abovementioned provisos. The results of this 
calculation (6) are given in the next table. 
Table 1 Prevalence estimated from incidence rates, according to 
age group 
Estimated annual pre-
Annual incidence valence in 1980 
Age in years per 100.000 (1978-1980) !! per 1000 
o- 4 6. 8 142 0. 2. 
5- 9 11.0 598 0.6 
10-14 14.4 1346 1.1 
15-19 10.5 2149 1.7 
0-14 11.1 2086 0.7 
0-19 11.0 4235 1.0 
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An increase in the incidence? 
The thus calculated annual prevalence of 18 year old boys for 
1980 was 1.96 per thousand, the observed annual prevalence in ar-
my conscripts between 1978 and 1981 was 1.72 per thousand. The 
difference between this expected prevalence (projected from inci-
dences observed 1978-1980) of 1.96 °100 at age 18 and the obser-
ved prevalence at age 18 1978-1980 of 1. 72 °/00 for the male 
sex represents an educated guess because of the provisos made. It 
would suggest that a further rise in the prevalence of childhood 
diabetes incidence might be expected during the next decade in 
the Netherlands. A rise in the incidence of childhood diabetes 
during the past decades was however found in other north-western 
European countries as indicated in the previous paragraph. 
Comparison with other countries 
Table 2A shows the magnitude of the differences in incidences 
found between 1970-1980 for children 0-14 years old in north-wes-
tern European countries, performed on a nation-wide scale. Table 
2B shows the methods used and the ascertainment-percentages. 
Table 2A 
Country 
Finland 
Sweden 
Norway 
Denmark 
Netherlands 
Studies of the incidence of diabetes mellitus in 
children up to 14 years old over north-western 
Europe (1970-1980). 
Population - Time of Registration 
seize study 
1. 03 X 10 6 1970-1979 hospital-files 
(retrospective) 
1. 68 X 10 6 1977-1980 central registry 
(prospective) 
0.95 X 10 6 1973-1977 hospital-files 
(retrospective) 
0.51 X 10 6 1970-1975 hospital-files 
(retrospective) 
3.25 X 10 6 1978-1980 doctor's ques-
tionnaire 
(retrospective) 
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Table 2B. Ascertainment-procedures and incidence-rates found. 
Country 
Finland 
Sweden 
Norway 
Denmark 
Netherlands 
Ascertainment 
drug-registry 
hospital-files 
national insurance 
doctor's question-
naire 
death certificate 
army conscript data 
patient's question-
naire 
* after correction for ascertainment 
Percentage 
94 
93 
91; 93 
88;98 
90 
Incidence 
per 100.000 
28.6 
22.7 
17.6 
14.0 
11.1 * 
To illustrate that the design of these epidemiological surveys 
may have profound influences on the findings: in Sweden (7) a 
retrospective study (1970-1975) was conducted (foregoing the 
prospective study in this country comprised in table 2A and 2B) 
in 7 different hospital areas with a total population of about 
331.000 showing a mean yearly incidence of diabetes in children 
(0-14 years) of 19.6 per thousand. The prospective study (1977-
1980) over the whole Sweden found an annual incidence of 22.7 per 
thousand. More importantly, differences were seen in the varia-
bles studied: notably there was a significant increase of boys 
under age 5 developing the disease compared to the former study 
(8). In both the retrospective and the prospective survey there 
was no seasonal variation in the onset of diabetes in children 
below age 5. 
In the other studies of table 2 seasonal variation was also lack-
ing in these very young children. In the dutch survey, reprinted 
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in paragraph 2, this association was absent until an age of onset 
of 10 years. 
2. Viruses as exogenous factors 
Peak-incidences in the autumn and winter months have ofteh been 
taken to support the idea that viral infections might trigger the 
susceptibility to develop childhood diabetes. What is the eviden-
ce for this hypothesis from viral studies? 
Several studies have proposed a relationship between insulin-de-
pendent diabetes and Coxsackie virus (9), Rubella (10) and Mumps 
(12), next to Epstein-Barr virus, cytomegalia and poliomyelitis 
(11) . The evidence for Coxsackie virus (type B) is strongest and 
will therefore be considered in some detail. A two-year prospec-
tive study in the Montreal area (13) found no differences in an-
tibody titres to any of these single viruses in newly diagnosed 
diabetic children, compared to changes in antibody titres found 
in their healthy· siblings. It is of note though, a fourfold rise 
in antibody-titre to one or more Coxsackie (B1, B3, B4, B5) vi-
ruses was found in 30 of the 109 diabetics studied as compared to 
7 of the 72 healthy siblings. None of these diabetic children, as 
a subgroup, differed from the others, with regard to age or sea-
son of onset. This speaks against a common viral denominator as a 
single causative event of diabetes in childhood, despite the 
seemingly uniform clinical presentation of these children at 
diagnosis. Obviously, increases in viral antibody titres between 
0 weeks (at diagnosis) and 4 weeks later, provide circumstantial 
evidence only for viruses as causative agents. An interesting ob-
servation has been that two Mumps-epidemics were associated with 
two peaks in the incidence of childhood diabetes with an interval 
of about three years (12). 
Ji Won-Yoon et al. (9) reported direct evidence for viral invol-
vement as the cause for a first diabetic ketoacidosis, implica-
ting a variant of Coxsackie virus B4. They were able to isolate 
this virus from the pancreas of a 10 year old boy who died from 
this ketoacidosis, 7 days later. This, by itself, is a rare event 
in a clinic with much expertise in the treatment of that condi-
tion. It may therefore be that the sequence of events in this 
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particular patient was exceptional. Nevertheless, inoculation of 
mice with this human isolate produced hyperglycemia, inflammatory 
cells in the islets of Langerhans and beta-cell necrosis. In 1979 
for the first time, these authors were able to implicate a virus 
as the cause of diabetes in a child, fullfilling Koch's four pos-
tulates. However, the best evidence that viruses have a causative 
role in insulin-dependent diabetes has come from animal studies. 
In mice, the M variant of encephalomyocardi tis (EMC) virus can 
infect pancreatic beta-cells and produce a diabetes-like syndrome 
in certain inbred strains (14). In addition, variants of two vi-
ruses of human origin, reovirus type 3 and Coxsackie virus B4, 
could infect pancreatic beta-cells and produce a diabetes-like 
syndrome in, again, certain strains of mice (15,16). 
How do these virologic data fit together? Concentrating on Cox-
sackie B4 for the moment, diabetes seems unlikely to be a common 
sequela of this infection, as antibodies to this virus occur in 
about half the population (17,18), whereas the prevalence of dia-
betes mellitus before age 19 is much lower. Antisera prepared to 
prototype strains of Coxsackie virus sometimes produce little, if 
any, neutralization of newly isolated strains (19). Differences 
in the degree of neutralization also occur among subpopulations 
of Coxsackie virus particles isolated from the same virus pool 
(20). Finally, continuous passage of Coxsackie viruses in animals 
as well as in cell culture can alter their antigenicity (19). 
Preliminary studies with monoclonal antibodies prepared against 
Coxsackie B4 indicate that this serotype does not represent a 
single virus, but many variants which differ antigenically (21). 
This implies that Coxsackie-viruses may at present be difficult 
to detect serologically as a cause of childhood diabetes, but 
this certainly does not exclude the possibility thereof. Epide-
miologic evidence in England (22), the United States (14) and In-
dia (23), next to the prospective Montreal study as foremen-
tioned, support this view. Occasional reports of diabetes with 
rapid onset, during infections with Coxsackie B1 and B5 (24), B2 
(25), B4 (26), B5 (28) in addition to the evidence provided by Ji 
Won-Yoon (9) generate a compelling issue. 
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Animal experiments supporting the evidence are reviewed briefly 
next. 
In Ji Won-Yoon's case the isolated virus readily induced a diabe-
tic condition in certain strains of mice, neutralization tests 
indicated a close relationship between the virus isolated from 
the childs pancreas and another strain of Coxsackie developed in 
the laboratory with the purpose of inducing diabetes in these 
mice. Strains of viruses generated to induce diabetes in labora-
tory animals are developed by enriching pancreatropic viral sub-
populations through passaging the virus colonies on cultured be-
ta-cells, obtained from those laboratory animals, mostly mice 
(29, 21). To such diabetogenic viral populations not all labora-
tory animals (mice) were susceptible, For example, the mouse-
strains DBA/2J, SJL/J and Swiss were susceptible to such virus-
populations, with the exception that DBA/2J were resistant to 
Coxsackie B4. BALB/c and C3H failed, in any case, to develop vi-
rus induced diabetes (15). 
These experiments suggested the presence of a genetically con-
trolled common receptor on the surface of beta-cells, shared by 
different viruses. In the case of encephalomyelitis and Coxsackie 
B4 virus induced diabetes, not all mice reacted within the sus-
ceptible inbred strains, although mice of the same age and sex 
were used. This suggests that intrinsic, ~-genetic factors 
(e.g. metabolic factors) did have an effect on the extent of the 
virus induced diabetes. Successful attempts have been made to 
render mice more susceptible to virus-induced diabetes with 
treatments of subdiabetogenic doses of streptozotocin and gluco-
corticoids (32) . The fact that glucocorticoids rendered these mi-
ce more susceptable to virus induced diabetes, may be related to 
the clinical history of patient 3 {Chapter I - paper 4). 
Further evidence for non-genetic susceptibility to diabetes in-
duced by streptozotocin comes from the observation that the like-
lihood of diabetes-induction is inhibited by oestrogens, but po-
tentiated by androgens in BALB/C and C57BL/6 mice {31). 
This is of interest in relation to the decline of the incidence 
of diabetes during puberty observed in girls, preceded by a peak 
at the onset of their puberty, whereas in males a gradual but 
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higher incidence was observed throughout puberty (paragraph 2) . 
Mice have been shown to develop insulin-autoantibodies after vi-
ral infections (34). This raises another pathogenetic possibility 
resulting in a modification of the presentation of diabetic syn-
dromes, involving the hormone itself rather than the organ pro-
ducing it. The question than must be raised whether viruses in-
ducing diabetes in these laboratory animals are "pancreo-tropic" 
and/or "insulino-tropic". In the past 5 years we have noted the 
spontaneous occurrence of "classic" insulin-antibodies in 1 out 
of 59 (1978-1982) newly diagnosed diabetic children, i.e. prior 
to the administration of insulin. This occurred in 1978 in a four 
year old girl, but her sample was not further analyzed at the 
time, nor was it used for any of the studies of this thesis. 
Another aspect of viral involvement in the genesis of experimen-
tal diabetes should be mentioned: some beta-cell cytotropic reo-
viruses can infect the anterior pituitary and produce hypophysi-
tis (35) • This finding may be related to the fact that 16 percent 
of newly diagnosed children had antibodies reacting with diffe-
rent cells of the hypophysis (36) . The question whether viruses 
can be implicated in the cause of multiple endocrinopaties of 
which human diabetes mellitus takes part (adrenalitis, thyreoidi-
tis, pernicious anemia, e.g. diabetes-type-lb - table 1, Chapter 
I) 1 is at present unanswered. 
Taken together, viruses may be pancreo-tropic, insulino-tropic 
and they may also be implicated in the autoimmunities towards 
other endocrine organs. Variants of known experimental viruses 
could cause this spectre of autoimmunities in suitable animals. 
Such variants may well go undetected by the serologic techniques 
used for the detection of the species the variants are derived 
from. Furthermore 1 it has been suggested the susceptibility of 
the infected animals to develop insulin dependency may be enhan-
ced by sex-hormones and corticosteroids. 
The difficulty to identify the nature of diabetogenic viruses re-
mains, but again novel techniques may elucidate some of the pro-
blems. Dr. A.L. Notkins and his associates, at the National In-
stitute for Dental Research in Bethesda, discussed some of their 
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latest results using RNA-fingerprints to identify variants of the 
EMC-virus (encephalomyelitis-virus) at the IVth International 
Workshop on immunology of diabetes, held in London in 1983 (37). 
They suggested that there are two variants of EMC; variant D 
which causes diabetes in some strains of mice and variant B which 
does not. Biologically they are very different, but serologically 
not. Only RNA fingerprints show the difference between these vi-
ruses. At least one spot, spot 7A, is present in the D variant, 
but not in the B variant. Mengo virus causes also diabetes in 
mice, but it rarely affects humans. It causes diabetes in animals 
much more rapidly than EMC virus. The difference between Mengo 
and EMC does not show up serologically, but there are obvious 
differences in the nucleotide sequence of these viruses. There 
may be two types of receptors in the cells of susceptible hosts, 
one for Menge virus, one for EMC virus. 
To investigate receptor susceptibility to infection they studied 
the binding of EMC virus and Mengo virus to cells. Each virus was 
internally labelled through radiation and added to a suspension 
of pancreatic cells in which the binding of the virus was measu-
red. The rate of binding was rapid and (as expected) Menge virus 
was found to bind faster than EMC virus. In other tissues of the 
body, such as the thymus and spleen, the binding rate was very 
slow. Other tissues were therefore considered negative and were 
not affected by the viruses (37). 
These experiments show different affinities of viruses with a 
known chemical structure to specific organs e.g. the islets of 
Langerhans. The same group showed that the spleen cells of these 
mice could be stimulated with these viruses, indicating the viral 
receptors were in a dynamic state and could be modulated or in-
duced. This provides strong evidence for heterogeneity in viral 
receptiveness. It may be that such receptor heterogeneity is as-
sociated with the clinical variability of the expression of is-
let-cell damage: children at toddler's ages seem to suffer from a 
more rapid devastation of beta-cell function of the pancreatic 
islets than older children (1). 
The role of viruses in the etiology of childhood diabetes has 
further been underlined in the literature by the finding that one 
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third of the second cases in families already having a diabetic 
child would develop the disease clinically within three years of 
the first case (Chapter I - paragraph 5). In our own 22 multiplex 
families (Chapter I - paper 1) this was not the case. The time-
span between the clinical onset of insulin-dependency between the 
first and the second child (before the age of 19 years) varied 
from 3 months to 13 years. Only 3 of 22 such sibpairs became in-
sulin dependent within three years from each other. The develop-
ment of the disease in parents, if present, was even further 
apart in time. 
Such sequence of events questions the role of viruses in the sen-
se of viral infections in man. What other pathogenetic mechanism 
apart from infection may be suspected from viruses in the etiolo-
gy of type-1-diabetes? 
Retroviruses are the only group of RNA viruses that replicate 
through a DNA intermediate. Some members produce tumors or non-
neoplastic disease, others are not noticeably pathogenic. Retro-
viral genomes are essentially ubiquitous in vertebrate species 
and are maintained in nature predominantly as proviruses integra-
ted in the host chromosomes, thus being transmissable to the pro-
geny, as Mendelian genetic traits (endogenous retroviruses) • The 
activation of viral genes does not result necessarily in the pro-
duction of complete viral particles. Most often, the viral genome 
is only partially expressed (38). Products of endogenous retrovi-
ruses may stimulate specific humoral and cell-mediated immune 
responses in wild and laboratory animals. Natural antibodies to 
murine retroviruses are present in most mouse strains (39). Most 
recently, it has been demonstrated retrovirus genomes may be ex-
pressed at the pancreatic beta-cells of mice both in vitro and in 
vivo (38). It might be worthwhile investigating whether this ten-
dency is associated with an immune response to retroviral anti-
gens. As the expression of endogenous retroviruses is regulated 
by viral and host mechanisms and may be influenced by genetic and 
epigenetic factors, this hypothesis will be very difficult to 
test in man. Indirect evidence for this hypothesis may however be 
obtained by the finding of the integration of retroviruses to 
specific locations on chromosomes, in association with the ex-
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pression of type-1-diabetes, analogous to the expression of some 
forms of leukemia and mouse mammary tumours by viral integration 
and activation of oncogenes. 
Such mechanism of the involvement of virus particles would better 
fit the erratic and very partial inheritance of type-1-diabetes. 
With this concept of genetic susceptibility and viral particles 
acting in concert to cause the disease (Chapter I) , epidemiologi-
cal surveys may "create an awareness of the nature of the envi-
ronment in which disability arises, of the factors in the commu-
nity which contribute to its causation and, in turn, its effect 
upon the community." The incidence in male toddler • s may show 
other alterations over time than the incidence in, for instance, 
girls well into puberty. To monitor such alterations, ongoing 
prospective incidence studies are necessary. These prevail in 
Scandinavian countries. From Finland and Sweden a quite unexpec-
ted drop of 30 and 20 percent in the overall incidence of child-
hood diabetes (0-14 years) , respectively, has been noted begin-
ning in 1980 (Dr. J. Nerup, personal communication). 
Another major advantage of prospective surveillance of new cases 
of childhood diabetes is that it would provide a structure for 
the detection of sibs at risk for the development of the disease 
from the moment the first family member developed the disease. 
Family members are the prime population for the consideration of 
immune-preventive measures (Chapter I - paragraph 5). 
With this perspective, the study reprinted in paragraph 2 might 
have served as a pilot-study for the feasibility of ongoing pros-
pective studies in the dutch health-care system. 
Should it not be possible to establish ascertained ongoing pros-
pective surveys in the Netherlands, the presently identified re-
latively large group of diabetic children may be willing to co-
operate with retrospective investigations into environmental cir-
cumstances. These circumstances might include the influence of 
the vaccination status (40), of parental age (41) and of nursing 
habits (42). 
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§4. Summary 
The findings of Chapter II may be summarized as follows: 
1. The incidence (newly diagnosed children per year) of childhood 
diabetes in the Netherlands under the age of 19 years is 10.9 
per 100,000, under the age of 14 years 11.1 per 100,000, 
2. There is indirect evidence for a rising prevalence with time 
in the Netherlands. 
3. As in other surveys, young male children (0-4; 5-9 years) ap-
pear to be more susceptible than young female children, girls 
well into puberty have a lower incidence than pubertal boys. 
4. A seasonal variation is not seen in the age-cohort from 0-9 
years, for 10-19 year olds the incidence is higher in the au-
tumn and winter than it is in the summer months. 
5. No pronounced differences in incidence were found in the Ne-
therlands between provinces nor with different degrees of ur-
banization of the living place at the time the first insulin 
injection was administered. 
6. There appears to be a north-south gradient in the incidence of 
childhood diabetes over north-western Europe: the incidences 
reported are three times higher in Finland, two times higher 
in Norway and Sweden and slightly higher in Denmark, compared 
to the present rates in the Netherlands. 
7. Viral studies in newly diagnosed children have only occasio-
nally provided evidence for viruses as causative agents. 
8. Classic serologic techniques to detect viruses as causative 
agents are likely to fall short to do so. 
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9, The mechanism by which viral particles induce insulin depen-
dence in man may be examined by searching for integrations of 
retroviruses, known to be expressed on pancreatic beta-cells 
of mice. 
10. For a better understanding of factors associated with the cli-
nical expression of childhood diabetes ongoing, prospective, 
incidence studies are recommended. 
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CHAPTER III TREATMENT 
Primum nil nocere 
(Galenus) 
§l, An inventory of past and present trends 
Table 1 is a schematic representation of factors involved in 
the treatment of any chronic disorder of childhood, defined as 
lifelong illness. Factors are arranged at three levels of inter-
action (A, B and C) . Only those factors are included that under-
went most change during the past ten years with regard to the 
treatment of childhood diabetes. The purpose of this arrangement 
into three levels of interaction is to demonstrate that until 
some ten years ago two levels of table 1 appeared to belong to a 
separate realm of the literature. Studies on "attitudes" (table 1 
- A) were found almost exclusively in the psychosocial or public 
health literature. The instruments of the treatment proper (table 
1 - C) were the domain of the classic medical journals. In the 
past ten years medical units - pediatric and adult - have started 
programs to study the effects of modes of therapeutic interven-
tion at several levels of interaction. The determinants of thera-
peutic intervention (table 1 - C) are placed in the middle and 
are recurrent themes throughout the literature to date. 
Table 1. A schematic representation of the dynamics of the stra-
tegy of therapeutic intervention in childhood diabetes. 
A. Attitudes involved in therapeutic intervention. 
The family The child The Therapist 
B. Determinants of therapeutic intervention. 
State of Disease Aims Location 
C. Instruments of therapeutic intervention. 
Practical means Guidance Education 
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Before that time, the scope of studies was usually limited to in-
teractions within the levels indicated in table 1. For example, 
the need for patient-education has been recognized as long as in-
sulin-substitution exists (1) . 
At pediatric ages the increased awareness of all three levels of 
table 1 interacting in the treatment of childhood diabetes came 
also from experiences with summer camps for diabetic children 
{2). As a consequence, hospital-units started adding social wor-
kers and psychologists to their teams mostly consisting of a nur-
se, a dietrician and a physician. With these facilities, the 
scene was set to study different levels of interaction in the 
same group of children, pioneered by Prof. Z. Laron in Israel, 
Prof. D. Etzweiler in the U.S.A. among other investigators. 
It is of interest to note that countries, such as the Nether-
landsT that had no summer-camps for diabetic children, were late 
in establishing such teams. There was a well-known home for dia-
betic children with an experienced (para-)medical staff (Bosch en 
Duin 1972 - 1976). This however functioned as a residential care 
centre, despite efforts to have it function as an educational 
centre (3). 
In this inventory of past and present trends the most significant 
changes in concept over the past ten years will now be mentioned 
or briefly reviewed: 
A. Attitudes involved in therapeutic intervention . 
..!_. The family. 
The powerful role of the family in the management of childhood 
diabetes has been a recurrent theme throughout the literature. 
However, the studies used to be based on a linear model of family 
functioning. Interpersonal influences between parent (usually the 
mother) and child were seen as extending exclusively from parent 
to child. Because of its limits this approach has been seriously 
challenged {4). The focus of research has shifted to the broader 
family milieu, with an emphasis on patterns of cooperation and 
conflict among all members of the child 1 s family in implementing 
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the diabetic regimen. Major factors affecting the familial impact 
were the time spent in the home managing the disease and the 
amount of change in family life-style that had to be made (5). 
The above-mentioned shift in research on family-interactions to 
all family members does not imply a denial of the mother as the 
person most intimately bound to the repercussions of the disease. 
Earlier studies indicated that the following 11 aspects of care 
were of concern to mothers of diabetic children: injections, 
diet, control, hypoglycemic episodes, urine testing, finances, 
amount of help and support available, time demands, independence 
of the child, feelings that the disease is a stigma and fears 
about the future (6,7). 
A recent study explored how age, sex of the child, age at diagno-
sis and socio-economic status were related to the mother's per-
ception of problematic aspects of care {8). It was found that, 
for example, the younger the child was at diagnosis, the more the 
mother worried about hypoglycemic reactions; a short duration of 
the disease wa_s related to concern about insulin injections. 
This recent study described interactions between the mother's 
concerns and states of the disease, whereas earlier studies ex-
plored mother's fears as such. 
2. The child. 
At all ages, the occurrence of diabetes super-imposes new tasks 
and coping demands. It poses significant challenges to the normal 
developmental processes of childhood. Actual consequences of this 
fact have not been drawn systematically however. This is hardly 
surprising as most health-care professionals, patients and fami-
lies had no model that clarified the nature of such challenges in 
order to provide defined principles of effective treatment and 
preventive intervention. 
Only recently multivariate models for coping with predictable 
crises have been developed. The model referred to (5) is based on 
a construct of crisis, coping and social support as well as on a 
developmental and life course perspective. The essence of this 
model is that a time of crisis is not only one of demand and dis-
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tress, but also one of opportunity for a child that has most of 
its living time still to go. In predictable crises anticipatory 
coping can provide a basis for knowledgeable, competent health-
care behaviour and for mastery and personal growth in the face of 
adversity. 
Children show widely different levels of functional ability and 
personal satisfaction, independent of the degree of illness (9). 
Adopting a "wellness"- or a "sick"-stance is only very partially 
related to the state of the disease, as the perception of such 
stances during childhood will depend on family member interac-
tions, as forementioned. The medical desirability of metabolic 
control in childhood is unlikely to become achieved unless the 
diabetic life is tolerated by the child as a routine in the back-
ground of otherwise normal development. 
What are examples of predictable crises in childhood diabetes? 
1. disease-specific emotionally distressing symptoms 
{nycturia, failure to grow, early chronic complications); 
2. hospitalizations or increased frequency of hospital visits 
(fear for separation, impending separation, guilt-feelings); 
3. response to minor acute complications 
{fear for injections, low bloodglucose without symptoms); 
4. confrontation with therapeutic choices 
(seeing yet another specialist, advise of more insulin-injec-
tions per day) ; 
5. failure to obtain a desired therapeutic response 
(high bloodglucose despite diet-keeping); 
6. threat of coma 
(stepping up insulin-dosage, intercurrent illnesses)~ 
7. jealousy or resentment by sibs 
(extra attention devoted to patient, having to share limita-
tions of diseased sibling) ; 
B. fear of loss of esteem by peers 
(not being invited on parties or with the engagement of roman-
tic relations) . 
Readers familiar with the daily management of insulin dependency 
187 
will recognize each of such predictable crises and will be able 
to think of many more, challenging the emotional development of 
diabetic children. 
3. The therapist. 
In psychotherapy the attitude of the therapist is viewed as part 
of the medication. In somatic medicine there is the threshold of 
the power and magic physicians appear to operate with. 
Even to date, systematic investigations into the characteristics 
of attitudes that are associated with positive patient-physician 
interaction, desired by patients, are relatively rare in the me-
dical literature. Di Matteo et al (10) define the desired atti-
tudes (not knowledge or ability) of physicians by patients suffe-
ring from chronic disorders as follows: 
1. adopts a "person" rather than an "illness" orientation and is 
aware of developmental, psychological and socio-cultural fac-
tors; 
2. establishes a relationship of trust, shows respect for family 
members and has a non-authoritan, responsive mode of communi-
cating; 
3. works out mutual agreement with the patient On treatment goals 
and takes both medical and psychosocial needs into account; 
4. establishes a therapeutic team that includes the family, ad-
junct medical staff and physician as leader; 
5. emphasizes patient education, self-motivation and personal 
responsibility for implementing the medical regimen; 
6. is aware of predictable crises in the course of illness and 
provides anticipatory guidance, to minimize the impact and 
gives extra support during crises; 
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7. is aware of indications for counceling or psychiatric refer-
raL 
B. Determinants of the strategy of therapeutic intervention. 
1. The state of the disease 
A first requirement of knowledge on the nature and state of any 
disease is its frequency (Chapter II) • Ascertained studies on the 
incidence of childhood diabetes in large populations are not ol-
der than ten years, with a few exceptions (11). 
A second requirement of knowledge to the design of therapeutic 
strategy regards the "natural" course of childhood diabetes. This 
involves temporal courses - initial keto-acidosis, temporary re-
missions and the propensity of chronic complications - courses at 
different ages - toddlers - schoolchildren and adolescents - next 
to incidental courses - with infections, stress, excercise and 
with emotional upheaval - all of which go along with different 
requirements of insulin, hence strategies of therapeutic inter-
vention. The delineation of these temporal, age-related and inci-
dental courses of childhood diabetes has become increasingly more 
important throughout the medical literature of the past decades: 
the numbers of pages devoted to these aspects of the therapy of 
childhood diabetes in pediatric or diabetes textbooks has about 
doubled in the past ten years. The one characteristic of the dis-
ease that dominates all others with regard to the aims of treat-
ment is the relation between the quality of the metabolic control 
of the treated disease and the propensity of a great variety of 
chronic complications. The past ten years have not resolved this 
issue. Conflicting editorials in reknown medical journals and nu-
merous publications on the subject illustrated this. The recent 
initiative of the National Institutes of Health to reexamine this 
controversy by a multi-million dollar study is indicative of the 
persisting uncertainty. Both objectively quantifying degrees of 
vascular disease (12) and the accurate assessment of states of 
metabolic control (13) constitute major problems in resolving 
this classic dispute of internal medicine. In both fields signi-
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ficant advances have been made. To mention two examples: elegant 
techniques to evaluate early states of retinopathy (14) and neu-
rophysiologic studies on functional neuropathy (15). To illustra-
te the complexity of pathogenetic mechanisms underlying the con-
troversy: it was recently suggested that glycosylation of colla-
gen may result in the recognition of fibrous tissues as "foreign" 
by the immune-system (16). 
Aims 
Of course the aims of therapeutic intervention are in the centre 
of table 1. Although hotly disputed, they have changed little in 
the past ten years. Most pediatricians experienced in the treat-
ment of childhood diabetes would agree with the following four 
aims: 
1. normal physical development; 
2. normal emotional development; 
3. absence of overt acute symptoms of diabetes mellitus; 
4. metabolic control as good as acceptable by the child. 
Location 
A marked change in the past ten years came with the introduction 
of methods for self-monitoring of bloodglucoses (17). Management 
of diabetes, unlike that of many other disorders, depends on ac-
tive participation by the patient. This implies that diabetic 
control will be achieved by the patient at home and requires the 
establishment of a partnership between doctor and patient. Until 
the introduction of self-monitoring of bloodglucoses, it was cus-
tomary to employ urine testing as an index of metabolic control. 
The limitations to the usefulness therof are presently widely ac-
cepted (17), excepting the use of urinary ketones to detect immi-
nent metabolic disregulation at home (18). 
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C. Instruments of therapeutic intervention. 
Education 
The need for education of patients in treating their disease is 
as old as insulin itself and already Joslin indicated its para-
mount importance in 1924. In the past ten years separate sections 
of professional societies for diabetes education have started 
flourishing, in keeping with the notion that medical doctors are 
generally not trained to become teachers to their patients. Sys-
tematic studies evaluating various methods of teaching to pa-
tients or to patient groups have been published recently (19). 
Such studies comprised some quarter of the contents of diabetes 
journals as "Diabetes Care", established in 1976 through the ini-
tiative of the American Diabetes Association, to be followed by 
"Diabetic Medicine" in Europe in April 1984. 
Guidance 
Guidance is a terrible word as it pretends a lot while it may 
mean little by its passive significance. It is still used in the 
present context to indicate that scholarly knowledge and capabi-
lity of patients to manage their diabetes with the means provi-
ded, does not imply patients will thereby do so. The weight of 
individual circumstances, prevailing in the homes of children 
with diabetes, cannot be overestimated. Adolescents may resent 
their diabetes to the point of consequent denial and mothers of 
diabetic toddler's may be so entrenched in their fear for noctur-
nal hypoglycemia, that it may become difficult to have them cut 
down on the number of fingerpricks to measure bloodglucose in 
their child. Individual circumstances require the development of 
adapted strategies for such and other sub-groups of diabetic mi-
nors. The development of such strategies has only recently begun, 
in particular for adolescents (20). 
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Means of treatment 
Apart from the introduction of means for self-monitoring of 
bloodglucose, the most significant change of the past ten years 
was insight into the pharmaco-kinetics of various insulin prepa-
rations. The introduction of human insulins may represent pro-
gress to a lesser degree, as the immediate effectiveness thereof, 
compared to highly purified porcine insulins, differs hardly 
(21) . It is now clear (22) that 60 percent of al~ variation in 
bloodglucose-profiles of treated patients is associated with va-
riation in resorption from the subcutaneous depot, highly puri-
fied porcine- and human-insulin alike. It is perhaps surprising 
that it took more than half a century of insulin usage to arrive 
at this explanation. However, until recently, mono-iodinated in-
sulin tracers suitable for the study of the subcutaneous fate of 
injected insulins, were not available. It should be noted that 
the above figure of 60 percent was derived under metabolic ward 
conditions, with standardized injection techniques. It may well 
be that 60 percent is an underestimate in every day life, espe-
cially in children resisting the injections, resulting in even 
larger variation in bloodglucoses. 
Another new tool in the treatment deals with the evaluation of 
metabolic control: glycosylated hemoglobins. Although recently 
applauded in an Editorial of the New England of Medicine (13) its 
merits as an index of control in labile forms of childhood diabe-
tes have been insufficiently assessed. In view of the great po-
tential value of an independent measure of glycemic control in 
labile childhood diabetes, the clinical usefulness of different 
components of glycosylated hemoglobins was investigated in the 
second paper reprinted in this chapter. 
The first paper reprinted is a comparative study on modes of 
health-care delivery to diabetic children. Many of the factors of 
the strategy of therapeutic intervention aforementioned were in-
volved in this comparison. Present trends in therapeutic inter-
vention were incorporated, that were either emerging or ongoing 
at the moment the home-care study was initiated. It should be em-
phasized this was possible as all participants of the team for 
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the home-care had extensive experience with the treatment of 
childhood diabetes before. An important aspect of this study, its 
experimental design, is reported on first in the next paragraph. 
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§2. Design of the home care program 
The aim of the home-care-study 1 reprinted in the following para-
graph, was to investigate whether "home-care" might be a better 
and cheaper treatment modality for childhood diabetes than the 
current "hospital-based" systems in the Netherlands. 
The terms "home-care" and "hospital-based" suggest that the loca-
tion is the prime difference between these two systems. 
As will be demonstrated in the reprint, also the amount and type 
of education offered to the families differed, next to the avai-
lability of materials for the self-measurement of bloodglucoses 
at home, of a 24 hours telephone service and of regular advice by 
child-psychiatrists to the team treating the children. 
The keyperson in the execution of the home-care-program was and 
is the nurse practioner visiting the homes of the children. 
First, a prospective random assignment of all children attending 
the diabetes clinic to either home-care or continuation of hospi-
tal-based-care was considered, In the original proposal to the 
Ethical Committee of the Sophia Children's Hospital early in 
1978, a comparison between the results obtained in 18 months time 
in each group was planned. One of the provisos made by the Ethi-
cal Committee, worded by Dr. E. BenGershOm, was that this ap-
proach needed to be interrupted, as soon as it became obvious 
that children >vith home-care were better of in terms of admis-
sion-rates for metabolic disregulation or emergency visits to the 
out-patient department. 
The nurse practioner engaged in this study, Sister J.J. de Vis-
ser, started her work in September 1978. Her excellent training 
and subsequent experience in the ongoing treatment of children 
with diabetes from her previous position as nursing director of 
"Bosch en Duin" {home for diabetic children - Dr. S. G. Th. Hulst, 
medical director) soon paid off: in three months time, before 
Christmas 1978, the abovementioned proviso of the Ethical Commit-
tee appeared prophetic. Six children assigned to the "home-care-
group", known with a variety of problems with regard to their 
diabetes, improved considerably. It was obvious that children 
suffering from similar problems, but assigned to the other study-
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group, could morally not be withheld from the home-care for one 
and half a year for scientific purposes only. 
The randomized prospective design of the investigation comparing 
"hospital-based" versus "home-care" was then changed into a 
longitudinal follow-up comparing relevant parameters before home-
care was introduced (September 1977-September 1978) to changes 
found in a three year follow-up (September 1978 September 
1981) offering all children attending the clinic home-care at the 
same time. 
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§3. Addendum 
Paper 1 
Home Care for children with diabetes mellitus in the Netherlands 
G.J. Bruining, J.J. de Visser, A.E. Hart, M.S.Ph. Zwakhals, 
R.S.R. Aarsen 
Department of Pediatrics, subdivision of endocrinology, Universi-
ty Hospital/ Sophia Children's Hospital, Erasmus University, Rot-
terdam, the Netherlands 
Reprinted from: Recent Progress in Medico-Social Problems in Ju-
venile Diabetics. Z. Laron and A. Galatzer Eds. Pediat. Adolesc. 
Endocr. val. 11, pp. 81-85 (Karger, New York 1983), with permis-
sion. 
Introduction 
A three-year longitudinal study was done to compare effects of 
(traditional) "hospital-based-care" versus "home-care" (table I) . 
As parameters of effect three variables were chosen: (1) Admis-
sion rates to the hospital for newly diagnosed diabetes and pre-
existing diabetes, because of metabolic disregulation. (2) "Acu-
te" (i.e. non-planned) outpatient clinic visits, because of meta-
bolic disregulation. (3) The quality of metabolic control as evi-
denced by glycosylated hemoglobin. 
The crucial role of the nurse-practioner can be appreciated from 
her 5-fold task: (a) To evaluate knowledge and ability of diabe-
tic self-management as taught in five evening sessions, concluded 
by an examination. (b) To evaluate the execution of clinical ad-
vice at home and modulate it in timing and to individual family 
circumstances. (c) To visit homes in case of threatened disregu-
lation. {d) To ensure medical and social adjustment at school 
(half of the children gave a talk in the classroom. "Is diabetes 
contagious?" was a common question). (e) To signal long-term psy-
chosocial complications. These were discussed by the diabetes 
team including a child psychiatrist once monthly. 
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Table I. Sophia Children's Hospital - Diabetes Clinic 
Team 
A 
Hospital-based care 
2 pediatricians 
3 dieticians 
(no nurse-practitioner) 
Outpatient 3 - 4 times per year 
visits 
Telephone 
services 
Metabolic 
control 
Patient 
education 
(classes) 
Patient 
education 
(indivi-
dually) 
Child-
psychia-
try 
to pediatric 
resident-on-call 
only in emergencies 
fractionated 24-hour 
urines collected at 
home every 3 weeks 
on Sundays 
1 evening a year on 
mixed topics 
no structured program 
at clinic visits by 
dietician and doc-
tor 2 - 3 times a 
year 
only in emergencies 
B 
Home care 
2 pediatricians {the same 
3 dieticians as in A) 
1 nurse-practitioner 
3 - 4 times per year 
to nurse-practitioner or 
pediatrician, 24 hours a 
day, encouraged 
glycosylated hemoglobins 
at each clinical visit 
self-monitoring by urinary 
and blood strips 
5 evenings a year 
structured program direc-
ted at self-care 
at home (5 - 15 1-hour vi-
sits to each patient) 
at clinic visits by dieti-
cian, nurse and doctor, 
3 - 4 times a year 
round-table meeting with 
diabetes-team-members 
every 4-8 weeks, 1 hour 
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Subjects and Methods 
Table II shows the design of the study and characteristics of the 
41 children out of 78 selected for the longitudinal study compa-
ring the (traditional) hospital-based system and the home-care 
system. All children who had diabetes for 1.5 years or longer by 
September 1978, using 0.6 units of insulin or more per kilogram 
body weight per day, which excludes children with protracted re-
mission phases, were included. Newly diagnosed patients were all 
excluded for the longitudinal comparison, as well as referrals of 
children with treated diabetes. From September 1977 to September 
1981, 11 patients were referred to internists because of their 
age {15.6 - 18.1 years). Their average HbA1 was 12.1%. 
Temperature-controlled "Isolab" minicolumns were used to measure 
HbA1 . Bloods were drawn on ice at each clinic visit. Samples 
from patients to serve as internal standards were chosen, accor-
ding to suspect quality of control, yielding high, medium and low 
diabetic HbA1 percentages. Standards were stored for 2 12 
months and measured every week. The results are expressed as 
means ± 1 SE. 
High HbA1 ( > 13%) 18.0 ± 0.4% n 10 
Medium HbA 1 (10 - 13%) 12.3 ± 0.3% n 9 
Low HbA1 << 10%) 7.4 ± 0.2% n 8 
This implies an average coefficient of variation between assays, 
using the micro-column (Isolab) system, of 10 - 15% or, in terms 
of percentage HbA1X ± 1.0% (95% confidence limits).* 
* Total-glycosylated hemoglobins were assayed, e.g. without dis-
carding the fast-glycosylating component (paper 2) . 
Table II. Sophia Children 1 s Hospital - Diabetes Clinic 
Number of 
children 
Average 
age 
Age range, 
years 
Mean dia-
betes du-
ration, 
years 
Duration 
range, 
years 
Mean 
HbA1 , % 
Range 
HbAl, % 
1 Not done 
Sept. 1977 
to Sept. 
1978 
41 
9. 9 
4.0-13.8 
5.3 
1. 6-9. 9 
1 
1 
hospital 
based 
Sept. 1978 
to Sept. 
1979 
41 
10.9 
5.0-14.8 
6.3 
2.6-10.9 
12.9 
10.2-19.3 
home care 
Sept. 197 9 
to Sept. 
1980 
41 
11.9 
6.0-15.8 
7.3 
3.6-11.9 
13.2 
9.2-18.1 
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Sept. 1980 
to Sept. 
1981 
41 
12.9 
7.0-16.8 
8.3 
4.6-12.9 
12.7 
9.1-18.7 
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Table III. Hospital admissions at Sophia Children's Hospital 
Diabetes Clinic 
Number 
of child-
ren seen 
Admis-
sions 
days 
Metabolic 
disregula-
tion (ex-
eluding 
newly diag-
nosed) 
"acute" 
visits 
Newly 
diag-
nosed 
Admis-
sian 
days 
Sept. 1977 Sept. 1978 Sept. 1979 Sept. 1980 Diffe-
to to to to renee 
Sept. 1978 Sept. 1979 Sept. 1980 Sept. 1981 factor 
1977-
1980 
78 88 99 106 
160 (2. 4) * 65 (0. 8) * 38 (0. 4) * 8 (0. 08) * - 30x 
24 (0. 3) * 10 (0. 09) * 3 (0. 02) * 1 (0. 01) * - 30x 
11 10 12 8 
209 (19) 141 (14) 40 (3. 3) 26 (3. 2) - 6x 
hospital 
based 
home care 
* the numbers between parentheses represent averages per child in 
the years indicated 
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Results 
Table III lists the hospital admission rates before and during 
the home-care system. Also the number of "acute" (i.e. non-plan-
ned) clinic visits are shown. The numbers between parentheses in-
dicate the number of hospital days and acute visits per child. 
Finally the numbers of hospital days for newly diagnosed children 
(initial treatment) are given. With the home care the number of 
hospital days, because of metabolic disregulation, excluding ini-
tial treatments, decreased 30 times, as was the decrease in acute 
visits. 
The first HbA1 value during the period September 1978 to Septem-
ber 1979 in the 41 children was 14.2% compared to an average va-
lue of 12.9% for the whole year, suggesting an improvement asso-
ciated with the change in medical regimen. Girls in puberty did 
much worse than boys, their average HbA 1 over the 3 years fol-
lowed was 14.3 versus 12.2% in boys. Whereas boys were able to 
maintain the same level of control before and in puberty, the pu-
bertal girls did not. 
Discussion 
As early as 1924 Joslin (1) recognized the paramount importance 
of diabetes education to adults and children alike. Since diabe-
tic regimens involve diet, insulin injections, testing of urine 
or blood, diabetes treatment became teamwork, including dieti-
cians, nurses and doctors (2). Centres treating childhood diabe-
tes have added social workers and psychologists or child psychia-
trists to these teams, as it became obvious that psychological 
stability of the families of these children was a major determi-
nant for the outcome in terms of hospitalization and quality of 
metabolic control (3). 
Approaches such as these have indeed led to fewer hospitaliza-
tions and better metabolic control, as evidenced by patient's 
urinary test results (4). From this achievement on, pediatric 
centres have focused on behavioral or psychologic issues, such as 
coping styles (5) , compliance (6) , maternal emotional adjustment 
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(7). More recently the focus of this sort of research has shifted 
to the broader family milieu (8) and it became apparent that all 
family members are active and interdependent contributors to the 
effectiveness of diabetes management at home. If one accepts this 
viewpoint it is obvious that the home of the children deserves 
more attention. The 96% acceptance rate of the families receiving 
the nurse-practioner in their homes 2 - 15 times per year illus-
trates that she was not felt to be an intruder into family inti-
macies nor to impose unintelligible or impossible medical desir-
abilities on the families. 
In a country with small distances and with an unbridgeable gap 
between the hospital and the homes, as all internists and pedia-
tricians act as consultants, the visiting experienced nurse-prac-
tioner is a crucial and economic adjunct to the care for diabetic 
children. 
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Paper 2 
Limitations to the use of glycosylated hemoglobins as 
a parameter of glycemic control in childhood diabetes 
Aanstootl' . . 1 H.J. G.J. BruJ.nJ.ng S. Zwakhals 1 , A. van Rhijn2 
From the Department of Pediatrics, Subdivision of Endocrinology, 
Erasmus University and University Hospital/Sophia Children's 
Hospital, Rotterdam1 and Kinabu, Soesterberg2 , the Netherlands 
Submitted for publication. 
Abbreviations used: 
HbA 1 (%) 
t-HbAl (%)= 
glycosylated hemoglobins, percent of total hemoglobin 
total-glycosylated hemoglobins, percent of total he-
moglobin 
f-HbA 1 (%)= fast-glycosylated hemoglobins, percent of total hemo-
globin 
s-HbA1 (%)= stable-glycosylated hemoglobins, percent of total 
hemoglobin 
IEF 
bgl 
Summarv 
iso-electric-focussing 
bloodglucose concentration in roMol/L. 
The clinical utility of glycosylated hemoglobins to interprete 
degrees of hyperglycemia in childhood diabetes was investigated 
by in vitro and irr vivo studies. Two components of glycosylated 
hemoglobins (fast- and slow-glycosylating) were measured by stan-
dardized micro-column-cationexchange chromatography. Stable-gly-
cosylated hemoglobin assayed by this method correlated well with 
iso-electric-focussing (r = 0.92). 
Red-cells of normal subjects and diabetic children were incubated 
with physiologic and supraphysiologic (25 mMol/L) glucose to stu-
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dy the formation of fast-glycosylating hemoglobin after 24 hours 
incubation. Red-cells were separated according to their age in 
the circulation by discontinuous density gradients. 
Young red-cells already contained 60 percent or more of the gly-
cosylated hemoglobins of older or all red-cells, both in normals 
and in diabetic children. These young red-cells acquired fast-
glycosylated hemoglobins much more readily on incubation with 25 
mMol/L glucose for 24 hours than older red-cells. 
Glycosylated hemoglobins in young red-cells, fast-glycosylated 
hemoglobins and stable-glycosylated hemoglobins in all red-cells 
were compared to different time-courses of glycemia in eight la-
bile diabetic children over eight weeks time. The findings cau-
tion against the use of these measures of glycosylated hemoglo-
bins as parameters of hyperglycemia in labile type-1-diabetic 
children: correlations between any of the measures and time-cour-
ses of hyperglycemia never exceeded r = 0.6 by Spearman's test. 
The determination of t-HbA1 , f-HbA1 and HbA1 content of erythro-
cyte-age-separations did not reflect the glycemia of labile dia-
betic children. 
Introduction 
To obtain an index of previous mean glucose concentrations over 
weeks or months, the measurement of glycosylated hemoglobins 
(HbA 1 ) is advocated {1,2). HbA 1 are known to consist of at least 
two components, one fast-glycosylated {f-HbA1 J, the other stable-
glycosylated (s-HbA1 J (3). 
In this investigation the significance of these two measures to 
retrospectively interprete time-courses with different degrees of 
hyperglycemia in labile childhood diabetes was explored. 
First, the most commonly used method for the assay of HbA1 
{micro-column-cationexchange chromatography) was compared to iso-
electric-focussing (IEF). Given a satisfactory comparison, a 
standardized micro-column-procedure was used throughout the stu-
dy. 
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Second, the time kinetics of the formation of f-HbA 1 and s-HbA1 
from glucose was studied in vitro. This was done before and after 
separating the red-cells according to age on discontinuous densi-
ty gradients and subsequently incubate these red-cell populations 
with normal and supraphysiologic glucose concentrations. These 
procedures provided data on the content and saturability of to-
tal-HbA1 (t-HbA1 ) , f-HbA 1 and s-HbA1 in young and older red-cell 
populations in the circulation of diabetic children, compared to 
those of normal subjects. 
These measures were then compared to blood-glucose-profiles found 
over eight weeks time in eight labile diabetic children staying 
in a residence. 
Methods 
All assays took place within three hours after sampling. Hepari-
nized blood aliquots were kept at 4°C in the meantime. 
1. Columnchromatography for HbA1 
Micro-columns (IsolabR Akron, Ohio, U.S.A.) were used according 
to the procedure from the manufacturer and kept in a constant 
temperature-water-bath (22°C), while standard hemolysates were 
co-measured in all tests. These standards of t-HbA1 (diabetic 
plus non diabetic) were kept at -70°C and results of these were 
as follows (means ± S.E.) 
High HbA 1 standard ( > 13%) 
Medium HbAl standard (10 - 13%) 
Low HbA 1 standard << 10%) 
18.0 ± 0.4% 
12.3 ± 0.3% 
7.4 ± 0.2% 
n 
n 
n 
= 
= 
10 
9 
8 
This implies an average coefficient of variation between assays, 
using the micro-column-(Isolab)-system, of 10 - 15% or, in terms 
of percentage HbA 1 : ¥ ± 1.0% (95% confidence limits). 
To determine s-HbA1 blood was washed two times, the erythrocy-
tes diluted in 1:10 saline and incubated at 37°C for six hours. 
To determine t-HbA 1 , 50 microliter of whole blood was immediate-
ly hemolysed. 
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2. !so-electric-focussing (I.E.F.) 
This method was originally described and modified by Jeppson (4). 
LKB AmpholineR FAG-plates (LKB-Produkter AB, Sweden) were used. 
The coefficient of correlation (Spearman's test) gave a rho of 
0.92 for IEF versus s-HbA1 % by micro-columns chromatography for 
45 samples over a s-HbA1 range of 7 - 16 percent. 
3. Incubations of erythrocytes 
Blood was taken by venapuncture from six diabetic and four non-
diabetic subjects. Red-cells were washed three times in saline. 
t-HbA1 was determined before the red-cells were incubated for 
six hours in saline to determine s-HbA1 . After this the cells 
were washed and diluted to a hematocrite (Ht) of 0.50. A sample 
was then taken to determine s-HbA1 . 
Incubations were in basal medium Eagle (BME) with Hanks salts 
(GibcoR biocult) with added adenine, bicarbonate and glucose to 
physiologic concentrations. A 37°C incubator with 5 percent co 2 
was used. Cells were suspended in the medium and put in Petri-
dishes. Dilution was at an hematocrite of 0.20 1/1, glucose con-
centrations used for incubation were 5 and 25 mMol/1. HbA 1 was 
determined every four hours until a maximum of 24 hours. After 
harvesting the erythrocytes, a sample of the medium was taken to 
exclude hemolysis. The cells were then washed three times and 
glycosylation measured as f-HbA 1 and s-HbA1 . Young cells and 
unfractionated erythrocytes (see below) were incubated, one in 
5mMol/l glucose, the other in 25 mMol/1 glucose. Diabetic as well 
as non-diabetic erythrocytes in sterile conditions were studied. 
4. Density separation of erythrocytes according to age 
A modification of the method described by Rennie et al (5) was 
used: discontinuous gradients were prepared to harvest a greater 
and quantifiable amount of erythrocytes of a different age. This 
was done by taking different mixtures of BSA-PercollR (Pharmacia, 
Sweden) and the BSA-water solutions and carefully layering these 
on top of each other by means of threechannel-peristaltic pumps. 
First testruns were made with 74 - 85 percent BSA-PercollR >vith 
steps of 2 percent. For each layer 1. 5 ml was used. After the 
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testruns a suitable gradient was chosen with narrower ranges of 
percent BSA-Percoll R, to yield five different layers (red-cell 
age groups). Ten tubes were used for each person. 
After washing in saline, 1.5 ml of suspended erythrocytes 
{Ht = 50 percent) were layered on the top of these gradients. 
Centrifugation was according to Rennie et al (5). 
A small amount of clumped cells was exclusively found in the bot-
tom layer and data from this layer were excluded from further 
analyses. The method separated young cells from old cells: no re-
ticulocytes were found in layers lower than the top one. For 
cell-age control various tests were used immediately after sepa-
ration. 2,3-diphosphoglycerate (2,3-DPG, mMol/1 ery) (6), gluco-
se-6-phosphate dehydrogenase (G-6-PD, mU/10 9 ery's) (7), pyruva-
tekinase (PK, mU/ 10 9 ery's) (7), reticulocytes (0 /00) and mean 
cellular volume (MCV, fl) ( 6) were decreased in older erythrocy-
te fractions, as expected. These parameters were determined in 
young (layer 1), medium (layer 3) and old erythrocytes (layer 4). 
Hematological indices were calculated after determination of Hb, 
Ht and erythrocytes number in a Coulter counter. Enzymes and 
2, 3-DPG were tested with BoehringerR Testki ts (Boehringer-Mann-
heim, FRG). All determinations were in duplo. The results are in 
table l. 
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Table 1. Density red-cell separation of blood of four diabetics 
and four normal subjects: data expressed (± 1 S.D.) as 
percentage of all washed cells (100%) of diabetics 
(upper half) and of normals (lower half) 
washed 
cells 
young 
cells 
(layer 1) 
Diabetic 
old 
cells 
(layer 4) 
Diabetic 
young 
cells 
(layer 1) 
Non-Diab. 
old 
cells 
(layer 4) 
Non-Diab. 
reticulo- MCV 
cytes 
100% 100% 100% 
266±53 104±3.0 82±4.0 
0% 98±1.5 106±3.5 
250±20 101±0.4 85±3.8 
0% 98±2.0 109±5.0 
G-6PD PK 2,3-DPG 
100% 100% 100% 
244±114 223±45 140±20 
97±20 70±21 80±32 
198±12 131±12 110±10 
86±11 57±21 45±12 
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Patients 
An 8 weeks' study with eight diabetic children was conducted at 
the Kinabu medical residence (consultant pediatrician A.v.R.), to 
which the children were admitted because of inadequate metabolic 
control, with or without psychosocial problems. The eight child-
ren (mean age 13. 6 ± 2. 2 years, range: 10-16) and their parents 
gave their written consent to have bloodglucose-determinations by 
fingerprick, urinary glucose and ketones twice daily in addition 
to 24 hours-bloodglucose-profiles once a week, during 8 weeks. 
This "home"-monitoring was under day and night supervision of the 
health-care-personnel as was the administration of insulin. Body-
weight was determined once a week. Changes in diet and insulin 
were done by one of us (A.v.R.), who was kept unaware of the HbA1 
results. Four children and parents also agreed to have venapunc-
tures once a week to determine additional HbA1 measures, inclu-
ding erythrocyte-age-separation. Daily records of each child were 
kept of daily activities, symptomatic hypo/hyperglycemias and in-
tercurrent illnesses, 
All children were well beyond the remission-phase of their diabe-
tes and were on combinations of long and short acting highly pu-
rified porcine insulins twice daily. The findings on HbA1 % and 
on insulin dosages and diets used are in table 2. 
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Table 2. Total and stable glycosylated hemoglobins (± 150) in 8 
labile diabetic children over 8 weeks time with 
averaged insulin dosages and caloric intake. 
patient rrean rrean s-~ change in rrean insu- rrean 
t-HbA1 s-HbA1 1in/U/kg/ Kcallkg/ 
weekl-8 day day 
1. 14.4 ± 0.8 12.9 ± 0.7 + 1.1 0.8 25 
2. 12.8 ± 0.8 11.9 ± 0.6 - 0.1 0.4 55 
3. 15.7 ± 0.5 13.9 ± 0.6 - 0.5 0.6 28 
4. 11.6 ± 0.8 10.4 ± 0.4 + 0.7 o. 7 41 
5. 12.9 ± 0. 7 12.1 ± 0.8 - 0.4 0.6 52 
6. 14.9 ± 0.6 13.8 ± 0.8 + 1.9 0.8 39 
7. 12.3 ± 0.8 11.1 ± 0.5 - 0.4 1.2 49 
8. 10.8 ± 2.1 9.4 ± 0.2 + o. 7 0.9 68 
rreans 13.2 ± 1.7 11.9 ± 1.6 
Changes in s-HbA1 (95 percent confidence limits - 1% s-flli11_) between the 
beginning of the study (~k 0) and the end ('week 8). There was no correlation 
(p { 0. OS) between the averaged insulin dosage and the averaged calories taken 
per day. Patients 1 and 3 used rrost insulin ccmpared to their caloric intake. 
Bloodqlucose and urine analysis 
done with Ames-glucometersR 
which correlated well capil-
Bloodglucose-determinations were 
(Ames Netherlands B.V., Mijdrecht) 
lairy GOD-determinations (r = 0.93). 
M-values were calculated as the index of glycemic excursions for 
the whole period according to Schlichtkrull et al. (8). All 
children at the residence had M-values above 30, confirming the 
lability of their diabetes. 
Urine analysis was done with Ames-GlucosticksR and -KetosticksR 
twice daily. 
The findings on bloodglucose-profiles and M-values are in table 
3. 
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Table 3. Glucose-Erofiles in 8 labile diabetic children over 8 
weeks time. 
patient age mean blcxxl- mean bql. du- mean fas- mean of mean 
in glucose ring first 2 ting bgl. 24-hours M-
years in rrMol/L weeks minus profiles value 
mean bgl. du- of bgl. (see 
ring last 2 text) 
weeks 
l. 16 16.5 ± 2.4 + 2.5 15.4 ± 2.3 15.7 ± 3.0 68 
2. 12 10.5 ± 3. 7 + 4.2 9.9 ± 3.1 10.5 ± 3.7 32 
3. 15 10.2 ± 6.9 - 6.4 9.5 ± 6.3 9.9 ± 4.5 67 
4. 16 11.0 ± 5.5 + 1.0 10.0 ± 3.9 9.2 ± 3.8 50 
5. 10 11.7 ± 4.3 - 0.6 10.0 ± 3.9 12.1 ± 4.4 45 
6. 12 12.4 ± 5.8 + 6.2 9.9 ± 4.8 11.3 ± 2.8 61 
7. 15 9.6 ± 3.8 + 0.3 8.3 ± 1.7 11.3 ± 2.3 33 
B. 11 12.4 ± 5.0 + o.s 12.1 ± 4.9 11.3 ± 2.8 55 
means: 12.4 11.8 ± 2.2 10.8 ± 2.2 11.4 ± 2.0 51 
Patients 1 and 3 were selected for a visual comparison between bloodglucoses 
and glycosylating components of~ (figure 2). 
Results 
1. In vitro studies: incubation of red-cells of diabetic children 
and normal subjects. 
Table 4A contains the findings by incubating red-cells at 5 
rnMol/L glucose (normal concentration) and 25 mMol/L glucose (su-
praphysiologic concentration) in young and all red-cells of four 
normal subjects. Table 4B contains the same data on red-cells ob-
tained from six diabetic children. 
By these short-term incubations the s-HbA1 content did not 
change and the difference between "starting s-HbA1 " and "final 
t-HbA1 
11 was due only to increment of f-HbA 1 , as indicated next 
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in figure 4A. Young red-cells acquired f-HbA1 significantly fas-
ter on incubation in 25 mMol/1 glucose, both from diabetics and 
from normals. Calculated slopes in increment were respectively 
0. 20 and 0.17 for these categories, whereas all red-cells had 
slopes of 0.06 and 0.09 for diabetics and for normals. The fin-
dings demonstrate different kinetics for the formation of 
f-HbA 1 in young cells as a fraction of all red-cells. 
Furthermore, young red-cells before incubation contained already 
60% or more of the HbA1 contents of all red-cells. This relation-
ship was also found in 30 other 
in figures 4A and 4B. In these 
content (t-HbA1 
0.5-3.0%. 
s-HbA1 ) was 
diabetic samples, not comprised 
30 samples the average f-HbA1 
1.7% HbA1 with a range of 
Table 4A. Increment in f-HbA1 by the incubation of red-cells 
in two glucose-concentration over 24 hours in young 
red-cells and all red-cells of four normal subjects 
- means and ranges. 
All red-cells 
in 5 Itt>bl/L 
in 25 Itt>bl/L 
Young red-cells 
in 5 Itt>b1/L 
in 25 Itt>bl/L 
Starting 
s-~% 
7.6 
7.6 
5.6 
5.6 
(6.5-8.1) 
(4.9-6.3) 
Final 
t-~% 
7.3 (5.5.-9.1) 
9.1 (8.6-9.5) 
7.9 (7.5-8.3) 
8.9 (8.6-9.2) 
Calculated 
slope of 
increment 
0 
0.09 
0.12 
0.20 
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Table 4B. The same experiment as in table 4A, for red-cells of 
six diabetic children. 
All red-cells 
in 5 nMol/L 
in 25 nMol/L 
Young red-cells 
in 5 rrMol/L 
in 25 rrMo1/L 
Starting 
s-HbA1% 
13
·
8 {13.5-14. 7) 
13.8 
not done 
7.7 (6.7-8.9) 
Final 
t-HbA1% 
14.0 {13.3-14.9) 
15.4 (13.3-16. 7) 
11.1 (10. 7-12.1) 
Calculated 
slope of 
increrrent 
0.01 
0.06 
0.17 
2. Clinical studies: Comparison between bloodglucose-profiles and 
HbA 1 
All measures of glycosylated hemoglobins (f-HbA1 , t-HbA 1 , s-HbA1 
of all red-cells and t-HbA1 of young red-cells) were compared to 
glucose-profiles of the eight children studied over 8 weeks (glu-
cose in the bloodsarnple itself, 24 hours bloodglucoses on the 
previous day, the same day, the previous 1 - 8 weeks and all 8 
weeks). Glucosuria was also compared to these measures of HbA 1 . 
The linear regression coefficient was never greater than 0.6 ex-
cepting for a comparison between: 
the bloodglucose of the sample itself and t-HbA1 
{r = 0.96) and s-HbA1 (r = 0.91); 
mean of 24 hours bloodglucoses the same day and t-HbA1 
(r ~ 0.60) 
It was to be expected that the mean of these widely fluctuating 
bloodglucoses over the 8 week period correlated only weakly to 
final glycosylated Hb-values (t-HbA1 : r 0.34, s-HbA1 : r 
0. 20) • 
To illustrate the lack of correlation between components of 
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HbA 1 and episodes of glycemia in these labile patients visually, 
the clinical time-course of two children is represented in figure 
2. 
Figure 2. 
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In the upper panel averaged bloodglucoses of 24 hours profiles 
(closed circles) and means of daily bloodglucoses (open circles) 
were plotted against time. In patient 1 high, but stable blood-
glucoses were seen, whereas patient 3 had {symptomatic) hypogly-
cemia during week 2 and 3, despite the temporary decrease of her 
insulin dosages. 
In the middle the t-HbA1 % of both young and old cells failed to 
show a significant decrease up to five weeks after this hypogly-
cemic episode in patient 3, whereas patient 1 showed a decrease 
in t-HbA1 % of young cells during the first three weeks, not re-
flected by the expected closely time-related changes in bloodglu-
cases. 
Discussion 
Although the existence of fast- and stable- glycosylating compo-
nents of HbA1 has been well recognized (9,10,11), the time-kine-
tics of the formation of these two components have not been re-
solved {10). Yet the separate measurement of these two components 
might be useful if fast-glycosylation reflected glycemic control 
over shorter periods and stable-glycosylation over longer periods 
of time. 
In the present study fast-glycosylation was examined by the sepa-
rate assay of f-HbA1 (t-HbA1 minus s-HbA1 ) and by the HbA1 con-
tents of young erythrocytes, that have had shorter exposure times 
to the glucose of the plasma than older red-cells. 
The precision of the micro-column system used was 1 percent of 
HbA 1 (95 percent confidence limits), s-HbA1 thus measured compa-
red well to the IEF-method. 
In individual samples f-:HbA1 did not correlate with either t-HbA1 
or s-HbA1 , endorsing the premise that f-HbA1 might separately re-
flect short episodes of hyperglycemia. This however could not be 
demonstrated from the correlation with glycemia over short pe-
riods of time in eight labile diabetic children. 
Also, the HbA 1 content of young erythrocytes failed to do so, 
which could be explained by the finding that these young red-
cells contained olready 60 percent or more of the total HbA1 con-
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tent of all red-cells, despite their shorter living time in the 
circulation. Furthermore, young red-cells (of normals as well as 
of diabetic children) acquired HbA1 faster than all red-cells on 
incubation in supraphysiologic glucose-concentrations. 
These findings suggest that shorter episodes of glycemia cannot 
be detected by either f-HbA 1 or by the HbA1 content of young red-
cells. The red-cell separation method was validated by the fin-
ding of the expected differences in hematologic as well as bio-
chemical parameters for red-cell age. Red-cells from layer 4 in 
the present discontinuous density separation experiments correla-
ted with age parameters for all red-cells, including HbA1 , indi-
cating this separate represented average red-cells. This is ex-
plicable by the fact that the young cells thus separated compri-
sed only 10 percent of the red-cells (6,10). In keeping with this 
study Spicer et al (12) found that incubation of red-cells with 
different glucose-concentrations showed a linear increment of the 
HbA1-content with time, in red-cells of normals and of diabetics. 
As in this study, this increment was due to f-HbA 1 and not to 
s-HbA1 . Gillery et al (13) reported that young cells are capable 
of actively transferring glucose to hemoglobin by means of a red-
cell membrane fraction. Kinetics might therefore differ in young 
cells. Differences in passive glucose permeability between red-
cells were found by Higgins et al {14) . Furthermore glycosylated 
products with other time-kinetics may be assayed by the present 
methods as recently suggested by Garlick et al (15). These au-
thors found that by rechomatographing "HbAlc" (from Biorex-70 
columns) on a Glycogel B boronate affinity resin gave a 70 per-
cent adherence indicating that less than 30 percent of the 
"HbAlc" consisted of hemoglobin with beta-chain terminal valine-
bound glucose, The remainder of this "HbA1c" was glycosylated 
HbA0 , with 14 percent alpha-chain N-terminal valine-bound gluco-
se, 40 percent alpha-chain lysine- and 46 percent beta-chain ly-
sine-bound glucose. The kinetics of these compounds are diffe-
rent, compared to each other. This may be connected to the pre-
sent finding, that even s-HbA1 correlated with glucose of the 
sample itself. 
To circumvene the co-chromatography of glucose-adjuncts to hemo-
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globin other than at the beta-chain terminal valine (HbA1c) , 
the thiobarbituric-acid-method has been propagated. One of the 
problems with this method however is that the colour-development 
differs with the incubation conditions of the hemolysate and with 
the use of acetic acid instead of oxalic acid in the incubation 
mixture (16). 
In this study there was no relation between the formation of com-
ponents of HbA1 and the glycemic control in labile diabetes of 
childhood. The determination of fast glycosylated products or the 
HbA1 content of young erythrocytes did not reflect shorter epi-
sodes of glycemia, studied over 8 weeks time. 
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§4, Additional findings with home care 
The purpose of this paragraph is to communicate additional fin-
dings with the home-care project. These findings relate to: 
a. Patient-selection. 
b. Nature of admissions and acute visits. 
c. Patient education. 
d. Self-monitoring. 
e. Metabolic control. 
f. Economy of home-care. 
a. Patient-selection. 
The deviation from a randomized prospective design with the home-
care study (described in paragraph 2 of this chapter) necessitates 
a more detailed account of the selection of patients that 
participated in the comparison between "hospital-based" and 
"home-care". This comparison dealt also with HbA1 % before and af-
ter the introduction of the home-care system (table II of paper 1 
- page 198) and involved 41 children. 
In the year before the home-care system was introduced 78 child-
ren (table III of paper 1 - page 199) visited the diabetes clinic, 
from which 78 - 41 = 37 were excluded by the following criteria: 
having diabetes for 1.5 years or less by September 1977 25 
newly diagnosed between September 1977 and September 1978 11 
referred by pediatrician and back to pediatrician 1 
37. 
Newly diagnosed patients and children with a duration of 1. 5 
years or less may have (remnant) endogenous insulin secretion, 
which facilitates the achievement of good metabolic control. Such 
achievement would not be due to the home-care system employed. 
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The changes in admission-days and acute visits (table III of pa-
per 1 - page 199) before and after home-care was introduced were 
plotted against the number of all children attending the qiabetes 
clinic. Table 4.1 of the present discussion indicates the numbers 
of children entering or leaving the diabetes clinic, during the 
follow-up. 
Table 4.1. Flux of patients seen at the Sophia Children•s Diabe-
tes Clinic. 
All children 
seen 
Newly 
diagnosed 
Referred 
with trea-
ted diabe-
tes by pe-
diatri-
cian {n=19) 
Referred back 
to -pediatri-
cian (n=lO) 
Referred to 
internist (n=ll) 
Moved out 
of area (n=2) 
11Drop-outs" 
{n=2) 
September 1977 September 1978 September 1979 September 1980 
September 1978 September 1979 September 1980 September 1981 
78 88 99 106 
11 10 12 8 I 
in 
1 7 7 4 l 
0 2 l 7 1 0 4 4 3 
out 
l 0 0 1 1 2 0 0 0 
"hospital-based" "hare-care" 
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Children leaving the diabetes clinic ("out" in the table above) 
comprised: 
10 children referred back to the pediatrician elsewhere. These 
10 children all came from the 19 referred to the clinic be-
tween September 1977 and September 1981 by pediatricians else-
where ("in" in the table above). None of these 10 children re-
ferred back was admitted to the hospital, nor did they visit 
the clinic in emergency situations. 
11 children were referred to the internist because of their 
age. Between September 1977 and September 1978 their averaged 
number of admission-days was 2.0 days, less than the average 
of 2. 4 days for the whole patient-population in that time-
span. The same applied for acute visits. Between September 
1978 and September 1981 none of these children was admitted 
nor did they visit the clinic acutely because of metabolic 
disregulation. Their HbA1 were 12. 2% on the average (with a 
range of 10 - 16.3%) not different from the HbA1 % of the 41 
children of table II of paper 1 - page 198. 
2 children moved out of the area, without being admitted or 
visiting the clinic acutely, their averaged HbA 1 being 11.8% 
and 12.0%. 
1 patient was excluded from these tabulations: she was refer-
red in November 1979 with an extremely brittle diabetes, ne-
cessitating the use of subcutaneous continuous insulin infu-
sion started in July 1980. She was admitted for more than 100 
days and her case history has been reported elsewhere (23) . 
Taken together, there is no evidence for referral bias with re-
gard to admission-days, acute visits or HbA1 % in the conventio-
nally treated children with diabetes mellitus tabulated in table 
III of paper 1 - page 199. The same reductions in admissions or 
acute visits for metabolic disregulation were seen with the in-
troduction of the home-care system in the 41 children that were 
selected for the follow-up of metabolic control, as in all child-
ren attending the diabetes clinic. 
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b. Nature of admissions and acute visits. 
The next tabulation (table 4. 2 of this discussion) summarizes 
numbers of children, the nature of their admissions, acute visits 
before and after home-care, including the number of newly diag-
nosed children that received initial treatment without being ad-
mitted to the hospital. 
Table 4.2. Nature of metabolic disregulation before and after 
horne-care. 
Number of ad-
mission-days 
Number of 
children ad-
mitted 
Hyperglyce-
mia/ketosis 
Hypoglycemia 
Number of 
acute visits 
Hyperglyce-
mia/ketosis 
Hypoglycemia 
Number of new-
ly diagnosed 
children 
Number of new-
ly diagnosed 
children not 
admitted for 
initial treat-
ment 
September 1977 September 1978 September 1979 September 1980 
September 1978 September 1979 September 1980 September 1981 
160 
13 
9 
4 
24 
10 
14 
11 
0 
65 
5 
3 
0 
10 
5 
5 
10 
0 
38 
3 
2 
1 
2 
0 
2 
12 
5 
8 
1 
1 
0 
1 
0 
1 
8 
6 
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After the introduction of home-care the principal reason for ad-
mission was decreased consciousness. In cases of hyperglycemia/ 
ketosis, this coincided with a blood Ph of 7.25 or less including 
more than 5 percent dehydration by weight. In cases of hypoglyce-
mia, this involved failure of self-administered glucagon and sub-
sequent carbohydrate intake to normalize consciousness. In the 
first year of the home-care project (September 1978 - September 
1979) three of the five acute visits occurred because of hypogly-
cemia in families that had not yet been trained in the use of 
glucagon. A similar situation led to admission in two of the 
three admissions for hyperglycemia/ketosis in that year: these 
two families called the help of the nurse practioner only 48 
hours after the initiation of symptoms. 
Not given in the above table are the numerous visits by the nurse 
practioner, especially during the first year of the horne-care, to 
assist families in actually treating hypoglycemia or hyperglyce-
mia/ketosis at home: the nature and severity of such metabolic 
disregulations varied too much to allow a classification thereof. 
c. Patient-education. 
Teaching to patients was both to individual families at home and 
in "class-rooms" in the hospital. 
Home-teaching was mainly on insulin-injections (all patients ha-
ving diabetes, except the two "drop-outs", were put on insulin 
injections twice daily once the "honey-moon"-phase was over), 
self-monitoring and adaptation thereof in individual circumstan-
ces (sports, parties etc.). 
Class-room-teaching was in five evening sessions held once a year 
for parents of whom the children were first seen during that 
year. By this sequence class-room teaching reinforced the indivi-
dual lessons taught at home. The evening sessions contained an 
intermission of of half an hour, during which parents got to know 
each other. In the first two years of home-care separate evenings 
were held for the parents of the other children, that were not 
newly diagnosed during that year. 
The program was: 
1st evening 
2nd evening 
3rd evening 
4th evening 
5th evening 
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a. causes of diabetes; 
b. insulins, insulin action. 
a. self-monitoring (also practical); 
b. special situations to use self-monitoring. 
a. diet and dietary allowances; 
b. insulin, self-monitoring and diet. 
a. inheritance, chronic complications, 
choice of profession; 
b. pregnancy, anti-conception, 
future developments. 
a. multiple choice examination; 
b. results of examination, final discussion. 
Part a. (before the intermission) took three quarters of an hour, 
part b. (after the intermission) also, including one quarter for 
questions and discussion. The setting was informal, not involving 
more than 35 parents per class. The attendance-rate was 70 - 80 
percent of the parents invited. Care was taken not to expose pa-
rents of very recently diagnosed children to this program, but to 
advise them to participate in the next years class. 
This examination is reprinted next. 
Exam for parents of children having diabetes mellitus 
All questions are multiple choice. You are kindly requested to 
darken the circle left of the right answer. 
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Example: 
Diabetes of childhood is caused by taking too much sweets. 
a. 0 partially correct 
b. e not correct 
c. 0 correct 
b right answer. 
1. A "hyper" (high bloodsugar) is caused by ... 
a. 0 too little insulin-effect 
b. 0 too much insulin-effect 
c. 0 too little food 
d. 0 a + b 
2. Glucose (the main energy source of the body), in case of too 
little insulin-effect, is ..• 
a. 0 not taken up sufficiently by body-cells and subsequently 
utilized to yield energy 
b. 0 converted into ketones 
c. 0 taken up rapidly by body cells and subsequently utilized 
to yield energy 
3. Ketones (acetone) appears in the urine, if 
a. 0 too much fat is broken down, because there is too much 
insulin-effect 
b. 0 too much fat is broken down, because there is too little 
insulin-effect is. 
c. 0 none of these (a + b) 
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4. A child with diabetes may have high bloodsugars (or urinesu-
gars) also if the child eats little or nothing. This is be-
cause 
a. 0 the body will produce glucose from the liver, if there 
is too little insulin-effect 
b. 0 food is not carbohydrates only and the body can make 
glucose from other nutrients 
c. 0 both answers (a + b) are correct 
5. The following values of a home-made bloodglucose (day + night) 
profile are within the "diabetes-norm 11 : 
a. 0 2. 2 
b. 0 4. 4 
c. 0 4. 4 
22.2 
10.0 
13.3 
6. Reading the Hemoglucotest (Chemstrip) you will note by prefe-
rence? 
a. 0 2.2 4.4 
b. 0 2. 2 
c. 0 4. 4 
7. The strip for urinary ketones is called? 
a. 0 Diabur 
b. 0 Hemoglucotest (Chemstrip) 
c. 0 Ketur 
8. The new strip for urinary glucose can read? 
a. 0 until 5 grams per 100 ml urine 
b. 0 until 2 grams per 100 ml urine 
c. 0 until 10 grams per 100 ml urine 
9. Using Hemoglucotest (Chemstrip) the use of a stopwatch is 
a. 0 desirable 
b. 0 necessary 
c. 0 cumbersome 
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lO.Glucagon-injections are used in case of ... 
a. 0 low bloodsugar 
b. 0 low bloodsugar if the child cannot or will not take su-
gar 
c. 0 with vomiting 
ll.Glucagon is injected 
a. 0 like insulin 
b. 0 in the muscle 
c. 0 both answers (a + b) are correct 
12.Glucagon will ... 
a. 0 raise the bloodsugar 
b. 0 raise the blood sugar within 10 minutes 
c. 0 raise the blood sugar within 10 minutes, but the child 
must eat subsequently and have bloodsugars measured 
13.Insuline Actrapid works ... 
a. 0 12 hours 
b. 0 6 hours 
c. 0 24 hours 
14.Insuline Mixtard is ... 
a. 0 1/3 short acting, 2/3 long acting 
b. 0 1/2 short acting, 1/2 long acting 
c. 0 2/3 short acting, 1/3 long acting 
15.The most common cause of swinging bloodsugars is 
a. 0 eating too much 
b. 0 irregular resorption from the injection site 
c. 0 irregular meal-times 
16.The most common cause of fat-pads is ... 
a. 0 injecting too superficially 
b. 0 injecting at one spot 
c. 0 both answers {a + b) are correct 
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17.A five year old child wakes up and is drowsy, nauseated, re-
fuses breakfast. What would you do? 
a. 0 take the body-temperature, weight and test for urinary 
ketones and call the hospital 
b. 0 give the usual insulin-dose and do as under a 
c. 0 give sugarwater and do as under b + a 
d. 0 take bloodsugar and do as under a 
18.This child has diabetes for one half year and takes 18 U of 
insulin per day in the morning only. The bloodsugar is 
13.3-22.2 and urinary ketones are 2+. No fever. The doctor/ 
nurse advises to give 4 U Actrapid insulin extra. What would 
you do next? 
a. 0 check every urine for glucose and ketones 
b. 0 check bloodsugar and urinary ketones some 4 hours later 
and call back. 
c. 0 go to the hospital 
19.Another child, 10 years old, wants to participate in an eve-
ning running-match over 5 miles. She takes 24 U of insulin in 
the morning and 8 U in the evening. What would you do? 
a. 0 give extra food before the match 
b. 0 as a, but give 4 U instead of 8 U 
c. 0 as a + b and check bloodsugars before and after the 
match 
20.The following week she has a barbecue-party at 20.00 hours. 
What would you do? 
a. 0 give 12 U instead of 8 U at her usual dinner time 
(± 18.00 hours) and have her take her usual dinner 
b. 0 give the usual 8 U at ± 19.30 hours and tell her to take 
as much food at the party as she would at dinner time 
c. 0 give her 12 U at ± 19.30 hours if she wants to eat more 
at the party than at dinner, after explaining her how to 
do this 
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2l.This same girl is on summer-vacation in Southern-France. It is 
warm and she runs, swims the whole day. What do you suspect? 
a. 0 that less insulin will be needed 
b. 0 as a and try this by taking morning and late afternoon 
bloodsugars 
During the intermission of the last evening the answers were 
checked, the number of correct answers indicated and the forms 
returned to the parents. The average percent of acceptable an-
swers was 85 percent, with an annual range from 70 - 92 percent. 
Answers to questions on materials and their use (insulin, blood-
glucosestrips) were almost invariably correct. Mostly also on the 
(difficult) clinical questions at the end of the examination. In-
terestingly, most errors were in answers on questions on insulin 
action, apparently by their abstract nature. 
d. Self-monitoring. 
The primary aim of self-monitoring was avoidance of hypoglycemia 
and symptomatic hyperglycemia. The secondary aim of self-monito-
ring was to get an impression of bloodglucoses during a given 
day-and-night, taken four times a year. Children and/ or parents 
preferring not to do the latter, got treatment advices on the ba-
sis of clinic visits once every 6 - 8 weeks. This included histo-
ry-taking and the measurement of HbA1 %. This latter category con-
sisted entirely of children of 12 years or older. They constitu-
ted about half of the population over that age seen in the first 
year of home-care. Presently (1983) 24 of 71 of the children of 
12 years or older prefer not to note and report their bloodgluco-
ses to the clinic, except under pressing circumstances, such as 
intercurrent illnesses with impending ketosis. Of these 4 will 
not visit the clinic at the recommended 3 - 4 monthly intervals. 
It should be mentioned here that dutch health-care insurance com-
panies, with few exceptions, cover the costs, for 80 - 100 per-
cent, of 25 bloodglucose-strips per month since 1983. Before that 
time the costs were covered by the home-care project budget and 
by the separate support of the local national insurance institu-
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tion (Stichting Rotterdamse Ziekenfondsen) mediated by its medi-
cal advisor Mrs. dr. H. Boers. 
An important aspect of self-monitoring of bloodglucose is quality 
control. Measured in a glucose-reflectometer the linear correla-
tion coefficient of these strips with the laboratory GOD-method 
on 100 diabetic samples was r = 0.96. 
The form used by the families to note self-measured bloodglucoses 
is reprinted next. 
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Bloodsuqar day-and-night curve 
Name ••••• , • , . • • • • • • . . • . . . . . . • . . . . . . Doctor's notes •.......... 
Day and date 
Insulin dose and sort ......•••.•• + 
1 hr after before 1 hr af- before 
n.p.o. breakfast lunch ter lunch supper 24 hrs 3 hrs 
n.p.o. 
Tirre 
(marine 
times) 
Blood-
sugar 
Urine-
test 
Extra 
food 
Extra 
exer-
cise 
Hyp:::>'s? 
Hyper's? 
Note: it is assumed taking the rreal takes not rrore than 20 minutes. 
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The day-and-night curves of 15 families, were time-labelled by 
the families and stored in the container of the bloodglucose-
strips, that has an exsiccator. In the hospital these were read 
again within 48 hours and compared to the values reported by the 
families. This involved 105 bloodglucose-strips in total. The 
bloodglucose-strips used (Hemoglucotest 20/BOOR, Boehringer, 
Mannheim, F.G.R.) are read in ranges: 1.1 - 2.2 mMol/L, 2.3 - 4.4 
mMol/L, 4.5- 6.6 mMol/L, 6.7- 10.0 mMol/L, 10.1- 13.3 rnMol/L, 
13.4 - 22.2 mMol/L glucose. The fifteen families were selected in 
case of doubt of the quality of their bloodglucose-assessments. 
The following deviations were noted with these 105 strips: 
failure to note two rather than one glucose-
value as the estimate of bloodglucose, but 
otherwise agreement 
hospital reading off one range of estimate 
by patient (all at 3 A.M.) 
not readable 
hospital reading off more than one range 
of estimate by patient 
skipped time-points of day-and-night curve 
(6x at 3 A.M.) 
£• Metabolic control. 
25 X 
3 X 
4 X 
0 X 
30 X 
During the hospital-based period the assay of glycosylated hemo-
globin (HbA1 ) was not available, hence a comparison between gly-
cemic control achieved by hospital-based and by home-care with 
this parameter is not possible. 
During the three years of the home-care project total glycosyla-
ted hemoglobins (t-HbA1 %) were measured (table II of paper 1 -
page 198). The findings of paper 2 however question the signifi-
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cance of this measurement. Therefore no statistic was used to 
examine possible changes in t-HbA1 % during the horne-care. 
With the limitations of HbA1 % as an index of glycemia in mind, 
the self-measured bloodglucoses of the 41 children (table II of 
paper 1 - page 19 8) were examined. This method was introduced 
with the home-care system, hence only changes during home-care 
were evaluated. 
The following scoring-system was designed, using the bloodgluco-
se-strips described earlier. 
Result of self-measurement 
glucose mMol/L 
< 1.1 
1.2 - 2.2 
2. 3 - 4.4 
4.5 
-
6. 6 
6.7 
- 10.0 
10.1 
- 13.3 
13.4- 22.2 
>22.2 
Points 
3 
2 
1 
0 
0 
1 
2 
3 
As indicated earlier almost half of all children seen of 12 years 
and older preferred not to produce bloodglucose day-and-night 
profiles at each 3-4 monthly visit. 
38 of the 41 children chosen for the follow-up (that were much 
younger, see table II of paper 1 - page 198) had home-profiles 
made at the frequency intended throughout the three years of the 
follow-up of home-care. Only if the 3 A.M. value was included and 
contained seven or more time-points measured in total, their pro-
file was used to calculate "points" according tot he above sco-
ring-system. The parents were instructed to avoid days with in-
tercurrent infections, and unusual physical exercise. The fami-
lies produced three or more of such profiles during each year of 
the home-care. The "points" of each child's profile were counted 
and its summation averaged per child per year of home-care. This 
is represented in the following tabulation. 
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First year Second year Third year 
Scoring points 4.18 3. 74 2.66 
(means and 
range) (3 - 1 0) (2 - 10) (1 - B) 
% lower than 
4.4 mMol/L 4 6 9 
% higher than 
10 mMol/L 43 37 24 
To clarify the significance of this scoring-system: 2 scoring-
points implies that 5 of 7 glucose-measurements of a given pro-
file were between 4.4 and 10.0 mMol and that 2 measurements were 
one range below or above this value. In the last year of the pro-
ject and thereafter (1982 - 1983) many curves were seen with a 
one-hour post breakfast-value of 10 - 13.3 mMol/L and a 3 A.M. 
value of 2.1 - 4.4 mMol/L, the remaining values between 4.4 and 
10.0 mMol/L. This does not necessarily imply improved overall me-
tabolic control. The trend indicates only that parents, along 
with home-care, were able to arrive at improved bloodglucose-pro-
files. 
f. Economy of home-care. 
The costs of the home-care during 1980 were in Hfl.*: 
Nurse-practioners-salary + social securities 
Nurse-practioners-transport 
Telephone (hospital + parents) - estimated 
Strips for selfmeasuring glucose-ketones 
Secretarial help, printing, mailing 
60,000.--
10,000.--
2,000.--
10,000.--
8,000.--
90,000.--
* 1 Hfl. 1 dutch guilder equals about 30 (US) dollar cents 
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The hospital-costs during home-care in 1980 were in Hfl.: 
1 acute visit (hospital + parents) - estimated 
8 admission-days for treated diabetes 
(1 hospital-day in 1980 casted 400) 
26 admission-days for 8 newly diagnosed dia-
betic children (26 x 400 = 10,400) 
400.--
3,200.--
10,400.--
14,000.--
In 1980 106 children attended the diabetes clinic and a total of 
Hfl. 104,000.-- was spent or Hfl. 980.-- per child. 
The costs of the hospital-based-care during 1977 were in Hfl.: 
Telephone (hospital + parents) - estimated 1,000.--
Fractioned 24 hrs urinary glucose- and ketone-
determinations n = 42 
a. transport by parents - estimated 
b. laboratory costs 
5,000.--
10,000.--
16,000.--
The hospital costs during hospital-based-care, based on 1980-
norms were in 1977 in Hfl.: 
24 acute visits (hospital +parents) - estimated 9,600.--
160 admission-days for treated diabetes 64,000.--
209 admission-days for 11 newly diagnosed dia-
betic children corrected to 152 days for 8 
(the number of newly diagnosed children in 
1980) 60,800.--
134,400.--
In 1977 78 children attended the diabetes clinic and a total of 
Hfl. 158,400 was spent or Hfl. 2,030.-- per child. In conclusion, 
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in the same clinic the costs per diabetic child were two-fold 
lower with home-care than with the hospital-based-system-care. 
The savings by decreased admission-days for newly diagnosed 
children were almost as high as those by savings on admission-
days for treated diabetes. 
The Netherlands have a national hospital registry (Stichting Me-
dische Registratie in Utrecht) , which collects all admissions to 
95 percent of all hospitals in the Netherlands. The admissions 
are distinguished by principal and primary (or secondary) diagno-
ses e.g. diabetes mellitus (principal diagnosis), metabolic dis-
regulation (primary diagnosis) . The sex and age of the patient 
are noted as well as the duration of each admission. Data were 
purchased from the Stichting Medische Registratie for 0 - 16 year 
old children with the abovementioned principal and primary diag-
nosis: 
Nation-wide admission-days (1978-1980) 
Diabetes mellitus, metabolic disregulation, 0 - 16 years. 
1978 
1979 
1980 
or 
19,800 
21,100 
20,900 
61,800 
20,600 days per year averaged. 
The average duration for diabetes mellitus/metabolic disregula-
tion - first admission - was 21 days. This figure compares well 
to the 19 days in 1977 during hospital-based-care in our clinic, 
spent by newly diagnosed children for initial treatment. For the 
nation-wide incidence study (Chapter II) an ascertainment correc-
ted number of newly diagnosed children (0 - 16 years of age) du-
ring those same years of 1,320 children was found, or 440 child-
ren per year. The nation-wide number of admission-days for ini-
tial treatment may be estimated at 440 x 21 days per child: 9,240 
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days. By substraction of this number from the total number of ad-
mission-days (20,600) the annual number of admission-days for me-
tabolic disregulation after initial treatment may be estimated: 
20,600 - 9,240 = 11,460 days. 
With an estimated prevalence for diabetes (0 - 16 years) of 3,000 
(Chaper II) it follows that each diabetic child would be admitted 
for metabolic disregulation after initial treatment for almost 4 
days per year on the average! This is even higher than the 2.4 
days per diabetic child found during hospital-based-care in the 
Sophia Children's Hospital in 1977 (table III of paper 1 - page 
17). 
With these nation-wide data on all admission-rates, the costs 
were 20,600 x 400 = Hfl. 8,36 million in 1980. The savings by a 
(hypothetical) nation-wide introduction of the home-care-system 
would comprise Hfl. 4 million if only the savings observed in the 
Sophia Children 1 s Hospital were extrapolated. From this amount of 
money alone, some 40 home-care-projects could be maintained, each 
costing Hfl. 100,000.-- per year. 
By assigning 100 children to each project, the total prevalence 
of childhood diabetes in the Netherlands (0 - 19 years) would be 
covered. 
240 
§5. Discussion 
Large reductions in admission-rates of diabetic patients after 
reorganization of care to these patients was first reported in 
1972 from a large U.S. county hospital (24), followed by other 
centres for adult patients (25) and children (26). The efficacy 
of our present home-care system was assessed by comparing admis-
sion-rates before and after the introduction of the home-care. 
Also nation-wide admission-rates were used for this purpose. Na-
tion-wide admission-rates were collected from a central hospital 
registry, marked by "diabetes mellitus - primary diagnosis, meta-
bolic disregulation - secundary diagnosis". This should exclude 
for example "diabetes mellitus, appendicitis", but the data pur-
chased from the central registry were not ascertained. 
In the Funen County of Denmark (450,000 inhabitants) hospitali-
zations of all previously ascertained type-1-diabetic patients 
were followed for eight and a half years by record linkage, but 
the data were also scrutinized from the medical records them-
selves by the investigators (27). Age, sex and nature of admis-
sions were recorded. Boys from 1 - 14 years spent 3.62 days per 
child per year in the hospital for metabolic disregulation of 
their diabetes, girls 5.90 days. These admission-rates from the 
Funen County were virtually identical to the admission-rates seen 
in the Sophia Children's Hospital before the introduction of 
home-care: 160 days for 78 children with treated diabetes and 209 
days for 11 newly diagnosed children, totalling 4.19 days per 
diabetic child per year (table III -paper 1 -page 17). 
The health-care system employed in the Funen County resembled the 
hospital-based system of the Sophia Children's Hospital very clo-
sely (27) and suppo;ted the use of the hospital-based data as a 
reference for the efficacy of home-care indirectly. 
Again in Denmark, but in another area, a home-care study very si-
milar to the present one was initiated at exactly the same time 
as the present one (28). This study was a randomized prospective 
investigation involving newly diagnosed patients (mostly adults) 
to be followed over two years. A 2. 4-fold drop in readmission-
days was found in patients receiving home-care compared to the 
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group of patients, not visited at home. 
At the same time stable glycosylated hemoglobins in these newly 
diagnosed patients were significantly better in the home-care 
group, but not the profiles of home-bloodglucose or -urinary glu-
cose measurements. In the present study an improvement in scores 
of home-glucose-profiles was found, but glycosylated hemoglobins 
were found unreliable in children, that were all well beyond 
their remission-phase. 
It should be emphasized however the improvement in bloodglucose-
profiles may not have been due to home-care as a system, but ra-
ther to the fact that almost all patients were put on a twice 
daily insulin regimen with the introduction of horne-care. Also 
improved bloodglucose-profiles do not necessarily implicate bet-
ter overall metabolic control, but they indicate better patient 
education and ability to arrive at such improvement by patients. 
No firm conclusions can be drawn with respect to changes in the 
quality of metabolic control by virtue of the present home-care. 
The potential economic savings by home-care, extrapolated from 
the savings found by reduced admission-rates in the Sophia Child-
ren's Hospital appeared large enough to justify wider application 
of home-care for diabetic children. Yet the calculations used may 
be invalid. Citing an economist: "You did not save Hfl. 400. per 
admission-day reduced as hospitals won't close down beds. You 
saved mainly hospital-meals and -laundry". On another occasion 
with tenured health-care politicians: " .... nice study .... , but 
this system affronts present health-care policies attempting to 
have health-care provided at home by family physicians and local 
general nurses, away from hospitals". The author wishes to ac-
knowledge the economic, medical and nursing directory of the So-
phia Children's Hospital for their offering the nurse practioner 
of this study a position in their nursing staff to continue home-
care. Their decision to do so was effectuated as soon as the 
funds for the home-care project, kindly donated by the Dutch 
Children's Stamp Fund and Novo Industri B.V., expired in 1981. 
Perhaps home-care is a model for other complex chronic disorders 
of childhood. 
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§6. Summary 
The findings of Chapter III may be summarized as follows: 
1, Home-care as a means of health-care delivery to children with 
diabetes mellitus leads to sustained marked reductions in ad-
mission-rates and acute out-patient visits. 
2. The commitment of an expert nurse-practioner, willing to work 
also outside regular hours, was crucial to the home-care-sys-
tem. 
3. Commonly used methods to measure glycosylated hemoglobins ap-
peared of very limited practical usefulness in the assessment 
of glycemic control of long-standing childhood diabetes with 
poor control. 
4. Glucose-determinations obtained by home-monitoring, reflecting 
the educational status of parents of pre-adolescent diabetic 
children, improved during home-care. 
5. The home-care-system was at least twice less costly as the 
hospital-based system and deserves wider application in the 
Netherlands. 
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Summary and conclusions 
This thesis contains investigations into three aspects of child-
hood diabetes: etiology (chapter I) , epidemiology (chapter II) 
and therapy {chapter III) . The cause (etiology) of the disease is 
unknown, the incidence (epidemiology) has not been investigated 
systematically in the Netherlands, the treatment (therapy) is un-
satisfactory: the burden for the child and its family is large. 
The long-term prognosis is not good. The so-called chronic com-
plications emerge after some 20 years of treatment and shorten 
the life-expectancy by one-third in years. 
It has not been established to what extend meticulous treatment 
will postpone the chronic complications. Apart from the mortali-
ty, the morbidity by the chronic complications is considerable. 
Diabetes mellitus is the leading cause for new cases of blind-
ness; terminal renal-insufficiency is seen llx more frequent than 
in the normal population; ischemic necrosis with amputation of 
bodylimbs 9x; myocardial infarction 7x. All of this next to an 
array of other invalidating abnormalities. 
It is hoped for the studies of chapter I will contribute to a 
future immune-prevention of this disease. In the first paper the 
role of immunogenetic factors, taking part of the major histo-
compatibility complex (MHC-complex), is investigated in a com-
bined population- and family-study. The association between HLA 
and insulin dependent diabetes mellitus is confirmed. The asso-
ciation with HLA-DR3 and HLA-DR4 is particularly strong in child-
ren. A predominance of HLA-DR4 is found in children younger than 
8 years of age. From the family-data the susceptibility to the 
disease appears to be connected to genes that are in "linkage-
disequilibrium" with HLA-haplotypes. The data disagree with ei-
ther simple recessive, intermediate or dominant Mendelian inhe-
ritance. Assuming HLA-haplotypes themselves are linked to the 
susceptibility to the disease, several forms of segregation can 
be tested. With this approach the haplotype combinations HLA-
Bl5/-DR4 and HLA-B8/-DR3 appear to contribute separately to the 
susceptibility to the disease. According to this model, in com-
bination with other findings in the study, the susceptibility to 
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diabetes is best explained by the effects of one or more genes 
situated between the HLA-B- and HLA-DR-loci. Also the possible 
linkage between non-HLA immunogenetic factors and childhood dia-
betes is examined: the Gm-markers investigated are however not 
linked to the disease. 
The second paper describes a diagnostic application of HLA-sero-
logy. A patient with diabetes in the first week of life is pre-
sented, which is extraordinary rare. This child has nor HLA-DR4 
or HLA-DR3 and lacks antibodies towards the islets of Langerhans, 
confirming the premise of an unusual pathogenesis of its diabe-
tes. Further examination reveals this child has features of the 
fetal alcohol syndrome. An association between insulin dependent 
diabetes and fetal alcohol syndrome has hitherto not been repor-
ted, 
The third paper explores another hallmark of childhood diabetes~ 
the transient occurence of antibodies against the islets of 
Langerhans, that normally produce the insulin. A previously es-
tablished method to estimate cytoplasmatic islet-cell fluorescen-
ce predicts insulin dependency in children, before any clinical 
or biochemical sign of diabetes is present. These antibodies were 
present 24 and 4 months in two children before symptoms develop. 
A third child has islet-cell membrane antibodies 32 months before 
the disease becomes manifest and has cytoplasmatic antibodies 
thereafter. 
The fourth paper examines the nature of cytoplasmatic islet-cell 
antibodies before and after the disease becomes manifest. Their 
complement fixing capacity is studied, as other investigators 
suggest this capacity prevails before the disease becomes mani-
fest and disappears thereafter. This sequence of events is not 
confirmed. Rather t~e assessment of complement fixing appears to 
depend on the sensitivity of the technique employed. Also, the 
demonstration of IgG-subclasses involved depends on the tech-
nique: the higher the titre, the more IgG-subclasses are detec-
ted. Two children however have high ti tres and IgG2 only and 
also have a family history of diabetes. 
So far the autoimmunity is examined mostly before the manifest 
disease prevails and insulin treatment is necessary. A pecularity 
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of insulin dependent diabetes is the so-called "temporary remiss-
ion": just after the initiation of insulin therapy the doses re-
quired often diminish in association with a temporary recovery of 
the islets of Langerhans to produce insulin. It is not clear why 
this remission in insulin requirements is temporary or why subse-
quently higher doses of insulin are needed. It is possible the 
insulin injections raise antibodies to the insulin receptor. In 
mice the injection {vaccination) with insulin causes the genera-
tion of antibodies towards the receptor for insulin. 
In the fifth paper the occurrence of insulin receptor antibodies 
in man is confirmed. Unexpectedly, these antibodies are also 
found before the initiation of insulin therapy. This suggests the 
insulin itself may be part of the disease process. The original 
hypothesis, the emergence of insulin receptor antibodies as the 
result of insulin injections holds for two of five children in-
vestigated. The effects of their insulin receptor antibodies are 
tested on rat-fat-cells. Their (paradoxical) lipogenic effect is 
confirmed. It is of note that these two children develop obesity, 
not easily explained from their insulin doses nor from their 
diets prescribed. The complexity of humoral antibodies relevant 
to childhood diabetes is elaborated in the discussion to chapter 
I. At the end of this discussion the significance of this com-
plexity is explored with regard to the findings of preliminary 
studies with immunosuppression in newly diagnosed diabetes of 
childhood. 
Chapter II contains an incidence study of diabetes mellitus among 
children aged 0-19 years, over all the Netherlands during 1978-
1981. The data are obtained retrospectively by questionnaires 
among all consultant dutch pediatricians and internists and as-
certained by gathering the same information among (parent-)mem-
bers of the patient-organisation (the Diabetes Vereniging Neder-
land). After correction for ascertainment-percentages, almost 500 
new cases are diagnosed each year and the number of prevailing 
0-19 year olds with diabetes is estimated at more than 4000. 
These data are used in the discussion of chapter I to calculate 
the logistics of a possible screening for childhood diabetes be-
fore the disease is clinically manifest in sibs of children that 
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already have the disease. 
The data are also used in the discussion of chapter III to calcu-
late the economy of "home-care" for diabetic children. The seaso-
nal variation in the incidence of childhood diabetes is used in 
the literature to suggest a role for viral infections with the 
clinical onset of the disease. In this dutch epidemiologic survey 
this variation is hardly seen; only in children that are older 
than 10 years of age when insulin is first administered, the in-
cidence is higher in the autumn and winter months, than it is in 
the spring and summer months. 
In the discussion the literature on the role of viral infections 
as causative agents is explored. A pathogenetic mechanism other 
than viral infections is supposed. 
Chapter III concerns the treatment of childhood diabetes. First, 
past and present trends in the literature over the past ten years 
are reviewed. Many of these changing concepts are incorporated in 
a new approach to the health-care delivery to the children, named 
"home-care". This home-care resulted in a rapid decrease of ad-
mission-days for metabolic disregulation of the treated diabetes 
as well as in emergency visits. Because of this preliminary fin-
ding, the original randomized prospective design to study the ef-
fects of home-care is interrupted. A follow-up study is reported 
instead, comparing admission-days and emergency-visits the year 
before home-care is introduced to three years of home-care there-
after. 
The first paper of this chapter briefly reports effects of the 
home-care: a thirty-fold decrease in both admission-days and 
emergency-visits is found. Also a marked reduction in admission-
days for the institution of insulin-therapy in newly diagnosed 
children is noted. 
The second paper examines the significance of various components 
of glycosylated hemoglobins as parameters of the quality of the 
metabolic control of the treated disease. This parameter is also 
followed during home-care. However, these components of glycosy-
lated hemoglobins appear not to be a suitable parameter in labile 
forms of childhood diabetes. 
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Subsequently the shift in patients during home-care is described. 
The techniques used by families at home to self-measure bloodglu-
cose are evaluated and the patient-teaching program are des-
cribed. It is calculated home-care is a much cheaper system than 
prevailing hospital-based health-care delivery: from the savings 
by home-care 40 projects may be run. If 100 children, aged 0-19 
years, are assigned to each project, the total prevalence in the 
Netherlands is covered. In the discussion the findings with home-
care are compared to those in other countries. 
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Samenvatting en conclusies 
Dit proefschrift beschrijft onderzoek over drie aspecten van dia-
betes mellitus bij het kind: de etiologie (hoofdstuk I), de epi-
demiologie (hoofdstuk II) en de therapie (hoofdstuk III). De oor-
zaak (etiologie) van deze ziekte is niet bekend. Het v66rkomen 
(epidemiologie) is in Nederland nag niet systematisch onderzocht. 
De behandeling {therapie) is onbevredigend: de belasting voor het 
kind en het gezin zijn groat. Op langere termijn is de prognose 
niet goed. De zogenaamde chronische complicaties treden op na ge-
middeld 20 jaar behandeling. Deze chronische complicaties bekor-
ten de levensverwachting met een derde in levensjaren. Het is on-
zeker in hoeverre nauwgezette behandeling deze lange termijn 
prognose kan beinvloeden. Afgezien van de mortaliteit, is de mor-
biditeit door de chronische complicaties aanzienlijk. Diabetes 
mellitus is thans de meest voorkomende oorzaak van blindheid; op 
den duur terminale nierinsuffici§ntie komt llx vaker voor dan bij 
de vergelijkbare normale bevolking; gangreen met amputatie van 
een ledemaat 9x; hart-infarct 7x. Dit alles naast tal van andere 
invaliderende afwijkingen. 
De onderzoeken van Hoofdstuk I dragen hopelijk bij tot een toe-
komstige preventieve behandeling van de ziekte. 
In het eerste artikel is de rol van genen die deel uitmaken van 
het major histocompatibility complex (MHC-complex) onderzocht, 
door middel van een gecombineerd populatie- en familie-onderzoek. 
De associatie van HLA met insuline afhankelijke diabetes mellitus 
wordt bevestigd. Vooral wanneer de ziekte zich bij het kind open-
baart, is de associatie met HLA-DR3 en/of -DR4 sterk. Bij kinde-
ren jonger dan 8 jaar lijkt HLA-DR4 te overwegen. Uit het fami-
lie-onderzoek blijkt dat de gevoeligheid voor het krijgen van de 
ziekte verbonden is met genen, die in "linkage disequilibrium" 
verkeren met HLA-haplotypen. De familiegegevens pleiten tegen en-
kelvoudige recessieve, intermediaire of dominante Mendelse over-
erving. 
Wanneer wordt verondersteld dat HLA-haplotypen zelve met gevoe-
ligheid voor diabetes mellitus zijn geassocieerd, kunnen diverse 
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vor.men van overerving worden getoetst. Met deze benadering lijken 
de haplotype-combinaties HLA-B8/-DR3 en HLA-Bl5/-DR4 elk een a-
parte bijdrage tot de predispositie voor diabetes met zich mee te 
brengen. Volgens dit model en een aantal andere bevindingen uit 
dit artikel wordt de predispositie voor diabetes, voor zover ge-
associeerd met het MHC-complex, het beste verklaard door gen-
effecten, gelegen tussen het HLA-B en het HLA-DR locus. Naast de 
immunogenetische factoren van het MHC-complex is de rol van Gm-
allotypen bij het ontstaan van diabetes bestudeerd. Deze allo-
typen blijken niet geassocieerd te zijn met het v66rkomen van 
diabetes in families. 
In het tweede artikel wordt een diagnostische toepassing van HLA-
serologie beschreven. Het gaat om een patient, die reeds een week 
na de geboorte diabetes krijgt, hetgeen extreem zelden gebeurt. 
Dit kind heeft noch HLA-DR3 noch HLA-DR4 waardoor het vermoeden 
op een afwijkende pathogenese wordt gesterkt. Oak ontbreken anti-
lichamen tegen de eilandjes van Langerhans. Bij nader onderzoek 
blijkt dit kind verschijnselen van het foetale alcohol syndroom 
te hebben. Een samengaan van diabetes mellitus en foetaal alcohol 
syndroom is tot dusverre niet beschreven. 
In het derde artikel is een ander hoofdkenmerk van diabetes on-
derzocht: het v66rkomen van antistoffen tegen de eilandjes van 
Langerhans, waar insuline normaliter wordt geproduceerd. Een te-
voren gestandaardiseerde methode om cytoplasmatische fluorescen-
tie aan te tonen, lijkt diabetes in-statu-nascendi bij kinderen 
te kunnen vaststellen; dat wil zeggen, v66rdat enig klinisch of 
biochemisch verschijnsel van diabetes aanwezig is. Bij twee kin-
deren kon worden aangetoond.dat deze antistoffen aanwezig waren 
24 en 4 maanden voordat de ziekte zich openbaarde; een derde kind 
had 32 maanden voordien alleen antistoffen gericht tegen de mem-
braan van eilandjes van Langerhans en vervolgens cytoplasmatische 
antistoffen, vanaf het moment dat de ziekte klinisch manifest 
was. 
In het vierde artikel is de aard van deze antistoffen onderzocht, 
zoals die voorkomen bij kinderen bij wie de ziekte zich klinisch 
heeft geopenbaard; in het bijzonder zijn de complement-fixerende 
eigenschappen van cytoplasmatische antistoffen onderzocht r di t 
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orndat andere onderzoekers suggereerden dat deze eigenschap zou 
verdwijnen bij het klinisch manifest worden van de ziekte. Een 
dergelijke samenloop bij het klinisch manifest worden van de 
ziekte wordt niet bevestigd. Daarentegen blijkt dat het vaststel-
len van complement-fixatie afhankelijk is van de gevoeligheid van 
de daartoe gebruikte techniek. Oak het aantonen van de IgG-sub-
klasse van deze antilichamen is van de gebruikte techniek afhan-
kelijk: hoe hager de titer, des te meer IgG-subklassen worden ge-
vonden. Bij twee kinderen met hoge titers van deze antilichamen 
werden alleen IgG2-antilichamen aangetroffen, waarbij opviel dat 
insuline afhankelijkheid vaker in hun farnilie voorkomt dan mees-
tal het geval is. 
Tot hier toe is het onderzoek gericht op de auto-irnmuniteitsas-
pecten van diabetes, v66rdat de ziekte klinisch manifest wordt en 
met insuline behandeling moet worden begonnen. Een bijzonderheid 
in het beloop van de behandeling met insuline is, dat de benodig-
de dosis na het begin van de behandeling vaak - tijdelijk - zeer 
veel minder wordt. Di t be rust op een hers tel van het insuline 
producerend vermogen van de eilandjes van Langerhans en wordt de 
"tijdelijke remissie-fase" genoemd. Het is onduidelijk waarom de-
ze remissie tijdelijk is en daarna weer hogere doses insuline no-
dig zijn. E§n van de mogelijkheden is dat de insuline injecties 
aanleiding geven tot de vorming van antistoffen tegen de receptor 
voor insuline. Daardoor zou het lichaam minder gevoelig kunnen 
worden voor eigen of toegediend insuline, waaruit een hogere in-
suline behoefte voortvloeit. Deze veronderstelling stoelt op ex-
perimenten bij muizen, waarbij de inspuiting (vaccinatie) met in-
suline antistoffen tegen de insuline receptor opwekt. 
In het vijfde artikel is het v66rkomen van dergelijke antistoffen 
bij de mens beschreven. Een onverwachte vondst bij dit onderzoek 
was dat zulke antistoffen ook worden aangetroffen bij kinderen, 
v66rdat insuline wordt geinjecteerd. Daarmede wordt de mogelijk-
heid geopperd dat insuline zelf bij de auto-irnmuniteit betrokken 
kan zijn, als oorzakelijke factoren in het ziekte-proces. De oor-
spronkelijke veronderstelling, het v66rkomen van antistoffen te-
gen de insulin~-receptor volgend op insuline-therapie, is bewaar-
heid bij 2 van de 5 daarop onderzochte kinderen. Deze receptor 
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antistoffen worden wat hun effect betreft getest op rattevetcel-
len en blijken een {paradoxaal) lipogeen effect te hebben. Ret is 
opmerkelijk dat juist deze twee kinderen heiden vetzucht ontwik-
kelden, die niet goed kan worden verklaard ui t de door hen ge-
bruikte insuline-doses, noch uit het voorgeschreven dieet. 
In de discussie bij hoofdstuk I wordt de complexiteit van de rol 
van hurnorale antistoffen bij diabetes toegelicht, naast de te-
kortkomingen van de thans beschikbare bepalingstechnieken. 
Tenslotte wordt ingegaan op de betekenis van elders lopende on-
derzoeken met immuno-interventie bij pas ontdekte diabetes, tegen 
de achtergrond van bovengenoemde complexiteit. 
In Hoofdstuk II is een incidentie-bepaling (het v66rkomen van 
nieuwe gevallen) beschreven van diabetes mellitus bij kinderen 
van 0 - 19 jaar, over geheel Nederland gedurende de jaren 1978 -
1981. De gebruikte gegevens zijn verkregen door middel van een 
enqu@te die werd gehouden onder alle klinisch werkzame internis-
ten en kinderartsen in het land. De betrouwbaarheid van dit re-
trospectieve onderzoek is onderbouwd door het apart opvragen van 
dezelfde gegevens bij leden van de patienten-vereniging, de Dia-
betes Vereniging Nederland. Wanneer met de onbetrouwbaarheid van 
de gegevens uit de specialisten-enqu€te wordt rekening gehouden, 
blijken gemiddeld bijna 500 nieuwe gevallen per j aar te zijn 
vastgesteld. Ret aantal bestaande gevallen van diabetes mellitus 
onder kinderen van 0-19 jaar is op ruim 4.000 geschat. 
In de discussie van Hoofdstuk II zijn deze incidentie-gegevens 
gebruikt om logistieke facetten van een eventuele screening op 
voorstadia van diabetes mellitus bij broers en zusters van kinde-
ren, die de ziekte al hebben, te berekenen. In de discussie van 
Hoofdstuk III zijn de gegevens gebruikt om economische aspecten 
van "thuisbehandeling" te belichten. 
Ret seizoengebonden v66rkomen van nieuwe gevallen van diabetes 
bij kinderen wordt in de literatuur gebruikt als aanwijzing voor 
een rol van virale infecties bij het manifest worden van de ziek-
te. In di t Nederlandse onderzoek is deze tendens maar zeer ge-
deeltelijk waarneembaar; namelijk alleen bij kinderen die ouder 
dan 10 jaar zijn, wanneer hun eerste insuline-injectie wordt toe-
gediend. 
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In de discussie werd de literatuur over de rol van virale infec-
ties bij het ontstaan van de ziekte nader onderzocht. Een ander 
pathogenetisch mechanisme dan virale infecties wordt geopperd. 
Hoofdstuk III gaat over de behandeling van kinderen met diabetes 
mellitus. Eerst wordt omschreven op welke marrier de opvattingen 
hierover zijn veranderd gedurende de afgelopen tien jaar. Veel 
van deze veranderde opvattingen zijn terug te vinden in een nieu-
we vorm van behandeling, die thuisbehandeling wordt genoemd. Deze 
aanpak leidde tot een zeer snelle vermindering van het aantal op-
name-dagen en het aantal acute polikliniek-bezoeken wegens ontre-
geling van de diabetes. Om die reden rnoest worden afgezien van de 
oorspronkelijke opzet van onderzoek naar de resultaten van thuis-
behandeling. Deze oorspronkelijke opzet betrof een vergelijkend 
onderzoek gedurende anderhalf jaar tussen thuisbehandeling ener~ 
zijds en de gebruikelijke behandelingswijze anderzijds. In plaats 
daarvan is een vervolg-onderzoek gedaan naar effecten van thuis-
behandeling. 
In het eerste artikel van dit hoofdstuk wordt in het kart be-
schreven in hoeverre het aantal opnarne-dagen en acute polikli-
niek-bezoeken vermindert gedurende drie j aar thuisbehandeling; 
dit wordt vergeleken met het aantal opname-dagen en acute poli-
kliniek-bezoeken gedurende het laatste jaar voordat met de thuis-
behandeling voor alle kinderen tegelijk is begonnen. Na drie jaar 
thuisbehandeling is er een 30-voudige teruggang opgetreden in het 
aantal opname-dagen wegens metabole ontregeling en in acuut poli-
kliniek-bezoek. Ook de daling in het aantal opname-dagen nodig 
voor het instellen van pas ontdekte diabetes is aanzienlijk. 
In het tweede artikel wordt de betekenis van diverse componenten 
van geglycosyleerd hemoglobine, als parameter van de metabole in-
stelling van de diabetes onderzocht. Deze componenten weerspiege-
len kortere perioden van glycemie echter niet. 
Vervolgens wordt toegelicht hoe de in- en uit-stroom van patien-
ten voor en gedurende de thuisbehandeling is geweest. De door de 
gezinnen thuis gebruikte technieken om zelf bloedsuikers te meten 
en het opleidingsprogramma voor de ouders van kinderen zijn nader 
uiteengezet. Ook is het verloop van het patroon in thuis gemeten 
bloedsuikers gedurende drie jaar beschreven. 
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Thuisbehandeling leidt niet alleen tot veel minder opnames en 
acute polikliniek-bezoeken, maar is oak aanzienlijk goedkoper: de 
besparingen uit thuis-behandeling kunnen de kosten van 40 derge-
lijke projecten dekken. Wanneer ieder project 100 kinderen van 
0-19 jaar oud bestrijkt, is de totale prevalentie in Nederland 
omvat. 
In de discussie van hoofdstuk III worden de bevindingen met 
thuisbehandeling naast die in het buitenland geplaatst. 
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Nawoord 
Dit proefschrift kwam voort uit samenwerkingsverbanden, zoals 
blijkt uit het auteurschap van de opgenomen artikelen. 
Ik wil hier mijn dankbaarheid betuigen aan vele anderen die hun 
bijdrage hebben geleverd. Ik beperk mij echter tot de direct bij 
het werk betrokkenen, wetend daarmee anderen, die daartoe bij-
droegen, te kart te doen. Ik hoop dat zij mij in de gelegenheid 
willen stellen hen op een andere wijze te bedanken. 
Prof. Dr. H.K.A. Visser, mijn opleider en promotor, heeft de om-
geving, of beter, het geestelijk klimaat geschapen, waarin di t 
proefschrift kon worden bewerkt. Dit lijkt een vanzelfsprekend-
heid. Dat is het niet wanneer men zich bedenkt, hoe complex de 
eindverantwoordelijkheid is voor optimale behandeling, onderzoek 
en onderwijs met name ten aanzien van zieke kinderen. Dit geldt 
zeker in een tijd waarin de mogelijkheden daartoe snel verande-
ren. 
Prof. Dr. J.J. van Rood, mijn co-promotor, dank ik voor de diep-
gaande belangstelling welke hij heeft voor de ziekte, waarover 
dit proefschrift gaat. Het vertrouwen dat hij ons samenwerkings-
verband schenkt vormt een zeer bijzondere stimulans. 
Prof. Dr. R. Benner en Prof. Dr. H.A. Valkenburg ben ik erkente-
lijk voor hun bereidwilligheid tussentijds advies te geven en 
voor de bijzondere aandacht welke zij aan het manuscript hebben 
be steed. 
I would like to acknowledge Dr. G.B. Forbes of the Rochester Me-
dical School, who lead my first steps in the area of childhood 
diabetes. 
Prof. Or. J .L. van den Brande bracht mij de beginselen van de 
kinder-endocrinologi~ bij en maakte mij vertrouwd met laborato-
riumtechnieken. 
Een proefschrift bewerken gaat altijd ten koste van dagelijkse 
werkzaamheden, in het bijzonder die van de diabetes-polikliniek. 
Deze polikliniek is een team-gebeuren en dit functioneert alleen 
wanneer de daarbij horende geest aanwezig is. Deze geest werd op 
onnavolgbare wijze vertegenwoordigd door: 
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Mw. Zr. J.J. de Visser, verpleegkundige, Mw, A.E. Hart, dietiste, 
Mw. E. Berkhouwer, secretaresse, Mw. C.E. de Beaufort en Mw. 
C.M.G.J. Houtzagers, artsen, Mw. Dr. F.M.E. Slijper, psychologe, 
R.S.R. Aarsen, kinderarts, H.J. Aanstoot, arts, R.B. Minderaa en 
F.C. Verhulst, kinderpsychiaters. Hen is veel dank verschuldigd 
voor hun aanhoudende steun. 
De diabetes-polikliniek rnaakt deel uit van de polikliniek voor 
endocrinologie en groeistoornissen. Veel is oak te danken aan de 
stimulans van Dr. S.L.S. Drop. Prof. Dr. H.J. Degenhart gaf waar-
devolle adviezen en beheerde het laboratoriurn. De Heer J.B.C. van 
Veen, directeur van de medische afdeling van Novo Industri B.V. 
te Amsterdam ondersteunde het onderzoek met literatuurgegevens. 
Mw. A. Aanstoot-Brandsma typte het gehele manuscript, nadat 
Mw. M. de Bruyne daarmee een aanvang had gemaakt. 
De beide paranymfen, Dr. C. Pries en Dr. R.J. in 't Veld met hun 
echtgenoten en kinderen zijn door jarenlange vriendschap verbon-
den met de verdediging van het proefschrift en bijbehorende stel-
lingen. 
Mijn ouders dank ik voor de opleiding waartoe zij mij in staat 
hebben gesteld. 
Mijn vrouw Wanda en onze kinderen Iris en Hilgo voltooiden deze 
periode met wijsheid. Ik verheug mij op onze vakantie. 
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Curriculum vitae 
De schrijver van dit proefschrift werd op 15 juli 1941 te Eindho-
ven geboren. Nadat hij in 1960 aan het Lorentz-lyceum te Eindho-
ven het diploma gymnasium b@ta behaalde, werd begonnen met de 
studie van de geneeskunde te Leiden met een beurs van het Phi-
lips-van der Willigen fonds, 
De stage pathologische anatornie werd aan de Royal Infirmary te 
Edinburgh gevolgd; een maand lang was hij werkzaam aan het H6pi-
tal des Maladies Contagueuses te Parijs. Als lid van het studen-
tenfaculteitsbestuur voerde hij in 1965 een orienterend onderzoek 
uit naar de appreciatie door studenten van het geboden candi-
daatsonderwijs, gecoached door wijlen Prof. Dr. C. Vervoort, on-
derwijssocioloog te Leiden. 
In 1968 studeerde hij af en werd hij als districtspsychiater toe-
gevoegd aan het Territoriaal Bevel Zuid van de Koninklijke Land-
macht onder leiding van Dr. L. Somers en Dr. D. Mulder. Tevens 
werkte hij op de afdeling Anthropogenetica te Leiden (Prof. Dr. 
M, Siniscalco) . 
In 1969 werd hij aangenomen als assistent-kinderarts in opleiding 
bi j Prof. Dr. H. K .A. Visser, in het Sophia Kinderziekenhuis te 
Rotterdam. 
In 1973 werd een vrije stage in de kinderendocrinologie gevolgd, 
geleid door Prof. Dr. J.L. van den Brande. 
Van eind 1973 tot begin 1977 was hij werkzaam als NIH-research 
fellow onder Prof. G.B. Forbes aan de University of Rochester Me-
dical School, Rochester (N.Y.), USA, het laatste jaar toegevoegd 
aan de staf als instructor of pediatrics, In die jaren werkte hij 
met Prof. I.B. Pless over diverse aspecten van diabetes mellitus 
bij kinderen als model voor chronische ziekte. 
In 1976 werd hem de Rochester Diabetes Award (van de American 
Diabetes Association) overhandigd door wijlen Prof. A. Lazarow. 
In 1977 keerde hij terug naar het Sophia Kinderziekenhuis en was 
hij werkzaam bij Prof. Dr. J.L. van den Brande. 
In 1978 werd een aanvang gemaakt met de in dit proefschrift be-
schreven onderzoeken. 
Intussen kreeg hij zitting in de medische subcommissie van de 
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Diabetes Vereniging Nederland (DVN) , werd hij lid van de Werk-
groep Diabetes Mellitus bij kinderen van de Nederlandse Vereni-
ging voor Kindergeneeskunde en was hij formeel oprichter van de 
Diabetes Education Study Group-Netherlands. 
De schrijver is gehuwd met Wanda Hartland. Zij hebben twee kin-
deren, Iris en Hilgo. 



